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CONTRIBUTION OF INTERLEUKIN 6 TRANS SIGNALING
IN PULMONARY FIBROSIS
THUY THANH LE, B.A.
Supervisory Professor: MICHAEL R. BLACKBURN, Ph.D.

Idiopathic Pulmonary Fibrosis (IPF) is a lethal lung disease with progressive fibrosis and
death within 2-3 years of diagnosis. IPF incidence and prevalence rates are increasing annually,
and because the pathogenesis is unknown, there are no effective treatments available. Inhibition
of interleukin 6 (IL-6) results in the attenuation of pulmonary fibrosis in mice. It is unclear
whether this is due to blockade of classical signaling, mediated by membrane-bound IL-6
receptor alpha (mIL-6Rα), or trans signaling, mediated by soluble IL-6Rα (sIL-6Rα). Our study
assessed the role of sL-6Rα in IPF. We demonstrated elevations of sIL-6Rα in IPF patients and
in mice during the onset and progression of fibrosis and showed that protease-mediated cleavage
was important in production of sL-6Rα in fibrotic lungs. In vivo neutralization of sIL-6Rα, and
resulting antagonism of IL-6 trans signaling, attenuated pulmonary fibrosis in mice. Decreases in
sIL-6Rα were associated with reductions in myofibroblasts, fibronectin and collagen. In vitro
activation of IL-6 trans signaling enhanced fibroblast proliferation and extracellular matrix
protein production, effects relevant in the progression of pulmonary fibrosis. These findings
suggest that IL-6 trans signaling influences events crucial in pulmonary fibrosis in vivo.
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IDIOPATHIC PULMONARY FIBROSIS
Definition and Epidemiology
Idiopathic Pulmonary Fibrosis (IPF) is a lethal lung disease of unknown etiology and
defined by chronic, progressive, irreversible interstitial fibrosis limited to the lungs(1, 2). It is the
most common form of idiopathic interstitial pneumonia (IIP), affecting older adults, with age at
diagnosis ranging from 55-75 years-old, median age of 66 years-old(2). Incidence increases with
increasing age, and a diagnosis in adults less than 50-years old is uncommon. IPF is more
prevalent in males than females (1.5-1.7:1)(1, 2). Recent estimates place the number of affected
individuals around 128,000 (with some reports of prevalence as high as 200,000) in the USA and
around 8 million worldwide. It is expected that 50,000 new IPF cases will be diagnosed each
year, with that number rising annually(1-3). Over the last two decades, there has been an upward
trend in incidence rates(3), emphasizing the increasing impact of this disease on the general
population.

Presentation & Diagnosis:
Patients commonly present clinically with progressive dyspnea on exertion and a chronic,
non-productive cough(1, 2). Other symptoms can include digit clubbing and bibasilar inspiratory
crackles. Diagnosis is made based on presenting symptoms, evidence of a usual interstitial
pneumonia (UIP) pattern on histology and imaging, and exclusion of other interstitial lung
diseases(1, 2). UIP pattern on histology includes: a spatial and temporal heterogeneity in
parenchymal involvement, appearance of fibrosis and honeycombing that is mainly subpleural
and paraseptal, presence of fibroblastic foci, and absence of features suggesting other
conditions(1, 2). UIP pattern on imaging includes: subpleural and basal involvement,
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honeycombing with or without traction bronchiectasis, and reticular abnormalities(1, 2).
Honeycombing refers to presence of airspaces that are cystic in appearance, lined with
bronchiolar epithelium and may contain inflammatory cells and mucin.
IPF can be broken up into sporadic and familial forms. Familial IPF, which accounts for
<5% (0.5-3.7%) of IPF cases, is indistinguishable clinically and histologically from sporadic
IPF, though they may have different genetic patterns and can present at a younger age(1, 2). The
genetic mode of transmission of familial IPF is most likely autosomal dominant with variable or
reduced penetrance(1, 2).

Cause(s) and Risk Factors:
As its name indicates, the cause or causes of IPF remain unidentified, though potential
risk factors include genetics, lifestyle choices, environmental or occupational exposures and comorbid diseases.2-3
Genetic factors: Studies have suggested that the gene ELMOD2 (located on chromosome
4q31), which has unknown functions, may confer susceptibility to familial IPF(1). Mutations in
human telomerase reverse transcriptase (hTERT) and human telomerase RNA (hTR), leading to
telomere shortening and cellular apoptosis, have been linked to familial and sporadic IPF
cases(1, 4). Mutations in surfactant protein C and A2 (SFTPC and SFTPA2) have been
associated with familial IPF(1, 4). Mutations in SFTPC have not been found in sporadic IPF.
SFTPA2 mutations are also associated with lung cancer(1).
Quite a number of genetic polymorphisms has been reported to be increased in sporadic
IPF and suggested to be involved in disease progression. The polymorphisms occurred in genes
encoding enzymes (α1-antitrypsin, angiotensin converting enzyme), cytokines (interleukins 1α, 4,
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6, 8, 10 and 12, tumor necrosis factor α, lymphotoxin α), fibrotic mediators (transforming growth
factor β1), immune modulators (complement receptor 1, NOD2/CARD15), coagulation pathway
elements (plasminogen activator inhibitors 1 & 2), matrix metalloproteinase 1 (MMP-1), and
surfactant proteins A and B (SFTPA, SFTPB)(1). Associations have also been made between
human leukocyte antigen class I and II (HLA-I, HLA-II) haplotypes and MHC class I chainrelated gene A (MICA) and IPF(1). A polymorphism in the promoter of the mucin gene MUC5B
has been associated with familial and sporadic IPF(5).
Lifestyle choices: Cigarette smoking is a significant risk factor in both familial and
sporadic IPF. There is a strong association between moking history of >20 pack-years and
development of IPF(1).
Environmental factors: Exposures to wood dust, like pine, and metal dusts, like lead,
steel and brass, significantly elevates risk of IPF(1). Hairdressers, farmers, and stone cutters also
experience increased risk, as does anyone with exposure to birds, livestock, animal dust and
vegetable dust(1).
Co-morbid conditions: Investigations into the involvement of viral infections as risk
factors revealed associations between IPF and Epstein-Barr virus, hepatitis C, and a few herpes
viruses(1). There were positive and negative associations studies reported with Epstein-Barr
virus (EBV), cytomegalovirus (CMV), and human herpesvirus 7 and 8 (HHV-7 & HHV-8).
Hepatitis C had variable associations, and elevated CMV antibodies have been reported in
IPF(1).
Gastroesophageal reflux (GER) abnormalities is common in IPF patients and has long
been thought to be a risk factor. Erosive esophagitis from GER was associated with development
of pulmonary fibrosis(1). Diabetes mellitus, obesity, obstructive sleep apnea, and coronary artery
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disease may play a role in IPF risk but that still remains to be determined(1, 2). There are many
confounding factors involved in reports of risk factors, so interpretation must be taken
cautiously(1).

Natural history & Clinical Phenotypes in IPF
The natural history of IPF is highly variable and unpredictable(1, 2). IPF was once
thought to simply be a slowly progressive disease, but over the years, there is increasing
awareness of the heterogeneity of the disease and discussion has revolved around possible
distinct IPF phenotypes that have may have genotypic associations and clinical features that
affect prognosis in terms of disease progression and mortality risks(2, 6).
Some patients with IPF have stable disease. Some have rapidly progressive disease.
Others exhibit gradual decline in pulmonary function over time(1, 2, 6). Some have co-morbid
conditions, including pulmonary hypertension and emphysema. All are at risk of possible
episodes of acute respiratory worsening, known as acute exacerbations(1, 2).
Subclinical IPF: Ley et al have defined various categories of disease in IPF, including
subclinical IPF, which refers to the period before diagnosis(7). Patients with IPF will typically
have symptoms prior to diagnosis for a median of 1-2 years. Prior to symptoms, however, there
may also be radiographic evidence of disease(7). These patients can progress from asymptomatic
to symptomatic disease over years or decades. This period of subclinical disease is not well
understood(7). Asymptomatic pulmonary fibrosis is now better reported because it has been
identified in family members of IPF patients, particularly individuals with smoking history. The
lungs of these individuals show histologic evidence of various subtypes of interstitial lung
disease (ILD)(7). High-resolution CT (HRCT) is the best modality to identify asymptomatic,
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subclinical IPF, though it is not yet known how to manage subclinical individuals(7). They may
be at higher risk for developing acute exacerbations after procedures(7).
Stable or slowly progressive IPF: Once diagnosed, some IPF patients will have stable or
slowly progressing disease(1, 2). These patients have usually presented with progressive dyspnea
on exertion and cough associated with decreased lung capacities and volumes(1, 2). The rate of
decline in these patients is 0.13-0.21 L in forced vital capacity (FVC)(2, 7).
Rapidly progressive IPF: IPF that is rapidly progressing typically occurs in males who
are smokers(2, 6, 8). At diagnosis, these patients have similar lung capacities and volumes, and
similar imaging and histological findings to stable or slowly progressive IPF patients(2). Despite
the similarities, rapidly progressive IPF differ in clinical course and transcriptional profile. This
accelerated version of IPF is associated with shortened survival(2, 6, 8). There is evidence of
transcriptional upregulation in pathways that affect alveolar epithelial and mesenchymal
functions(2). Boon et al reported upregulation in genes involved in the MAPK-EGR1-HSP70
pathway, a pathway known to regulate inflammation induced by smoking(9). Selman et al
reported overexpression of genes involved in migration/proliferation, oxidative stress,
morphogenesis, and fibroblast and smooth muscle cell genes along(8).
Acute Exacerbations: Acute exacerbations (AE) are defined by several measures. There
must be an abrupt decline in respiratory function, as evident by worsening dyspnea (in a matter
of days or weeks and less than 1 month) and worsening hypoxemia (decrease in arterial blood
PaO2)(1, 2). This rapid deterioration is associated with new radiologic findings of diffuse alveolar
damage (bilateral alveolar infiltrates and ground-glass opacities) on top of previous parenchymal
involved(1, 2). Importantly, there is an absence of identifiable precipitating triggers. Other
observed symptoms include fever, increased cough and increased production of sputum(1).
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Acute exacerbations occur in about 5-20% of patients(1, 2). Prognosis is grim and
mortality exceeds 60% with hospitalization(2). Survivors of AE have a greater than 90%
mortality risk within 6 months. In about 27% of IPF AE cases, torque teno virus was detected.
Pathogenesis of AE episodes are not known but excessive epithelial apoptosis and increased
circulating fibrocytes have been reported(2). It is unclear whether these episodes of acute
exacerbations had precipitating causes that were missed in diagnosis or if it is a reflection of
progression in the inherent IPF disease processes(1).
Combined pulmonary fibrosis and hypertension: Pulmonary hypertension (PH) is a
recognized complication of IPF(1). Though PH is typically seen in severe IPF, it is observed in
some patients with earlier stages of IPF(6). It is defined as mean pulmonary artery pressure
(mPAP) ≥25 mmHg at rest and ≥30 mmHg with exertion(6, 10, 11). Retrospective studies show
prevalence of IPF patients with PH to be between 31-85%(6, 12-14). The wide range may be due
to the fact that occurrence and severity of PH increases with time(15), so the number varies
depending on the timing of analysis and the patient population.
A number of studies have shown associations between PH and increased mortality risk in
IPF patients. Lettieri et al reported a correlation between PH (indicated by mPAP) and mortality
risk(12). Higher mPAP was associated with increased mortality risk(12). Hamada et al indicated
specifically that mPAP above 17 mmHg best indicates increased 5-year mortality rates(16).
Nadrous et al reported an inverse correlation between PH and diffusing capacity of carbon
monoxide (DLCO) in IPF patients(13). They also showed that estimated systolic pulmonary artery
pressure (sPAP) had a negative impact on survival, especially when higher than 50 mgHg(13).
Mortality rates increase in more in the presence of pulmonary fibrosis, emphysema and
pulmonary hypertension(6, 17).

19

Combined pulmonary fibrosis and emphysema: Recent retrospective studies place the
prevalence of co-existing pulmonary fibrosis and emphysema in IPF patients around 28-55%,
depending on the study population(6, 17, 18). Cottin et al first coined the name Combined
Pulmonary Fibrosis and Emphysema (CPFE) in 2005 when they formally described clinical
characteristics comprising this syndrome(18). Those characteristics included findings of dyspnea
on exertion, basal crackles, finger clubbing, upper lobe emphysema and lower lobe pulmonary
fibrosis on CT, abnormal spirometry, severe gas exchange impairment, and high prevalence of
pulmonary hypertension(18).
Mejia et al also reported an association between CPFE and pulmonary arterial
hypertension(17). In fact, they stratified pulmonary hypertension and further showed a positive
correlation between PH and extent of emphysema in their study population(17). The presence of
both pulmonary fibrosis and emphysema carries a poorer prognosis than IPF alone and mortality
is even worse if pulmonary hypertension is also present(6, 17, 18). The prognosis is dismal with
the combination of CPFE, severe pulmonary hypertension and severe pulmonary restriction(17).
Severe PH was defined as estimated systolic pulmonary artery pressure (eSPAP) greater than 75
mmHg. Severe pulmonary restriction was defined as forced vital capacity (FVC) below 50%.
Mejia et al reported that CPFE is associated with male gender and smoking(17). Though
the pathogenesis of CPFE is unclear, smoking appears to be a trigger(6, 18). Exposure to
agrochemical compounds has also been suggested to be environmental risk factors(6, 19). As for
genetic risk factors, it is not known if susceptibility to IPF and COPD may lead to CPFE or if
CPFE may have its own distinct genetic variations(6).
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Treatment of IPF
The latest published global recommendations regarding management of IPF was a joint
statement released by the American, European, Japanese, and Latin American thoracic and
respiratory societies in 2011. At the time, there was little evidence of effective pharmacologic
therapies for IPF(1). The statement did report strong recommendations against use of:
corticosteroids alone and in combination with immune modulators, colchicine, cyclosporine A,
interferon γ 1b, bosentan, and etanercept(1). Therapies that received weak recommendations
against (meaning it may be suitable in some patients) include: triple therapy (N-acetylcysteine,
azathioprine, and prednisone), N-acetylecysteine (NAC) alone, anticoagulants and pirfenidone.
Other recommendations included interventions to relieve symptoms in management of acute
exacerbations and chronic disease, with treatment of pulmonary hypertension, use of long-term
oxygen therapy and referral for lung transplantation in appropriate patients(1).
Pharmacologic options: Since the release of the joint statement, published outcomes
from various clinical trials have raised a need to modify treatment recommendations(20, 21).
Recommendations regarding the use of N-acetylcysteine monotherapy are expected to be
updated in 2014, pending report of results from the PANTHER-IPF randomized controlled trial
(RCT). NAC monotherapy was initially studied in the IPHIGENIA RCT. Results of
IPHIGENIA, released in 2005, demonstrated a significant reduction in decline of forced vital
capacity (FVC) and diffusion capacity with high-dose NAC(20, 21). The trial did not show
survival benefit and was criticized for various reasons, so NAC monotherapy was further studied
in the PANTHER-IPF RCT. The trial has concluded and final report is expected in 2014. In the
meantime, because NAC therapy is relatively well tolerated, it is widely used for IPF(20, 21).
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The PANTHER-IPF trial also tested efficacy of triple therapy (NAC, azathioprine, and
prednisone) in IPF as one of the treatment groups. In October 2011, the trial terminated its triple
therapy arm early when it became evident that triple therapy increased mortality, hospitalizations
and adverse effects. Reports of the detrimental effects have since shifted IPF treatment emphasis
away from immunosuppressants(20, 21). Another treatment option that also led to harmful
effects in IPF patients is warfarin. The ACE-IPF RCT, looking at warfarin therapy in IPF, was
terminated prematurely due to increased mortality. Most of the deaths in the warfarin group was
attributed to disease progression and acute exacerbations, not to complications of warfarin, like
bleeding(20). Ambrisentan, a type A endothelin receptor antagonist, was tested in the phase III
RCT ARTEMIS. ARTEMIS was terminated prematurely due to increased disease progression
and increased hospitalizations(21). Phase II testing of the efficacy of everolimus (MTOR
inhibitor) was discontinued due to increased disease progression and increased acute
exacerbations(21).
Therapies that have yielded no benefits in phase II RCT were imatinib mesylate (inhibitor
of PDGF receptors, c-kit and c-ABL tyrosine kinases), macitentan (dual endothelin receptor
antagonist) and tumor necrosis factor-α (TNF-α) antagonists(20, 21).
The good news, on the other hand, is that the pyridone analogue pirfenidone has been
gaining recognition as a novel, effective therapy for IPF. Pirfenidone is thought to have antiinflammatory, anti-fibrotic, and antioxidant effects(20-22). It is the first agent approved for
treatment of mild to moderate IPF, currently available in Japan, Europe, Canada and India(2022). It has not yet been approved in the USA despite a number of clinical trials showing efficacy
and improvement in IPF patients. The first phase II RCT of pirfenidone was conducted in Japan
and reported in 2005 by Azuma et al(20-22). The study was stopped early due to high numbers
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of acute exacerbations in the placebo group, but they did show significant reduction in decline of
FVC. Since then, three phase III RCT evaluating efficacy of pirfenidone have been completed
and two were able to show significant reduction in FVC decline(20-22). The first phase III RCT,
conducted in Japan, showed significant reduction in FVC decline at 52 weeks and improvement
in progression-free survival with high-dose pirfenidone therapy(20-22). This led to approval of
pirfenidone for use in Japan in 2008.
After that, two other phase III RCT trials, CAPACITY 1 and 2, were carried out
concurrently in North America, Europe and Australia. CAPACITY 1 met its primary end-point
of reduction in FVC decline at 72 weeks while CAPACITY 2 did not(20-22). However,
CAPACITY 2 did show improvement in 6MWT decline as a secondary endpoint. When the data
from both CAPACITY trials were pooled, there were significant differences in primary and
secondary endpoints. Pirfenidone therapy resulted in significant reduction in FVC decline, mean
decline in 6-minute walk test distance, and progression-free survival(20-22). When all four
pirfenidone clinical trials were analyzed by Cochrane meta-analysis, it was evident that
pirfenidone reduced disease progression risk by 30% in comparison to placebo(20-22). Based on
that evidence, in 2011, Europe approved the use of pirfenidone for mild to moderate IPF.
In the USA, however, the FDA decided in 2010 to withhold approval of pirfenidone until
more clinical trial data was obtained. They cited failure of CAPACITY 2 to replicate the
improvement in FVC decline seen in CAPACITY 1 as the reason. ASCEND, another phase III
RCT designed to test efficacy of pirfenidone in IPF, was initiated in 2011 and is currently in
progress in North America, South America and Australia. The primary endpoint for ASCEND is
FVC decline at 52 weeks(20, 21). Reassessment of FDA approval in the USA is expected to
come in the future, pending results of the ASCEND trial. In the meantime, investigations of
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high-dose pirfenidone side effects indicate long-term therapy is generally safe and well
tolerated(20-22). Pirfenidone represents a promising therapeutic option for IPF.
Sildenafil (phosphodiesterase inhibitor 5) was tested in phase III trial STEP-IPF. No
significant difference was observed in primary endpoint of ≥20% increase in 6MWT distance at
12 weeks, but secondary endpoints (quality of life and carbon monoxide diffusing capacity)
showed significant improvements(21).
An option that is currently in phase III RCT testing is treatment with a nintedanib or
BIBF 1120 (triple inhibitor of tyrosine kinases receptors). Nintedanib has been evaluated in the
phase II RCT TOMORROW, which showed improvement in FVC decline and fewer acute
exacerbation events(20). The targets of nintedanib are platelet derived growth factor (PDGF),
fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) receptors. The
results from TOMORROW led to two phase III RCT currently in progress(20, 21).
Current ongoing phase II clinical trials involve targeting: interleukin 13 with
lebrikizumab (QAX576, human anti-IL-13 monoclonal antibody), chemokine (C-C motif) ligand
2 or monocyte chemoattractant-1 with CNTO 888 (monoclonal antibody against CCL2),
connective tissue growth factor with FG-3019 (monoclonal antibody to CTGF), transforming
growth factor beta with GC1008 (antibody against TGF-β)(20, 21).
Other ideas currently in phase I testing include targeting lysyl oxidase and lysyl oxidaselike enzymes with simtuzumab (AB0024, monoclonal antibody against LOXL2) and
administration of mesenchymal stem cells for treatment of IPF(20, 21).
Lung Transplantation: Lung transplantation is effective at reducing risk of death and
prolonging survival in advanced IPF disease(1, 2). However, 5-year survival post-transplant is
still only about 44-56%(1, 2). It is unclear whether single versus double lung transplantation
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confers different survival benefits. Discussion of transplantation is appropriate at diagnosis and
referral of patients for transplant evaluation is recommended at first sign of deterioration(1, 2).
Treatment of Co-Existing PH and Emphysema: Regarding the treatment of pulmonary
hypertension in IPF, the joint committee gave a weak recommendation for a trial of vasodilator
therapy in IPF patients with moderate to severe PH that has been confirmed by right heart
catheterization(1, 2). Sildenafil, a phosphodiesterase 5 inhibitor, has been shown to improve
quality of life and dyspnea in cases of IPF patients with advanced PH(1, 2).
Treatment of combined pulmonary fibrosis and emphysema has not been clearly defined.
Cessation of smoking is advised and supplemental oxygen should be provided as needed for
hypoxemia(6). The use of sildenafil to treat pulmonary hypertension in this group has not been
evaluated(6).

Prognosis & Mortality
IPF prognosis is grim. Mortality in IPF patients is expected within 2-3 years of
diagnosis(1, 2). Mortality rate is about 40,000 deaths annually(1-3). Of increasing concern is the
upward trend in mortality rates for IPF over the past two decades(3). Particularly, from 1992 to
2003, the number of deaths secondary to IPF in the USA increased by 50%, a mortality rate
similar to and surpassing those of many cancers, emphasizing the devastating nature of this
disease(23, 24).

Pathogenesis of IPF
The dismal prognosis and paucity of effective treatment modalities in IPF is secondary to
inadequate knowledge of the pathways and factors that govern the development and progression
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of this complex disease. IPF was originally considered to be an inflammatory condition(1, 2).
However, when anti-inflammatory therapies failed to achieve an effect in IPF patients, the focus
shifted away from inflammation and towards an epithelium-centered disease model(1, 2).
Evidence to date indicates that epithelial injury and activation plays an important role in
IPF pathogenesis. Involvement of local mesenchymal cells and circulating fibrocytes, in this
process, leads to expansion of the fibroblast and myofibroblast populations that are responsible
for the exaggerated deposition of extracellular matrix and resulting destruction of pulmonary
architecture evident in IPF(2). Thus, of particular importance are efforts to understand the
contribution of factors generated during tissue injury and how those factors impact development
of fibrosis.

ADENOSINE IN CHRONIC LUNG DISEASES
One of the factors that has emerged as being central to injury response in the lung is the
signaling nucleoside adenosine. During times of tissue stress and damage, cells will release
adenosine triphosphate (ATP) into the extracellular space(25). There, ATP is rapidly
dephosphorylated and converted to AMP and then adenosine(25). Adenosine can then engage its
cell surface G-protein-coupled receptors (A1, A2A, A2B, and A3 adenosine receptors) to exert
various effects on inflammation, repair and remodeling processes(26), producing either tissueprotective or tissue-destructive results(25, 27).
Adenosine has been shown, in humans and mouse models, to be elevated in and
contribute to chronic lung disorders, including asthma, COPD, and pulmonary fibrosis(25).
Recent publications have reported, specifically, that it is the activation of the A2B receptor by
adenosine that mediates production of pro-fibrotic molecules, like interleukin-6, leading to
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chronic lung diseases(25, 28-31). Adenosine regulates production and release of IL-6 from
various cell types, including from lung epithelial cells(32), macrophages(33), smooth muscle
cells(34) and fibroblasts(35).

INTERLEUKIN 6 (IL-6)
Interleukin 6 (IL-6) is a pleiotropic cytokine first identified as a secretory product of
fibroblasts(36) and later recognized for the ability to stimulate the differentiation of activated B
cells into immunoglobulin-producing plasma cells(37). Since then, studies have reported
extensive effects in various systems, particularly the immune and hematopoietic systems. Aside
from mediating the differentiation of activated B cells, IL-6 induces growth and activation of T
lymphocytes and regulation of cytotoxic T cell differentiation(38, 39). With regards to
hematopoiesis, IL-6 mediates the expansion of hematopoietic progenitors(40), promotes
proliferation and differentiation of megakaryocytes, and regulates macrophage and neutrophil
differentiation(38). IL-6 acts in the liver as a hepatocyte stimulatory factor, regulating the
production of acute phase proteins like C-reactive protein (CRP) and fibrinogen, driving the
acute phase response(38, 41). In the musculoskeletal system, IL-6 is important for bone health
and remodeling. It acts to promote osteoclast differentiation, leading to bone resorption(42, 43).
IL-6 also mediates neural cell differentiation and homeostatic activities related to fatigue, mood
and pain through poorly understood mechanisms(43, 44).

INTERLEUKIN 6 SIGNALING PATHWAYS
IL-6 signals through a receptor complex consisting of two distinct glycoprotein chains –
the ligand-binding interleukin 6 receptor alpha (CD126, IL-6Rα) and the non-ligand binding,
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signal-transducing receptor gp130 (CD130)(38, 43, 44). While gp130 is expressed constitutively
as a membrane-bound receptor on most cells in the body, expression of IL-6Rα is more
limited(38, 43, 44). Membrane-bound IL-6Rα is present only on certain cells in the body,
primarily hepatocytes and leukocyte subpopulations – B and T cells, monocytes, and
neutrophils(45, 46). However, the presence of a natural, soluble form of the IL-6Rα (produced
through alternative splicing and proteolytic cleavage) drastically widens the range of cellular
targets and allows IL-6 to signal via two pathways(38, 43, 44, 47).
The first pathway is known as classical signaling and occurs on cells that co-express
membrane-bound IL-6Rα and gp130. Here, IL-6 binds a membrane-bound IL-6Rα, and this IL6/mIL-6Rα complex then triggers the association with two molecules of gp130 to initate the
signaling cascade (Figure 1.1A). In the alternative pathway, known as trans signaling, IL-6
complexes with a soluble form of IL-6Rα in order to associate with gp130 and initiate signaling
(Figure 1.1B)(38, 43, 44). In both pathways, binding of IL-6 to IL-6Rα causes association with
two gp130(48). This dimerization of gp130 in turn activates associated Janus tyrosine kinases
(JAK), leading to phosphorylation of gp130(49, 50). Activated gp130 then facilitates the
phosphorylation of signal transducer and activator of transcription 3 (STAT3)(51). PhosphoSTAT3 dimerizes and translocates to the nucleus, where it acts as a transcription factor to
regulate target genes(52).

GENERATION OF SOLUBLE IL-6R ALPHA
Soluble receptors for cytokines can be generated in two ways: 1) shedding (where limited
proteolysis of the membrane-bound receptor produces a soluble form of the receptor) and 2)
alternative splicing (where soluble receptors are produced via translation of differentially spliced
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mRNAs exhibiting deletions of transmembrane and cytoplasmic domains). Many soluble
receptors retain their ligand-binding capacity and have been characterized in biological
fluids(53).

Figure 1.1. Interleukin 6 (IL-6) classical and trans signaling pathways. (A) Classical
signaling occurs on cells that co-express membrane-bound gp130 and membrane-bound IL-6Rα
(mIL-6Rα). There, IL-6 binds mIL-6Rα to form the IL-6/mIL-6Rα complex to initiate signaling.
(B) Cells that express membrane-bound gp130 but lack mIL-6Rα can still be activated in the
presence of the soluble IL-6Rα. Activation in this manner is known as trans signaling. There, IL6 binds a soluble version of IL-6Rα to form the IL-6/mIL-6Rα complex. (C) In both pathways,
binding of IL-6 to either mIL-6Rα or sIL-6Rα leads to association with 2 membrane-bound
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gp130 molecules, which activates Janus kinases (JAK), which in turn phosphorylates gp130,
leading to phosphorylation of Signal Transducer and Activator of Transcription 3 (STAT3).
Phospho-STAT3 dimerizes and translocates to the nucleus, where it acts as a transcription factor
to facilitate transcription of target genes.

Figure 1.2. Mechanisms of generation of soluble IL-6Rα (sIL-6Rα). Soluble IL-6Rα (sIL6Rα) can be generated via (A) translation of alternatively spliced mRNA or (B) by proteolytic
cleavage of the membrane-bound receptor by metalloproteases such as ADAM17. Soluble IL6Rα retains its ability to bind IL-6 and has a binding affinity for IL-6 similar to the membranebound version. The complex of IL-6/sIL-6Rα can activate cells in an autocrine (1) or paracrine
(2) manner.
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Soluble IL-6Rα can be generated via translation of alternatively spliced mRNA but
mainly through proteolytic cleavage(44). Different studies have identified IL-6Rα mRNA
isoforms that, secondary to alternative splicing and resulting reading frame shift, encodes a
receptor that lacks the transmembrane and cytosolic domains and possesses a novel carboxyterminal protein sequence(54-56). Most of the focus, however, has been on unraveling the
mechanism of protease-mediated cleavage of membrane-bound IL-6Rα to produce a soluble
receptor. Mullberg et al demonstrated that a soluble form of the IL-6Rα is produced via shedding
of membrane-bound receptor from human peripheral blood monocytes(57). Protein kinase C
activity regulates this shedding process and the shed receptor retains IL-6 binding capacity(58).
Studies in subsequent years supported a role for the metalloprotease ADAM17 in mediating IL6Rα shedding in response to various stimuli, including apoptosis(59), Ca2+ mobilization(60),
cellular cholesterol depletion(61), leptin induction(62), TCR activation of CD4 T cells(63), and
bacterial activation of bronchial epithelial cells(64).

A DISINTEGRIN AND METALOPROTEASE 17 (ADAM17)
A Disintegrin and Metalloproteinase 17 (ADAM17) (previously known as TACE – tumor
necrosis factor-alpha converting enzyme) is a membrane-bound metalloprotease belonging to the
ADAM (a disintegrin and metalloproteinase) family that is responsible for cleaving cell surface
proteins. The list of substrates for ADAM17 includes a number of cytokines and growth factors
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(e.g. TNFα, TGFα, HB-EGF), cytokine receptors (e.g. IL-6Rα, TNFα-RI and RII), and adhesion
molecules (e.g. L-selectin, ICAM-1)(65), among others.
ADAM17 has been implicated as the main protease responsible for shedding IL-6Rα
from cell membrane surfaces of hepatocytes, peripheral monocytes, neutrophils and T cells(38,
59, 61-63). Increased levels of this protease have been found in association with diseases that
have reported increased sIL-6Rα levels(66-69). A related protease, ADAM10, has been
implicated in constitutive shedding of IL-6Rα, while ADAM17 is better known for rapid,
inducible shedding(38, 61).

INTERLEUKIN 6 TRANS SIGNALING AND DISEASE
IL-6 has comparable binding affinity to soluble IL-6Rα as it does for membrane-bound
IL-6Rα (mIL-6Rα). By binding IL-6 to form the IL-6/sIL-6Rα complex, soluble IL-6Rα
prolongs the plasma half-life of IL-6(70). At the same time, IL-6/IL-6Rα complex acts
agonistically, interacting with gp130 to initiate signaling, allowing for activation of cells not
responsive to IL-6 alone. Thus, soluble IL-6Rα provides an alternative mechanism of gp130
activation, which serves to widen the spectrum of IL-6-responsive cells and amplify IL-6 effects,
leading to important roles in chronic pathological states(44, 71).
IL-6 trans signaling has been implicated in the pathogenesis of a number of chronic
diseases, including myocardial fibrosis(72), rheumatoid arthritis(73), asthma(74), inflammatory
bowel disease (colitis) and colitis-associated cancer(38). IL-6 and sIL-6Rα levels are elevated in
association with these diseases and reported to contribute to their pathogenesis. Effects in
suppressing the generation of regulatory T cells (Treg) and promoting differentiation of T helper 2
(Th2) and T helper 17 (Th17) cells are important in chronic inflammatory and autoimmune
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diseases. By promoting osteoclast differentiation and angiogenesis via stimulation of synovial
fibroblast cells to produce receptor activator of NF-κB ligand (RANKL) and vascular endothelial
growth factor (VEGF), IL-6 is implicated in the pathogenesis of arthritic conditions, most
prominently in rheumatoid arthritis. Its induction of cellular proliferation, like in lymphoid and
epithelial cells, contributes to tumor growth and development and has significant ramifications
on inflammation-associated cancer, multiple myeloma, and lymphomas(71, 75). Given this
knowledge, studies have also been conducted to specifically block IL-6 trans signaling in vivo,
with resulting amelioration of disease, in colitis, arthritis, sepsis, asthma, and cancer(76-80).

INTERLEUKIN 6 SIGNALING AND FIBROSIS
In terms of its role in fibrosis, levels of IL-6 and soluble IL-6Rα are elevated in chronic
hepatitis and liver cirrhosis and correlate with disease severity, suggesting involvement of IL-6
trans signaling(81). In the kidneys, adenosine A2B receptor-mediated induction of IL-6 leads to
excessive pro-collagen production, resulting in renal fibrosis. Interleukin 6 is also said to
stimulate mesangial cell proliferation(75, 82). In the heart, IL-6 mediates the differentiation of
cardiac fibroblasts to myofibroblasts (the main effector cell of fibrosis) and contributes to cardiac
hypertrophy and myocardial fibrosis(72). IL-6 has been reported to promote collagen production
in dermal fibroblasts(75). Increased IL-6 levels correlated with extent of skin fibrosis in systemic
sclerosis(83), and levels of sIL-6Rα are increased in cases of systemic sclerosis patients with
pulmonary fibrosis(84).
In the lungs, IL-6 is important in airway remodeling in asthma(85), induces the
conversion of human lung fibroblasts to myofibroblasts(35), and promotes pancreatitisassociated lung injury(86). However, the role of IL-6 in pulmonary fibrosis was not defined until
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O’Donoghue et al. demonstrated that IL-6 ablation attenuated fibrosis in a bleomycin-induced
murine model(87). Pedroza et al previously demonstrated that IL-6 contributes to pulmonary
fibrosis when they reported that genetic or pharmacologic removal of IL-6 resulted in attenuation
of fibrosis(29). What is not known from those studies, though, is the role of IL-6 trans signaling
in pulmonary fibrosis.
It is with the intention of mending this deficit in knowledge that we have designed a
project to examine the role of IL-6 trans signaling in pulmonary fibrosis. We will be using IPF
human samples obtained from Methodist Hospital as well as two murine models of pulmonary
fibrosis to evaluate the role of this pathway in pulmonary fibrosis.

INTRAPERITONEAL BLEOMYCIN (IPB) MODEL OF PULMONARY FIBROSIS
The general consensus at this time is that there is no adequate model for IPF, though
previous models have employed the use of bleomycin, silica, fluorescein isothiocyanate (FITC),
irradiation, or other agents. The most frequently used model is one that involves exposure to
bleomycin. Bleomycin is a chemo-therapeutic agent known to cause pulmonary fibrosis in a
portion of patients exposed to it. This is secondary to the lower level of the enzyme bleomycin
hydrolase (responsible for inactivating bleomycin) in the lungs(88). Models of repetitive
bleomycin exposure have been demonstrated to better recapitulate features of IPF(89). Our lab
currently uses the repetitive intraperitoneal bleomycin (IPB) model of pulmonary fibrosis (Figure
1.3). In this model, mice are given intraperitoneal injections of bleomycin twice weekly for four
weeks, which lead to progressive development of pulmonary fibrosis(33, 90, 91). This model of
chronic bleomycin exposure has been demonstrated to recapitulate features of IPF, such as the
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presence of hyperplastic airway epithelial cells and fibrosis that radiates inward from the pleural
surfaces and is progressive, irreversible and lethal(92, 93).

Figure 1.3. Intraperitoneal Bleomycin (IPB) mouse model of pulmonary fibrosis. Wildtype
C57Blk6 male mice were injected intraperitoneally with saline or bleomycin twice weekly for 4
weeks, resulting in progressive development of pulmonary fibrosis. Mice were sacrificed and
samples collected on day 33.

Figure 1.4. Adenosine deaminase (ADA)-deficient mouse model of pulmonary disease.
ADA-deficient (ADA-/-) mice were identified at birth and maintained on PEG-ADA enzyme
replacement therapy until postnatal day 25. Therapy is then discontinued and endogenous
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adenosine allowed to accumulate in the lung. Mice were sacrificed and samples collected for
analysis on postnatal day 42.

ADENOSINE DEAMINASE (ADA)-DEFICIENT MODEL OF PULMONARY FIBROSIS
Another mouse model of pulmonary disease typically used by our laboratory is the
Adenosine Deaminase (ADA)-deficient model (Figure 1.4). The benefit of this model is that it
allows for evaluation of the role of adenosine in lung disease that consists of pulmonary fibrosis
and emphysema(28).
Blackburn et al first reported the generation of a viable mouse with complete genetic
deficiency in the enzyme ADA, an enzyme necessary to metabolize adenosine. ADA-deficient
mice exhibited severe metabolic disturbances and pulmonary insufficiency resulting in mortality
in the postnatal period(94). Specifically, ADA-deficient mice exhibited abnormal alveogenesis,
pulmonary inflammation and airway obstruction(95). The use of ADA enzyme supplementation
in these mice resulted in reduction of metabolic disturbances and survival of the animals(96).
The model now employs the use of enzyme replacement therapy from postnatal day 1 to
25 to allow normal pulmonary development in ADA-deficient mice. Discontinuation of therapy
allows endogenous adenosine levels to rise, leading to increasing pulmonary inflammation,
emphysematous distal airway enlargement and progressive development of pulmonary
fibrosis(29, 97). These mice exhibited features similar to IPF, such as fibroblastic foci and
hyperplastic airway epithelial cells (AEC)(29, 30).
Use of the ADA-deficient model allowed for exploration of adenosine in regulating
events pertinent in lung injury and fibrosis. Chunn et al revealed that chronic elevation of
endogenous adenosine in ADA-deficient mice resulted in pulmonary inflammation, expression
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of profibrotic mediators and collagen deposition, and that these effects were all reversible with
therapeutic administration of the enzyme ADA to lower adenosine(28). Blackburn et al reported
that the effects of IL-13 on pulmonary inflammation, remodeling and fibrosis are mediated
through augmentation of adenosine and its receptors(98). The adenosine A1 receptor (A1AR)
serves an anti-inflammatory, protective role in adenosine-mediated lung injury(99). ADAdeficient mice lacking adenosine 2A receptor (A2AAR) experienced enhanced pulmonary
inflammation, angiogenesis and mucin production(100). Antagonism of the adenosine 2B
receptor (A2BAR) resulted in a reduction in pulmonary inflammation, fibrosis and alveolar
airspace enlargement(97). Genetic removal of A2BAR in ADA-deficient mice, however, resulted
in loss of barrier function and neutrophilia with resulting enhancement of inflammation and
remodeling(101). This suggests a protective role for the A2BAR in acute stages. The adenosine 3
receptor (A3AR) is important in regulating neutrophilia and mucus production in the lungs(102).
Using this model, Schneider et al supported a role for osteopontin in mediating neutrophilia and
alveolar airspace enlargement(30). Pedroza et al supported a role for interleukin 6 in promoting
pulmonary inflammation and remodeling(29).

DISSERTION OVERVIEW
Idiopathic pulmonary fibrosis is a deadly lung disease that causes chronic, progressive,
irreversible fibrosis. IPF has a highly variable and unpredictable natural history. Most patients
experience respiratory decline with resulting respiratory failure and death within 2-3 years from
diagnosis. There are no known causes for IPF, no cure, and at this time, no effective therapies
available. The mortality rate for IPF is even worse than that of many malignancies. Of even
greater concern is the fact that within the last two decades, there has been a trend for increasing
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prevalence and incidence rates for IPF. There is an urgent need to better understand the pathways
and events that govern the onset and progression of pulmonary fibrosis in order to remedy the
lack of effective therapies. Production of the signaling nucleoside adenosine in response to lung
injury is an important factor in the regulation of fibrosis. Adenosine, through activation of its
adenosine 2B receptor (A2BR), initiates production and release of the cytokine interleukin 6 (IL6) in mice and humans with pulmonary fibrosis. Inhibition of IL-6, via pharmacologic blockade
or genetic removal, resulted in attenuation of pulmonary fibrosis in mice. IL-6 can mediate
tissue-protective effects via its membrane-bound receptor (mIL-6Rα) in a process termed
classical signaling. However, when IL-6 signals through an alternative trans pathway, via the
soluble form of its receptor (sIL-6Rα), the cytokine appears to exert a pro-fibrotic role.
Preliminary data reveals increased levels of sIL-6Rα in the lungs of mice and patients with
pulmonary fibrosis, suggesting involvement of IL-6 trans signaling. However, the role of IL-6
trans signaling in pulmonary fibrosis has not been examined. Given the findings in our lab, along
with published literature implicating IL-6 trans signaling in the pathogenesis of other chronic
inflammatory and fibrotic disorders, we developed the following specific aims to test the
HYPOTHESIS that: interleukin-6 trans signaling is critical for the development of
pulmonary fibrosis and in vivo neutralization of this pathway will attenuate fibrosis.

Specific Aim 1: To quantify levels of soluble IL-6Rα and characterize classical and trans
signaling components during the development and progression of pulmonary fibrosis.
We quantified soluble IL-6Rα levels in plasma and bronchoalveolar lavage fluid during
disease progression in the intraperitoneal bleomycin model. We characterized and monitor
changes in expression of membrane-bound IL-6Rα and soluble IL-6Rα over time. Utilizing dual
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staining protocols, we identified the pulmonary cell types that are responsive to IL-6 and
delineate those that exhibit classical signaling versus those responding to trans signaling. The
findings were validated in explanted human IPF lung samples, and the results from this aim are
presented in Chapter 3.

Specific Aim 2: Assess the role of protease-mediated shedding in the production of soluble
IL-6Rα during the development and progression of pulmonary fibrosis.
We characterized ADAM17 expression during development of pulmonary fibrosis in the IPB
model. To establish the role of ADAM17 as the main protease responsible for the generation of
sIL-6Rα in pulmonary fibrosis, we conducted in vitro stimulation and neutralization experiments
using bone marrow derived macrophages as well as primary alveolar macrophages. We
conducted experiments to directly stimulate shedding of IL-6Rα from cultured macrophages via
activation of ADAM 17 and to prevent IL-6Rα shedding using a pharmacologic inhibitor of
ADAM17 and ADAM17 siRNA. The results from this aim are presented in Chapter 4.

Specific Aim 3: Evaluate the therapeutic benefit of blocking IL-6 trans signaling in
pulmonary fibrosis.
In order to assess the impact of IL-6 trans signaling on the development of pulmonary
fibrosis, we conducted in vivo neutralization experiments using the IPB model. We subjected
mice to bleomycin exposure while also co-injecting them with either PBS alone (vehicle control)
or mouse recombinant gp130Fc (to selectively inhibit trans signaling). We assessed pulmonary
phenotypes, inflammation, various indexes of pulmonary fibrosis, and downstream mediators of
IL-6 signaling to determine the contribution of trans signaling. We stimulated IL-6 trans
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signaling in normal and IPF fibroblasts in vitro and assess changes to proliferation and
extracellular matrix protein production. The results from this aim are presented in Chapter 5.

Specific Aim 4: To characterize IL-6 trans signaling in a murine model of pulmonary
fibrosis and emphysema, the ADA-deficient model, and assess the impact of trans signaling
by neutralizing it in this model.
We attempted to verify results obtained in the IPB model by repeating experiments in the
above three aims but this time using the ADA-deficient model. We characterized changes in IL-6
classical and trans signaling as well as ADAM17 expression during onset and progression of
disease in the ADA-deficient model and conducted in vivo neutralization of IL-6 trans signaling
in ADA-deficient mice and assess changes to pulmonary inflammation and pulmonary fibrosis.
The results from this aim are presented in Chapter 6.

By accomplishing the above aims, we sought to gain novel insights about the pathogenesis of
IPF that will translate into more effective therapies for patients.
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CHAPTER 2
Experimental
Procedures
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HUMAN IPF SAMPLES
Deidentified explanted lung samples from IPF patients were obtained from the Methodist
Hospital J.C. Walter Jr. Transplant Center. Collection and use of these tissues for research were
in accordance with the guidelines approved by the Methodist Hospital Institutional Review
Board. Lung samples taken from unaffected lobes of IPF patients were used as controls.

ANIMALS
Mice used were ordered from Harlan Laboratories. They were inbred, male
C57Bl/6NHsd mice, 4-5 weeks old. Once they arrive at our institution, mice were allowed a
week to acclimate to their environment before the start of experiments. Maintenance and care of
animals were in accordance with NIH guidelines and those set by the Animal Welfare
Committee at the University of Texas Health Science Center at Houston. Mice were housed in
ventilated cages equipped with microisolator lids and maintained under strict containment
protocols. Housing conditions consisted of ambient temperature of 22°C and 12-hour light/dark
cycles, and mice were provided with food and water ad libium. All study designs were reviewed
and approved by the Animal Welfare Committee.

INTRAPERITONEAL BLEOMYCIN (IPB) MODEL
Male C57Bl/6 mice, 4-5 weeks old, were treated with intraperitoneal injections of saline
or bleomycin (Teva Pharmaceutical, Petach Tikva, Israel) (0.035U/g) diluted in sterile 1X
Phosphate Buffered Saline (PBS). A total of 8 injections were given twice a week for 4 weeks.
Mice were sacrificed at the end of the model, on day 33, and samples were collected to assess
pulmonary phenotype (Figure 1.3).

42

For the time course experiment, to evaluate pulmonary phenotype during development
and progression of disease in the model, mice were sacrificed at various points in the model, on
days 5, 10, 15, 20, 25, and 33. Day 0 mice are wildtype mice, who have not received any
injections, saline or bleomycin.

ADENOSINE DEAMINASE (ADA) DEFICIENT MODEL
Adenosine deaminase heterozygous (ADA+/-) and homozygous (ADA-/-) mice were
generated (on a C57Blk/6J background) and genotyped as described previously(96). Mice
homozygous for the ADA-null allele were identified at birth and supported with polyethylene
glycol modified ADA (PEG-ADA) enzyme therapy from postnatal day 1 to day 25 (Figure 1.4).
Intramuscular injections were given on days 1, 5, 9, 13 and 17 (0.625, 1.25, 2.5, 2.5 and 2.5 units
respectively). Intraperitoneal injections were given on days 21 and 25 (5 units each). Analysis of
pulmonary phenotypes was performed on postnatal day 42. All comparisons were done among
littermates of ADA-competent (ADA+/-) and ADA-deficient (ADA-/-) mice.

SOLUBLE GP130 INHIBITION OF INTERLEUKIN-6 TRANS SIGNALING
In vivo neutralization of interleukin 6 trans signaling was performed using recombinant
mouse gp130Fc chimera (R&D Systems) (Figure 5.1A). In the IPB model, male C57Bl/6 mice,
4-5 weeks old, were treated with bleomycin or vehicle (saline) intraperitoneally twice a week for
4 weeks. Beginning on day 19 and continuing daily until day 32, mice were treated with saline
(200µl 1X sterile PBS) or gp130Fc (250ng-2µg/mouse reconstituted in 200µl sterile PBS)
(Figure 5.1B). On treatment days that coincide with bleomycin injections, mice received
gp130Fc injections 1-2 hours before bleomycin. On day 32, arterial oxygen saturation levels
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were measured. On day 33, animals were sacrificed and samples collected to assess changes to
pulmonary phenotype.
In the ADA-deficient model, starting on postnatal day 30, mice were treated with saline
(200µl 1X sterile PBS) or gp130Fc (1µg/mouse reconstituted in 200µl sterile PBS) until day 41
(Figure 6.4A). On day 42, animals were sacrificed and samples collected to assess changes to
pulmonary phenotype.
The dosage and schedule of administration of soluble gp130 are adapted from previous
published studies that have shown effectiveness of this reagent in vivo(76-80, 103). The decision
of when to begin treatment with soluble gp130 was based on preliminary data regarding the
temporal course of disease development in both models (Figure 3.3 & 6.1).

ASSESSMENT OF ARTERIAL OXYGEN SATURATION
Assessment of arterial oxygen saturation was performed on conscious mice on day 32
using the pulse MouseOx software analysis (STARR Life Sciences Corp, Oakmont, PA). Mice
were shaved on day 31 to remove the hair around the neck to allow proper measurements by
collar clip light sensor. The MouseOx utilizes pulse oximetry measurements of light absorption
from the red and infrared LEDs (Light Emitting Diodes) to determine real-time percent oxygen
saturation of functional arterial hemoglobin.

MEASUREMENT OF RIGHT VENTRICULAR SYSTOLIC PRESSURE (RVSP)
Protocol for measurement of right ventricular systolic pressure (RVSP) is as previously
published(91). Briefly, mice were anesthetized with avertin and placed on heated pad
(Deltaphase Isothermal model 39; Braintree Scientific, Braintree, MA). Tracheostomy was
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performed and mice were connected to a ventilator (MiniVent, Hugo-Sachs Elektronik, MarchHugstetten, Germany) via a 19-gauge blunt needle (Brico, Dayton, NJ). Mice were maintained
on volume of 250µl and rate of 100/minute. Using a surgical microscope (SMZ-2B, Nikon,
Tokyo, Japan), the abdomen was accessed through an incision made below the xiphoid process.
A retractor (ALM-112, Braintree Scientific) was used to visualize abdominal contents. The heart
was exposed through an incision in the diaphragm and pericardium was removed. The right
ventricle (RV) was punctured with 27-gauge needle and catheterized with a 1-french pressure
catheter (SPR-1000, Millar Instruments, Houston, TX). RVSP was recorded using Chart5.3
software (AD Instruments).

COLLECTION OF BLOOD AND ISOLATION OF PLASMA
Mice were anesthetized with avertin and blood was collected via needle aspiration of the
left ventricle. Plasma was isolated via centrifugation at 10,000xG for 10 minutes at 4°C and flash
frozen for storage at -80°C for later use in ELISA analyses.

BRONCHOALVEOLAR LAVAGE (BAL) FLUID COLLECTION, CELL COUNT AND
DIFFERENTIALS
After collection of blood, the mouse trachea was exposed and cannulated to perform
bronchoalveolar lavage. Lungs were lavaged 4 times with 0.3 ml sterile PBS each;
approximately 1ml of pooled lavage fluid per mouse was recovered. An aliquot was sampled to
determine total BAL cells using a hemocytometer. The rest of the BAL fluid was spun at 1200
rpm for 5 minutes at 4°C. The supernatant was removed, aliquoted and flash frozen. Cell pellets
were resuspended in 100µl sterile PBS and aliquots were spun onto microscope slides (50µl for
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PBS samples, 10-20µl for bleomycin samples). The slides were stained with Diff-Quick (Dade
Behring, Deerfield, IL) and cellular differentials were performed. Remaining cells were pelleted
once again at 10,000xG for 5 minutes at 4°C and supernatant was removed. Cell pellets were
flash frozen. BAL fluid supernatant aliquots and cell pellets were stored at -80°C for later use in
protein quantification, ELISA and western blot analyses.

HISTOLOGY
After lavage was performed, mouse lungs were inflated with 10% phosphate buffered
formalin at 25 cm of pressure and fixed at 4°C overnight. Formalin-fixed lungs were dehydrated
through an ethanol gradient and paraffin-embedded. 5µm sections were cut and collected on
microscope slides for use in fibrosis assessment and immunohistochemistry staining.

IMMUNOSTAINING OF PARAFFIN-EMBEDDED LUNG SECTIONS
Lung sections were rehydrated through an ethanol gradient to water. Rehydrated sections
were incubated in 10% hydrogen peroxide to quench endogenous peroxidases. Antigen retrieval
(Dako Corp.) was performed at 95°C for 20 minutes and slides were allowed to cool to room
temperature for 20 minutes. Endogenous avidin and biotin were blocked using the Biotin
Blocking System (Dako Corp., Carpinteria, CA). Slides were blocked in 3% blocking solution
(goat or rabbit serum in PBS) for 1 hour at room temperature then incubated at 4°C overnight in:
anti-STAT3 (phospho S727) antibody (rabbit polyclonal, 1:100 dilution, Abcam, Cambridge,
MA), anti-prosurfactant protein C (proSP-C) (rabbit polyclonal, 1:1000 dilution, EMD Millipore,
Billerica, MA), anti-human S100A4 (rabbit polyclonal, 1:200 dilution, Dako Corp.), arginase 1
antibody (H-52) (rabbit polyclonal, 1:100 dilution, Santa Cruz Biotechnology, Dallas, TX), anti-
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ADAM17 (rabbit polyclonal, 1:100 dilution at 37°C for 1 hour, EMD Millipore). For alphaSMA staining, slides were processed with a Mouse on Mouse kit per manufacturer protocols
(Vector Laboratories, Burlingame, CA). Slides were then incubated in anti-actin, α smooth
muscle antibody (1:1000 dilution, 4°C overnight, mouse monoclonal clone 1A4, Sigma-Aldrich,
St. Louis, MO).
After incubation with primary antibodies, all sections were incubated at room
temperature for 1 hour in appropriate biotinylated secondary antibodies. Vectastain ABC
peroxidase rabbit IgG kit (Vector Laboratories) and 3,3’-diaminobenzidine (Sigma-Aldrich)
were used to develop stains for P-STAT3 and ADAM17. Vectastain ABC Alkaline Phosphatase
Standard Kit (Vector Laboratories) and Vector Alkaline Phosphatase substrate kit (Vector
Laboratories) were used to develop stains for alpha-SMA, pro-SPC, S100A4, and arginase 1. All
sections were counterstained with methyl green. Slides were mounted with cover slip and
Vectashield (Vector Laboratories) mounting medium.

IMMUNOFLUORESCENCE OF BAL CELLS
Aliquots of resuspended BAL cell pellets were cytospun onto microscope slides, allowed
to air-dry, then fixed in 3.7% paraformaldehyde in PBS for 10 minutes and permeabilized in cold
methanol for 10 minutes. Slides were blocked in 1% bovine serum albumin in PBS for 1 hour at
room temperature and then incubated in: anti-human CD126 (IL-6R) antibody (1:50 dilution,
4°C overnight, mouse monoclonal, ABD Serotec, Raleigh, NC). Incubation in secondary
antibody, Alexa Fluor 488 rabbit anti-mouse IgG (1:1000 dilution, Life Technologies, Grand
Island, NY) occurred for 1 hour at room temperature, protected from light. Slides were mounted
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with coverslip and Prolong Gold antifade medium with DAPI (Life Technologies) and let air dry,
protected from light.

DUAL IMMUNOFLUORESCENCE OF LUNG SECTIONS FOR P-STAT3 AND α-SMA
Rehydrated sections were processed as in above section on immunostaining with regards
to hydrogen peroxide quench, antigen retrieval, avidin/biotin block, and serum block. Slides
were incubated in anti-STAT3 (phospho S727) antibody (1:100 dilution, O/N, 4°C) then in
appropriate secondary antibody for one hour at room temperature. ABC Alkaline Phosphatase
Standard Kit and Vector Alkaline Phosphatase Substrate Kit were used to develop P-STAT3 as a
red fluorescence. From this point forward, all steps were performed in the dark and slides were
protected from light. Slides were washed in PBS to remove excess substrate and then processed
using the Mouse on Mouse Kit. Sections were incubated in blocking reagent for 1 hour at room
temperature then reagent diluent for 5 minutes at room temperature and then incubated in antiactin, α smooth muscle antibody (1:500 dilution, 4°C overnight). Secondary antibody incubation
in Alexa Fluor 488 rabbit anti-mouse IgG (1:1000 dilution) was performed for 1 hour to allow
detection of alpha-SMA as a green fluorescence. Slides were mounted with coverslip and
Prolong Gold antifade medium with DAPI and let air dry, protected from light.

FIBROSIS ASSESSMENT
Rehydrated lung sections were stained using a Masson’s trichrome protocol. Fibrosis was
quantified using the Ashcroft method of scoring. Scoring was performed blinded with regards to
animal treatment. All areas of the lung were scored and an overall average score was given per
lung section.
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The Sircol assay (Biocolor Ltd., Carrick, UK) was used to measure soluble collagen
content in BAL fluid. Transcript levels of collagen isoforms were quantitated using whole lung
mRNA. Fibronectin expression was determined using western blot analysis of lung lysates.

WESTERN BLOT ANALYSES OF PROTEIN LYSATES AND BAL FLUID
Protein lysates were prepared by homogenizing frozen lung tissue in cold protein lysis
buffer (1M Tris pH 7.4, 1M NaCl, 1% Triton-X 100) containing 1X protease inhibitor cocktail
(Thermo Scientific, Rockford, IL). Lysates were centrifuged at 14,000 rpm for 10 minutes at
4°C, supernatant was removed and aliquoted for use in western blot analysis. Protein
concentrations were determined using the Bradford assay (Bio-rad, Hercules, CA). Equal
amounts of total protein per sample (25-50µg) were prepared in SDS-Sample Buffer (6X,
reducing, Boston Bioproducts, Ashland, MA) and incubated at 95°C for 5 minutes.
Electrophoresis was performed on 10-12% SDS-PAGE gels (Bio-rad). Transfer onto ImmobilonP PVDF membranes (EMD Millipore) was conducted at 100V for 2 hours at 4°C. Membranes
were allowed to air dry, were trimmed and blocked with 5% (w/v) non-fat, dehydrated milk in
Tris-buffered saline-tween 20 (TBST) for 1 hour at room temperature. Membranes were then
incubated with shaking at 4°C overnight in: anti-human CD126 (IL-6R (1:500 dilution, mouse
monoclonal, ABD Serotec), anti-STAT3 (phospho S727) antibody (1:500 dilution, rabbit
polyclonal, Abcam), anti-ADAM17 (1:2000, rabbit polyclonal, Millipore), anti-fibronectin,
cellular antibody (1:2000, mouse monoclonal clone FN 3E2, Sigma-Aldrich) and anti-β-Actin
antibody (1:5000, mouse monoclonal clone AC-74, Sigma-Aldrich). Membranes were rinsed in
TBST and incubated with appropriate horseradish-conjugated secondary antibodies for 1 hour at
room temperature with shaking. Secondary antibodies used were: anti-rabbit IgG HRP-linked
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antibody (1:1000-4000 dilution, Cell Signaling, Danvers, MA) anti-mouse IgG HRP-linked
antibody (1:1000-10,000 dilutions, Cell Signaling). Signal was developed using Thermo
Scientific Chemiluminescent Substrate.
For BAL fluid samples, equal volumes of samples were prepared in 6X SDS sample
buffer and processed as detailed above.

ANALYSIS OF WHOLE LUNG RNA
Total RNA was isolated from frozen lung tissue using TRIzol reagent (Invitrogen) per
manufacturer protocol. Samples were treated with RNAse-free DNAse 1 (Invitrogen) and used
for quantitative real-time RT-PCR analysis. cDNA was made using Superscript II reverse
transcriptase (Invitrogen). Equal amounts of cDNA were analyzed for transcript levels of
COL1A2 and MCP-1 with normalization to beta actin and/or peptidylprolyl isomerase A (PPIA).
Primer sets used were: COL1A2 – forward 5’-AAGGGTGCTACTGGACTCCC-3’ and reverse
5’-TTGTTACCGGATTCTCCTTTGG-3’.

Primers

for

MCP-1

were:

forward

5’-

AGCATCCACGTGTTGGCTC-3’ and reverse 5’-TGGGATCATCTTGCTGGTG-3’. Data
presented as mean normalized transcript levels using the comparative Ct method.

ELISA ANALYSIS OF SOLUBLE INTERLEUKIN 6 RECEPTOR ALPHA (sIL-6Rα) IN
PROTEIN LYSATES, BAL FLUID AND PLASMA
Soluble IL-6Rα was quantified in protein lysates made from COPD & IPF lungs using
the Human IL-6R Alpha Duoset ELISA kit (R&D Systems). 10µl of lysate was diluted in 90µl
reagent diluent and subjected to ELISA analysis per manufacturer protocol. Murine BAL fluid
and plasma samples were processed using the Mouse IL-6R Alpha Duoset ELISA kit (R&D
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Systems). For BAL fluid samples, 100µl was used. For plasma samples, 10µl of plasma was
diluted in 90µl reagent diluent.

BONE MARROW MACROPHAGE ISOLATION AND CULTURE
Male C57Bl/6 mice, 4-5 weeks old, were euthanized via cervical dislocation technique.
Both femurs were isolated, removed and cleaned of surrounding muscles and tissues. The ends of
each femur were carefully cut off and a 5ml syringe with 21-22G needle was used to flush the
bone marrow cavity of the femur with complete macrophage medium, which is Dulbecco’s
Modification of Eagle’s Medium (Fisher Scientific) supplemented with 10% fetal bovine serum
and 20% L929 media supplement (see below for protocol for growing L929 cells and making
L929 media supplement). Femur cavity was flushed with 2-5ml of media, until bone appears
white. Flushed media was collected in a sterile 50ml conical tube and centrifuged at 500 X g for
10 minutes at room temperature to pellet cells. Cells were resuspended in macrophage media,
counted and plated in 100mm bacterial dishes (not tissue culture treated dishes). Plate cells to
have a total of 3-5x106 cells in 7.5ml media per dish. A yield of approximately 10-15 dishes is
typical per mouse. Cells were incubated at 37°C, 5% CO2 for 4 days, supplemented with an extra
5ml of media per dish and cultured until day 7-8, by which time most adherent cells are
macrophages. On day 7-8, culture media was discarded, fresh media was added (5ml per dish)
and a cell scraper was used to dislodge adherent cells. Detached cells were collected in 50ml
conical tube and centrifuged at 400 X g for 10 minutes at 4°C. Cells were then resuspended in
macrophage media and seeded in tissue culture plates for experiments.
To make L929 media supplement, L929 cells were obtained from our collaborator, Dr.
Sandeep Agarwal (Baylor College of Medicine, Department of Internal Medicine). Cells were
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plated at a density of 5x105 cells per T75 flasks in 55ml of media consisting of DMEM with 1%
HEPES, 1% penicillin-streptamycin, 1% L-glutamine and 10% fetal bovine serum. Cells were
cultured for 7 days, then media was harvested and sterile filtered for addition to macrophage
culture media.

DIFFERENTIATION OF MACROPHAGES WITH IL-4 AND IL-13
Day 7-8 bone-marrow-derived macrophages were plated in 6-well plates at a density of
1.5-2x106 cells/well and allowed to adhere 2-3 hours at 37°C, 5% CO2. Culture media and nonadherent cells were removed after 3 hours. Cells were then incubated in macrophage media
containing IL-4 (20 ng/ml) and IL-13 (10 ng/ml) (Peprotech, Rocky Hill, NJ) for 72 hours. Fresh
reagents were added daily. After 72 hours, macrophages were washed with sterile PBS and used
in TAPI-1 experiments.

TAPI-1 INHIBITION OF ADAM17 IN MACROPHAGES
The reagent phorbol 12-myristate 13-acetate (PMA) is known to activate ADAM17 and
induce receptor and substrate shedding. IL-4/IL-13-stimulated macrophages were incubated in
serum-free media containing PMA (10µg/ml, Enzo Life Sciences, Farmingdale, NY) for 2-3
hours at 37°C, 5% CO2, to activate ADAM17 and induce membrane IL-6Rα shedding. Inhibition
of ADAM17 activity was carried out by pre-incubation of macrophages with TNFα protease
inhibitor 1 (TAPI-1) (20µM) for 1 hour followed by PMA stimulation in the presence of TAPI-1.
After 2-3 hours exposure to media alone, media and TAPI-1, PMA alone, or PMA and TAPI-1,
culture media was collected and soluble IL-6Rα was quantified using ELISA. Macrophages were
washed with PBS and lysed in RIPA lysis buffer containing protease inhibitors. 5-10µg of
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protein per sample were subjected to western blot analysis to determine expression of arginase 1
(rabbit polyclonal antibody, 1:200 dilution, O/N incubation, 4°C, Santa Cruz), IL-6R (antihuman CD126 (IL-6R) antibody, mouse monoclonal, 1:500 dilution, 4°C overnight, ABD
Serotec, 1:500 dilution, O/N, 4°C), and ADAM17 (rabbit polyclonal antibody, 1:500 dilution,
O/N incubation, 4°C, EMD Millipore).

ADAM17 SIRNA SILENCING IN MACROPHAGES
For siRNA silencing of ADAM17, day 7-8 bone-marrow-derived macrophages were
resuspended in antibiotics-free macrophage media and seeded in 6-well plates and allowed to
adhere for 2-3 hours. Cells were then incubated in antibiotics-free media containing IL-4, IL-13,
Optimem (Invitrogen) with Lipofectamine RNAiMax (Invitrogen) and ADAM17 siRNA or
scrambled control siRNA (Sigma-Aldrich) for 24 hours. Final concentration of siRNA was
100nM. After 24 hours, media was changed and a second transfection was performed with fresh
reagents. Macrophages were incubated in the second transfection media for 48 hours. Fresh IL-4
and IL-13 were added to culture media daily. After 72 hours of stimulation and transfection, nontransfection macrophages, macrophages transfected with control siRNA, and macrophages
transfected with ADAM17 siRNA were stimulated with PMA in serum-free conditions for 2
hours. Culture media were collected and soluble IL-6Rα levels were quantified using ELISA.
Cells were washed with PBS and lysed in RIPA lysis buffer containing protease inhibitors. 510µg of protein per sample were subjected to western blot analysis to determine expression of
arginase 1 (rabbit polyclonal antibody, 1:200 dilution, O/N incubation, 4°C, Santa Cruz), IL-6R
(anti-human CD126 (IL-6R) antibody, mouse monoclonal, 1:500 dilution, 4°C overnight, ABD
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Serotec, 1:500 dilution, O/N, 4°C), and ADAM17 (rabbit polyclonal antibody, 1:500 dilution,
O/N incubation, 4°C, EMD Millipore).

SHEDDING

OF

MEMBRANE

IL-6R

ALPHA

FROM

PRIMARY

LUNG

MACROPHAGES
Bronchoalveolar lavage fluid was collected from Day 33 male C57Bl/6 mice treated with
PBS or bleomycin. Lungs were lavaged 10 times with 0.5 ml sterile PBS each; approximately
5ml of pooled lavage fluid per mouse was recovered. BAL fluid from all PBS mice or all
bleomycin mice were pooled and spun at 1200 rpm for 5 minutes at 4°C. The supernatant was
removed and cell pellets were resuspended in complete macrophage media (RPMI 1640
containing 10% FBS and 1% penicillin-streptomycin). Cells were counted by hemocytometer,
plated in 6-well plates at 1x106 cells/well and allowed to adhere 4 hours at 37°C, 5% CO2.
Culture media and non-adherent cells were removed after 4 hours by washing with serum-free
RPMI. Cells were then incubated in macrophage media containing PMA (10µg/ml, Enzo Life
Sciences, Farmingdale, NY) for 2 hours at 37°C, 5% CO2, to activate ADAM17 and induce
membrane IL-6Rα shedding. Inhibition of ADAM17 activity was carried out by pre-incubation
of macrophages with TNFα protease inhibitor 1 (TAPI-1) (20µM) for 1 hour followed by PMA
stimulation in the presence of TAPI-1. After 2 hours exposure to media alone, PMA alone, or
PMA and TAPI-1, culture media was collected and soluble IL-6Rα was quantified using ELISA.

CONTROL AND IPF FIBROBLAST CELL LINES
CCD8Lu and LL97A (AlMy) are control and IPF fibroblast cell lines, respectively,
purchased from American Type Culture Collection (ATCC, Manassas, VA). CCD8Lu was
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cultured in ATCC-formulated Eagle’s Minimum Essential Medium (ATCC), supplemented with
10% fetal bovine serum and 1% penicillin-streptomycin-amphotericin B mix. LL97A was
cultured in Ham’s F12K medium (ATCC) supplemented with 15% fetal bovine serum and 1%
penicillin-streptomycin-amphotericin B mix. Both cell lines were maintained in T75 flask with
10ml medium, at 5% carbon dioxide atmosphere in a 37°C humidified incubator. Medium was
changed every 3 days and cells were passaged using trypsin. For stimulation experiments, cells
were used between passages 4-8.

IN VITRO STIMULATION OF INTERLEUKIN 6 TRANS SIGNALING IN CCD8LU
AND LL97A
To assess the effects of IL-6 trans signaling on fibroblast proliferation, CCD8Lu and
LL97A cells were plated in 96-well plates at a density of 3-5x103 cells/well. They were cultured
until they reached 70-80% confluency, then washed with sterile PBS and serum starved for 24
hours. After 24 hours in their respective serum-free media, cells were maintained in serum-free
conditions and stimulated for 48 hours with: recombinant human TGF beta 1 (10ng/ml),
recombinant human IL-6 (50ng/ml), or IL-6 (50ng/ml) + recombinant human IL-6R alpha
(100ng/ml) (R&D Systems). Fresh reagents were added to culture media every 24 hours. Total
volume per well was 100µl after 48 hours. Cells were then subjected to proliferation analysis
using the Apo Tox-Glo Triplex Assay kit protocol (Promega, Madison, WI). Briefly, viability
reagent was added per well and fluorescence was measured after 30 minutes incubation at 37°C.
To assess effects of IL-6 trans signaling on extracellular matrix protein production,
CCD8Lu and LL97A cells were seeded in 6-well plates at a density of 1x105 cells/well. They
were allowed to reach 70-80% confluency, then washed with sterile PBS and serum starved and
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stimulated as mentioned above. After 48 hours of stimulation, cells were washed with PBS and
lysed in RIPA lysis buffer supplemented with protease inhibitor cocktail. Protein lysates were
subjected to western blot analysis (as detailed above) to detect extracellular matrix protein
production. Typically 5-10µg of protein per sample was loaded. Incubation was performed in
primary antibodies for collagen 1 (rabbit polyclonal, Abcam, 1:500 dilution, 48 hours, 4°C) and
fibronectin EDA (mouse monoclonal clone FN 3E2, Sigma-Aldrich, 1:4000 dilution, O/N, 4°C).

STATISTICAL ANALYSIS:
Experimental results were reported as mean ± standard error of the mean. One-way
ANOVA was used for comparisons among groups, and comparisons between groups were
completed with two-tailed Student’s t-test. Statistical significance for all comparisons were
presented as p-values. A p value less than 0.05 was considered to be significant.
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CHAPTER 3
Interleukin-6 (IL-6)
Classical and Trans Signaling in
Idiopathic Pulmonary Fibrosis (IPF) and
a Chronic Bleomycin Mouse Model
of Pulmonary Fibrosis
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EXPERIMENTAL RATIONALE AND KEY QUESTIONS
Idiopathic pulmonary fibrosis (IPF) is a deadly lung disease that causes chronic,
progressive, and irreversible fibrosis. IPF is characterized by abnormal wound healing processes
related to epithelial cell injury and turnover, fibroblast proliferation and differentiation, and
matrix deposition(2, 104). Most patients experience respiratory decline with resulting respiratory
failure and death within 2-3 years of diagnosis. There are no known causes for IPF and no cure.
At this time, there is no consensus on effective therapies though the use of an antifibrotic
pirfenidone is gaining support(1). The mortality rate for IPF currently surpasses that of many
malignancies, and over the last 2 decades, prevalence and incidence rates have continued to
increase(3, 23, 24). Thus, there is an urgent need to better understand the onset and progression
of pulmonary fibrosis in order to develop effective therapies against IPF.
The cytokine interleukin 6 (IL-6) is elevated in mice and humans with pulmonary
fibrosis(29, 31). IL-6 signals through two pathways, classical and trans (Figure 1.1), via a
receptor complex consisting of the ligand-binding interleukin 6 receptor alpha (IL-6Rα) and the
non-ligand binding, signal-transducing receptor gp130. While gp130 is expressed constitutively
as a membrane-bound receptor, membrane-bound IL-6Rα (mIL-6Rα) is expressed predominantly
on hepatocytes and leukocytes(38, 43-46). IL-6 classical signaling occurs on cells that co-express
mIL-6Rα and gp130, where IL-6 binds mIL-6Rα and associates with two molecules of gp130 to
initiate the intracellular signaling cascade. In the alternative pathway, known as trans signaling,
IL-6 complexes with a soluble form of IL-6Rα (sIL-6Rα) before it can associate with gp130 and
initiate signaling(38, 43, 44, 48). Soluble IL-6Rα is generated via translation of alternatively
spliced mRNA or by protease-mediated cleavage of membrane IL-6Rα to form the soluble
receptor(44, 56-61, 63, 70). In both IL-6 classical and trans signaling, binding of IL-6/IL-6Rα
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with gp130 activates associated Janus kinases and leads to phosphorylation of signal transducer
and activator of transcription 3 (STAT3), which dimerizes and translocates to the nucleus where
it acts as a transcription factor to regulate target genes(49-52). Thus, the presence of phosphoSTAT3 is used as an indication of IL-6-mediated cellular activation.
Because of the limited expression of membrane IL-6Rα, the presence of soluble IL-6Rα,
mediating IL-6 trans signaling, allows for activation of cells not inherently responsive to IL-6.
Thus, soluble IL-6Rα widens the spectrum of IL-6-responsive cells and trans signaling amplifies
IL-6 effects in the body, leading to important roles in chronic pathological states(44, 71). IL-6
trans signaling has been implicated in the pathogenesis of rheumatoid arthritis(73), asthma(74),
inflammatory bowel disease (colitis)(76) and colitis-associated cancer(78). IL-6 and sIL-6Rα
levels are elevated in association with these diseases, and in vivo blockade of IL-6 trans
signaling using the natural inhibitor soluble gp130(105, 106) has resulted in amelioration of
disease(73, 74, 76, 78).
Though the focus in published literature has been on the pathogenic role of IL-6 trans
signaling, it must be noted that classical signaling can contribute to disease as well. As evident in
studies in colitis, where it was demonstrated that IL-6 classical signaling was pathogenic but
trans signaling amplified those effects and contribute to the propagation of disease(76). Using
mouse models of arthritis, Lissilaa et al demonstrated that IL-6 trans signaling was responsible
for local inflammatory reactions but that classical signaling is required to promote T-cellmediated autoimmune responses that result in systemic disease(107). In an allergic asthma
model, Doganci et al demonstrated that sIL-6Rα mediates Th2 functions in T effector cells while
mIL-6Rα regulates differentiation of naïve CD4+ cells towards Th2 phenotype and suppressing
Treg development(108). On the other hand, IL-6 classical signaling has been shown to play
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protective roles in certain human conditions. Hoge et al reported that classical signaling is
responsible for the innate immunity response to and control of Listeria monocytogenes
infection(109). The authors concluded that IL-6 trans signaling does not protect against certain
bacterial infections. Therefore, its blockade may be of more benefit than global blockade of IL-6
signaling in chronic inflammatory diseases.
In terms of fibrosis, what is known is that levels of IL-6 and soluble IL-6Rα are elevated
in systemic sclerosis(83, 110) and liver cirrhosis(81), correlating with disease severity and
suggesting involvement of IL-6 trans signaling. In the kidneys, heart and skin, IL-6 induction
promotes collagen production(72, 75, 82). In the lungs, IL-6 is important in airway remodeling in
asthma(85), induces the conversion of human lung fibroblasts to myofibroblasts(35), and
promotes pancreatitis-associated lung injury(86). However, the role of IL-6 in pulmonary
fibrosis was not defined until O’Donoghue et al. demonstrated that IL-6 ablation attenuated
fibrosis in a bleomycin-induced murine model(87). Pedroza et al demonstrated that IL-6
contributes to pulmonary fibrosis when they reported that genetic or pharmacologic removal of
IL-6 resulted in attenuation of fibrosis(29). What is unclear from those studies, however, is the
differentiation of effects due to IL-6 classical signaling versus IL-6 trans signaling in the lungs.
Whether fibrosis in IPF patients develops due to effects of IL-6 classical signaling alone
or trans signaling alone or a mixture of both pathways is unclear. It is important to understand
this differentiation in order to develop targeted therapies for IPF since current therapies with
immunosuppressants carry with them many adverse side effects(1, 111, 112). Thus, to begin to
determine if IL-6 classical and/or trans signaling may be important in the pathogenesis of IPF, it
was necessary to first assess whether these pathways are enhanced in IPF lungs and characterize
them more thoroughly by answering the following questions:
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3.1

Is soluble IL-6Rα increased in patients with Idiopathic Pulmonary Fibrosis?

3.2

Is soluble IL-6Rα increased in bleomycin-induced pulmonary fibrosis?

3.3

What happens to soluble IL-6Rα levels as pulmonary fibrosis develops and
progresses in this model?

3.4

Is membrane IL-6Rα increased in patients with Idiopathic Pulmonary Fibrosis?
Which pulmonary cell types exhibit classical signaling in humans? Which ones
are susceptible to trans signaling?

3.5

Is there enhanced activation of STAT3 in patients with Idiopathic Pulmonary
Fibrosis?

3.6

Is membrane IL-6Rα increased in bleomycin-induced pulmonary fibrosis and
what happens as fibrosis develops and progresses?

3.7

Is there enhanced activation of STAT3 in mouse fibrotic lungs? What
pulmonary cell types exhibit classical signaling? Which ones are targets of
trans signaling?
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RESULTS
3.1 - Soluble IL-6R alpha is elevated in Idiopathic Pulmonary Fibrosis.
As an initial assessment of whether sIL-6Rα is elevated in fibrotic lungs, we measured its
levels in the lungs of Idiopathic Pulmonary Fibrosis (IPF) patients, first in bronchoalveolar
lavage (BAL) fluid, then in parenchymal lung samples. Bronchoalveolar lavage is a procedure
that involves flushing saline down the airways of the lungs to wash out what is present in the
airways. It is often performed in IPF patients for diagnostic purposes(1). Parenchymal lung
samples were obtained from the diseased lungs of patients undergoing lung transplantation
because of end-stage COPD or IPF.
ELISA quantification of soluble IL-6Rα was performed in BAL fluid samples from
different lobes of a single IPF lung. It revealed elevated sIL-6Rα in a fibrotic lobe (IPF LLL) but
not a non-fibrotic lobe (IPF RML) (Figure 3.1A). Protein lysates were prepared from explanted
COPD and IPF lung tissues, and ELISA measurement of sIL-6Rα in these samples revealed a
significant, 4-fold increase in IPF lungs versus COPD lungs (Figure 3.1B). Secondary
confirmation was achieved with western blot analysis of these samples, probing for expression of
sIL-6Rα, which revealed increased sIL-6Rα in IPF lungs, visible as a 50 kDa band (Figure 3.1C).
These findings demonstrate for the first time increased soluble IL-6Rα in IPF, specifically in
regions of fibrosis, suggesting IL-6 trans signaling may play a role in this disease.
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Figure 3.1. Soluble IL-6R alpha in Idiopathic Pulmonary Fibrosis (IPF). Soluble IL-6Rα
expression was assessed in patients with Idiopathic Pulmonary Fibrosis. ELISA quantification of
sIL-6Rα in (A) BAL fluid from non-fibrotic (RML) and fibrotic (LLL) lobes of an IPF patient,
and (B) lung lysates from patients with COPD and IPF. (C) Western blot analysis of sIL-6Rα in
lung lysates from patients with COPD and IPF. Results from A obtained by Mesias Pedroza,
PhD. All data presented as mean ± SEM, n≥4 for B, n=1 for A. *significant difference from
COPD; *= p<0.05, **= 0.001<p<0.01, ***= p<0.001.
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To further evaluate the role of soluble IL-6Rα in IPF, we turned to a chronic model of
fibrosis, the Intraperitoneal Bleomycin (IPB) model (Figure 1.3). In this model, mice are given
intraperitoneal injections of bleomycin twice weekly for four weeks, which lead to progressive
development of pulmonary fibrosis(33, 90, 91). This model of chronic bleomycin exposure has
been demonstrated to recapitulate features of IPF, such as the presence of hyperplastic airway
epithelial cells and fibrosis that radiates inward from the pleural surfaces and is progressive,
irreversible and lethal(92, 93).

3.2 - Soluble IL-6R alpha is elevated in bleomycin-induced pulmonary fibrosis.
To assess expression of sIL-6Rα in this model, protein lysates were made from day 33
lungs and western blot performed. Soluble IL-6Rα was absent in PBS-injected, non-fibrotic
lungs but present in bleomycin-exposed, fibrotic lungs (Figure 3.2A). Bands present at 55-65
kDa represent glycosylated versions of the soluble receptor. BAL fluid samples (which reflect
the local microenvironment of the bronchoalveolar compartment in the lung) were collected and
analyzed for presence of the soluble receptor. ELISA measurement of sIL-6Rα in BAL fluid
demonstrated a significant, 3-fold increase in bleomycin samples in comparison to PBS samples
(Figure 3.2B). Western blot analysis of sIL-6Rα in BAL fluid confirmed this increase (Figure
3.2C). ELISA measurement of sIL-6Rα in plasma (which reflects systemic conditions) from
these mice demonstrated no significant difference between bleomycin and PBS samples (Figure
3.2D), supporting the hypothesis that the increase in sIL-6Rα is a local occurrence in the lungs.
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Figure 3.2. Soluble IL-6R alpha in bleomycin-induced pulmonary fibrosis. Soluble IL-6Rα
expression was assessed in mice with pulmonary fibrosis. (A) Western blot analysis of sIL-6Rα
in lung lysates, (B & C) ELISA measurement and western blot analysis of sIL-6Rα in
bronchoalveolar lavage fluid (BAL fluid), and (D) ELISA measurement of sIL-6Rα in plasma
from wildtype C57Blk/6 mice given saline or bleomycin, day 33. All data presented as mean ±
SEM, n≥4. *significant difference from PBS-treated cohort; *= p<0.05, **= 0.001<p<0.01, ***=
p<0.001.
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Figure 3.3. Soluble IL-6R alpha as disease develops in bleomycin-induced pulmonary
fibrosis. Soluble IL-6Rα expression was assessed in mice with pulmonary fibrosis. (A) Sircol
analysis of soluble collagen in BAL fluid over time in a chronic bleomycin mouse model. (B)
ELISA quantification and (C) western blot analysis of sIL-6Rα in BAL fluid and (D) ELISA
measurement of sIL-6Rα in plasma during development and progression of pulmonary fibrosis in
the model. Results from A obtained by Ernestina Melicoff, MD. All data presented as mean ±
SEM, n≥4. *significant difference from PBS-treated cohort; *= p<0.05, **= 0.001<p<0.01, ***=
p<0.001.
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Figure 3.4. Membrane IL-6R alpha expression in human IPF lungs. (A) Western blot
analysis of mIL-6Rα in lung lysates from explanted COPD and IPF samples. (B) Dual
immunofluorescence to detect mIL-6Rα on macrophages isolated from IPF patients; CD-206
(red) = marker of M2 macrophages, human IL-6Rα (green), dapi (blue). (C) Q-rtPCR
measurement of IL-6Rα transcript in macrophages isolated from BAL fluid of IPF patients and
in type II pneumocyte cell lines (A549 and MLE-12). (D) Western blot analysis of mIL-6Rα in
protein lysates from control and IPF fibroblast cell lines (CCD8Lu and LL97A, +/- TGF-β) and
type II pneumocyte cell lines. Results in B & C obtained by Yang Zhou, PhD.
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3.3 - Soluble IL-6R alpha increases as pulmonary fibrosis develops and progresses.
We next asked how sIL-6Rα levels change as pulmonary fibrosis develops and
progresses. BAL fluid was collected at various time points during the course of the model (days
5, 10, 15, 20, 25 and 33). Analysis of soluble collagen in BAL fluid revealed progressive
development of fibrosis in the model, with significant increases in collagen already evident in
bleomycin lungs by day 5 and the most prominent increase present by day 20 (Figure 3.3A).
ELISA quantification of the samples showed a temporal increase in sIL-6Rα (Figure 3.3B) that
mirrors the changes in collagen, which has never been shown before. This pattern was confirmed
in a second manner by western blot analysis of sIL-6Rα in BAL fluid (Figure 3.3C). ELISA
quantification of sIL-6Rα in plasma samples revealed no significant difference over the course of
the model or between PBS and bleomycin samples (Figure 3.3D), again supporting the pattern
seen in IPF samples of a local increase in sIL-6Rα in fibrotic areas. Collectively, the above
findings demonstrate an association between increases in soluble IL-6Rα and increasing
pulmonary fibrosis and suggest a role for the soluble receptor in disease onset and progression.

3.4 – Membrane IL-6R alpha expression is elevated in alveolar macrophages and pulmonary
fibroblasts from Idiopathic Pulmonary Fibrosis lungs.
Recognizing that IL-6 classical signaling can play a pivotal role in disease pathogenesis,
we asked whether the impact of this pathway is detrimental, neutral or protective in IPF. So, we
proceeded to determine whether or not IL-6 classical signaling was elevated in IPF lungs.
Protein lysates from explanted COPD and IPF lung tissues were subjected to western blot
analysis to determine expression of membrane IL-6Rα. Western blotting revealed decreased or
absent expression of mIL-6Rα in IPF lungs in comparison to COPD lungs (Figure 3.4A). In the
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absence of normal lung lysates for a control, we had to use COPD lung samples as relative
controls. As such, it is unclear whether this pattern of mIL-6Rα expression in IPF lungs
represents a deviation from the norm or not.
Examination of mIL-6Rα expression in specific cell types in the lung yielded more
informative results. Bronchoalveolar lavage was performed on an IPF patient and alveolar
macrophages were isolated from BAL fluid. These macrophages underwent immunofluorescence
staining for detection of macrophage mannose receptor (CD206) and membrane IL-6Rα
expression. CD206 is a marker of alternatively activated macrophages, or M2 macrophages. M2
macrophages are found in the lungs of IPF patients and mice with bleomycin-induced pulmonary
fibrosis and are reported to drive progression of disease(31, 33, 113-117). Immunofluorescence
staining for CD206 in BAL cells from an IPF patient revealed that these cells were mainly M2 in
phenotype. Immunofluorescence staining to detect membrane IL-6Rα on these cells
demonstrated a significant proportion expressed membrane IL-6Rα (Figure 3.4B). Q-rtPCR
analysis of the isolated macrophages was performed to assess expression of membrane IL-6Rα.
IL-6Rα transcript was elevated in these macrophages (Figure 3.4C), confirming the increase in
membrane protein. In comparison, type II airway epithelial cell lines, A549 and MLE-12,
exhibited very low transcript levels of IL-6Rα (Figure 3.4C). Western blot analysis of mIL-6Rα
expression in protein lysates from these cells revealed absence of mIL-6Rα at baseline
(Figure3.4D). Evaluation of control and IPF fibroblast cell lines (CCD8Lu and LL97A) revealed
that fibroblasts express mIL-6Rα at baseline (Figure 3.4D). Stimulation of these fibroblasts with
transforming growth factor beta (TGF-β) induced their differentiation into myofibroblasts, which
enhanced expression of mIL-6Rα.
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In all, these studies allowed us to draw 2 conclusions. The first is that M2 macrophages,
fibroblasts and myofibroblasts are capable of IL-6 classical signaling while type II pneumocytes
are not. All are still susceptible to trans signaling in the presence of the soluble receptor. The
second conclusion is that M2 macrophages and fibroblasts and myofibroblasts from fibrotic lungs
are all potential cellular sources of shedding of mIL-6Rα to produce sIL-6Rα. Though soluble
IL-6Rα can be generated via translation of alternatively spliced mRNA, protease-mediated
cleavage of membrane IL-6Rα is largely responsible for the generation of sIL-6Rα(44, 56-61, 63,
70). Thus these potential cellular sources of sIL-6Rα may prove instrumental in the disease
process.

3.5 – STAT3 activation is increased in Idiopathic Pulmonary Fibrosis.
Both IL-6 classical and trans signaling lead to phosphorylation and activation of STAT3,
which acts as a transcription factor to regulate target genes(49-52). The presence of phosphoSTAT3 is used as an indication of IL-6-mediated cellular activation (Figure 1.1).
As part of the attempt to further characterize IL-6 signaling in IPF, we assessed activation
of STAT3 via immunostaining of lung sections from IPF patients and western blot analysis of
protein lysates from explanted IPF lung samples. Both immunostaining and western blot
revealed increased P-STAT3 in IPF samples (Figure 3.5A&B). Immunopositivity for P-STAT3
(brown) was seen in various cell types in IPF lungs, including what appeared morphologically to
be macrophages, fibroblasts/myofibroblasts and epithelial cells (Figure 3.5A). These results
suggest that, in IPF lungs, macrophages and fibroblasts/myofibroblasts could have been activated
either by IL-6 classical and/or trans signaling while type II pneumocytes appear to have been
influenced by IL-6 trans signaling.
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Figure 3.5. Activation of Signal Transducer and Activator of Transcription 3 (STAT3) in
IPF lungs. (A) Immunostaining for phospho-STAT3 in lung sections from COPD and IPF
patients. Scale bars: 50µm, 100x oil immersion. (B) Western blot analysis of phospho-STAT3 in
lung lysates from explanted COPD and IPF samples.
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Figure 3.6. Membrane IL-6R alpha in bleomycin-induced pulmonary fibrosis. Membrane
IL-6Rα expression was assessed in mice with pulmonary fibrosis. Western blot analysis of mIL6Rα in (A) lung lysates, (B) BAL cell lysates and (C) BAL fluid from wildtype C57Bl/6 mice
given saline or bleomycin, day 33. (D) Western blot analysis of mIL-6Rα in BAL fluid during
development and progression of pulmonary fibrosis in a chronic bleomycin mouse model.
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3.6 - Membrane IL-6R alpha is elevated in bleomycin-induced pulmonary fibrosis and
increases as pulmonary fibrosis develops and progresses.
Our evaluation of membrane IL-6Rα in IPF lungs indicated variable expression in
parenchymal tissue but elevation of membrane IL-6Rα was seen in M2 alveolar macrophages. As
such, we wanted to further understand classical signaling in our mouse model to better
understand its role in IPF lungs.
To determine if IL-6 classical signaling was elevated in mouse fibrotic lungs, we
performed western blot analysis of membrane IL-6Rα was on protein lysates from day 33 PBS
and bleomycin-exposed mouse lungs. Membrane IL-6Rα expression was present in PBSinjected, non-fibrotic lungs and enhanced in bleomycin-exposed, fibrotic lungs (Figure 3.6A).
Western blot analysis of mIL-6Rα in cells washed out of the lung during bronchoalveolar lavage
revealed miniscule levels in PBS samples and visibly increased expression in bleomycin samples
(Figure 3.6B). These cells have been shown to be primarily M2 activated macrophages from our
analysis (Figure 3.4B) and previous studies(33),(31, 113-117). Bronchoalveolar lavage (BAL)
fluid was collected and analyzed for presence of the membrane receptor in the airways and
airspaces of the lung. Western blot analysis of mIL-6Rα in BAL fluid demonstrated a significant
increase in day 33 bleomycin samples in comparison to PBS samples (Figure 3.6C).
To better understand how mIL-6Rα levels changed over the course of development and
progression of pulmonary fibrosis, BAL fluid was collected at various time points during the
course of the model (days 5, 10, 15, 20, 25 and 33). Western blot analysis of the samples showed
a temporal increase in mIL-6Rα (Figure 3.6D) that mirrors the changes in collagen and sIL-6Rα.
Collectively, these findings demonstrate an association between increases in membrane IL-6Rα
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and increasing pulmonary fibrosis and suggest a role for the membrane receptor in disease onset
and progression in our bleomycin-induced model of pulmonary fibrosis.

3.7 - STAT3 is activated in fibrotic lungs and fibroblasts, myofibroblasts and macrophages are
capable of classical signaling while type II pneumocytes are not.
To determine if there was increased IL-6 activity in fibrotic, bleomycin-exposed mouse
lungs, western blot analysis for expression of phospho-STAT3 was performed in lung lysates
from day 33 PBS-injected and bleomycin-treated mice. Results revealed an increase in P-STAT3
in bleomycin lungs in comparison to PBS lungs (Figure 3.7A), suggesting increased IL-6
signaling.
To understand where this increased IL-6 signaling is occurring in fibrotic lungs, sections
were cut from day 33 PBS and bleomycin lungs and immunostained for phospho-STAT3. Day
33

lungs

were positive for P-STAT3

in

what

appeared

morphologically to

be

fibroblasts/myofibroblasts, macrophages and type II airway epithelial cells (AEC) (Figure 3.7BE). To confirm, we performed dual staining on these lung sections for co-localization of PSTAT3 and cell-specific markers, including: arginase 1 (for activated macrophages), prosurfactant protein C (for type II pneumocytes), FSP1 (fibroblast specific protein 1 – to identify
fibroblasts), and α-smooth muscle actin (marker of myofibroblasts). Dual staining revealed
activation of STAT3 in fibroblasts, myofibroblasts, type II pneumocytes and activated
macrophages in bleomycin lungs (Figure 3.7B-E). These findings validate what was observed in
IPF samples, confirming that these cell types in fibrotic lungs are responsive to IL-6 signaling.
Whether activation of STAT3 in these cells, in IPF lungs as well as bleomycin-exposed lungs,
was due to IL-6 classical or trans signaling or both remain to be determined.
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Figure 3.7. STAT3 activation and membrane IL-6R alpha expression in pulmonary cell
types. (A) Western blot analysis of phospho-STAT3 in whole lung lysates from wildtype
C57Blk/6 mice given saline or bleomycin, Day 33. (B-E) Day 33 lung sections from control and
bleomycin-exposed mice were immunostained for P-STAT3 alone and P-STAT3 dual stains
with cell-specific markers for pulmonary myofibroblasts, fibroblasts, type II pneumocytes, and
macrophages. Arrows denote dual-positive cells. Images are representative of n≥4 animals from
each group. Scale bars: 50µm, 100x oil immersion.
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Collectively, the experiments in sections 3.5-3.7 helped delineate cell types susceptible to
classical versus trans signaling and identified potential cellular sources of generation of soluble
IL-6Rα in the fibrotic lung, key processes that regulate pulmonary fibrosis.

DISCUSSION
The experiments presented in this chapter were designed to characterize IL-6 classical
and trans signaling pathways and their activation during onset and progression of pulmonary
fibrosis in order to assess the significance of each pathway, particularly trans pathway.
Soluble IL-6Rα (sIL-6Rα) is a key feature of IL-6 signaling and a crucial component in
the regulation of IL-6 responses. Soluble IL-6Rα acts agonistically in vivo to either enhance IL-6
signaling on cells already expressing membrane IL-6Rα or render cells lacking mIL-6Rα
susceptible to the effects of IL-6 signaling(44, 71). Elevations of sIL-6Rα have previously been
demonstrated in a number of human diseases(73, 74, 76, 78) but not in IPF.
A major observation in this study was that soluble IL-6Rα is elevated in IPF lungs and in
mice with established pulmonary fibrosis (Figures 3.1&3.2), indicating its production and
presence may play a role in the disease process. This is in agreement with previous studies that
have demonstrated elevations in sIL-6Rα in established disease states(73, 74, 76, 78, 81, 110).
Ours, however, is the first to show that sIL-6Rα levels in the lungs increased in a temporal
pattern associated with the development and progression of pulmonary fibrosis in a mouse model
(Figure 3.3). This suggests involvement of IL-6 trans signaling in onset and progression of
pulmonary fibrosis. This knowledge raises the possibility of sIL-6Rα serving as a marker of
staging disease severity and progression. It also supports the concept of sIL-6Rα as a potential
target for therapeutic neutralization in pulmonary fibrosis. Interestingly, there is evidence that the
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increase in soluble IL-6Rα in IPF is a local occurrence, only seen in a fibrotic area of the lung
(Figure 3.1A). This data was supported by our mouse model findings and would suggest that
sIL-6Rα could be used as a diagnostic marker, perhaps in localizing sites of active fibrosis. It
may also serve prognostic values. Further investigation of soluble IL-6Rα in more IPF lavage
and lung samples from fibrotic and non-fibrotic lobes is needed to validate these initial human
sample findings.
To thoroughly understand the molecular mechanisms involved in regulating pulmonary
fibrosis, we also characterized the presence of IL-6 classical signaling in IPF lungs and
bleomycin-exposed, fibrotic mouse lungs by evaluating mIL-6Rα expression. We have seen
variable mIL-6Rα expression in IPF lung samples (Figure 3.4A). Due to lack of normal lung
samples for negative controls, we have had to make our comparisons of IPF findings relative to
those in COPD. As such, our conclusions with regards to mIL-6Rα expression in IPF lung
lysates are reported cautiously and we are aware further evaluation is necessary. In the IPB
mouse model, however, IL-6 classical signaling appears enhanced as evident by elevated
membrane IL-6Rα expression in whole lung protein lysates in comparison to PBS lungs (Figure
3.6). This begs the question of how much our findings about IL-6 classical signaling in the IPB
model will translate to the human disease. We did, however, determine that there is increased
STAT3 activation (indicative of increased IL-6 signaling) in both IPF and bleomycin-exposed
lungs (Figures 3.5&3.7). Further analysis, with normal lung for negative controls, is needed in
more whole lung human IPF samples to determine if mIL-6Rα is elevated or not in IPF.
Despite tentative conclusions about mIL-6Rα expression in parenchymal IPF samples,
examination of classical signaling in specific cell types revealed some interesting data. Our
studies clearly indicate that IL-6 classical signaling is enhanced in the bronchoalveolar
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compartment of IPF lungs, specifically in M2 alveolar macrophages. This finding is in agreement
with Matsumoto et al, who reported increased mIL-6Rα expression in colonic macrophages in
colitis-affected tissue (78). In our study, we were able to show augmented mIL-6Rα expression
in macrophages collected via bronchoalveolar lavage of IPF lungs (Figure 3.4B). To our
knowledge, this is the first study to illustrate elevations in mIL-6Rα in M2 alveolar macrophages
from IPF patients. This observation of enhanced mIL-6Rα in M2 macrophages was confirmed in
the IPB model, where membrane IL-6Rα expression was elevated in BAL cell lysates in
comparison to PBS lungs (Figure 3.6). We know from the literature that M2 alveolar
macrophages are implicated in pulmonary fibrosis(31, 113-117). Thus, it is of interest to assess
what role, if any, membrane IL-6Rα (and therefore IL-6 classical signaling) plays in regulating
the phenotype and actions of these macrophages. The finding of increased mIL-6Rα expression
in M2 macrophages informs us that these cells are capable of classical and trans signaling and
that they may serve as a potential source of shedding to produce the soluble IL-6Rα. Membrane
IL-6Rα has been shown to be shed from cell surfaces of peripheral monocytes, bronchial
epithelia cells, hepatocytes, neutrophils and T cells(38, 59, 61-64). Future experiments are
needed to determine if M2 macrophages do shed their membrane IL-6Rα to generate soluble IL6Rα in fibrotic lungs. If they do, it would support a pathogenic role for these cells in pulmonary
fibrosis.
We also evaluated mIL-6Rα expression in fibroblasts, myofibroblasts and type II
pneumocytes. Current understanding of the pathogenesis of IPF identifies two cellular targets as
key players in disease initiation and progression – fibroblasts and epithelial cells(118, 119).
Epithelial injury and dysregulated regeneration is thought to initiate disease(118) while aberrant
fibroblast activation, differentiation into myofibroblasts, and excessive collagen and fibronectin
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production and deposition in the lungs propagate the problem(2). Our study provides further
insight into the characterization of these cells in disease. We found that fibroblasts and
myofibroblasts are capable of IL-6 classical signaling while type II pneumocytes are not. All are
still susceptible to trans signaling in the presence of the soluble receptor. Our data indicate that
fibroblasts and myofibroblasts from fibrotic lungs express more mIL-6Rα than those from
normal lungs, so they are also potential cellular sources of shedding of mIL-6Rα to produce sIL6Rα. Further examination is required to understand the impact of IL-6 classical and trans
signaling in these individual cells.
Collectively, the findings in this aim illustrate the existence of IL-6 trans signaling in IPF
lungs and bleomycin-induced fibrotic mouse lungs. They demonstrate that soluble IL-6Rα is
present and increases in association with pulmonary fibrosis and expression of membrane IL6Rα is elevated in fibrosis. This suggests that IL-6 classical signaling is enhanced and trans
signaling is involved in the disease process in fibrotic lungs. Thus, there is a need to characterize
the generation of soluble IL-6Rα in fibrotic lungs (Chapter 4) and to assess the role of IL-6 trans
signaling in pulmonary fibrosis (Chapter 5). Chapter 4 will examine the role of proteasemediated generation of sIL-6Rα and Chapter 5 will evaluate the effects of in vivo neutralization
of IL-6 trans signaling.
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CHAPTER 4
ADAM17 Sheds Interleukin-6 Receptor
Alpha (IL-6Rα) in a Chronic Bleomycin
Murine Model of Pulmonary Fibrosis
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EXPERIMENTAL RATIONALE AND KEY QUESTIONS
From experiments presented in the last chapter characterizing IL-6 trans signaling in
pulmonary fibrosis, we know that soluble IL-6Rα is expressed in fibrotic lungs and increases in
association with increasing fibrosis. This points to a role for sIL-6Rα in pulmonary fibrosis and
emphasizes a need to evaluate the mechanism of its generation.
Soluble IL-6Rα is generated largely through protease-mediated cleavage of membranebound IL-6Rα(44, 58, 70) (Figure 1.2). ADAM17 (A Disintegrin and Metaolloproteinase 17) is a
membrane-bound metalloprotease belonging to the ADAM (a disintegrin and metalloproteinase)
family that is responsible for cleaving cell surface proteins. ADAM17 has been implicated as the
main protease responsible for shedding IL-6Rα from cell membrane surfaces of hepatocytes,
peripheral monocytes, neutrophils and T cells(38, 59, 61-63). Increased levels of this protease
have been found in association with diseases that have reported increased sIL-6Rα levels(66-69).
A related protease, ADAM10, has been implicated in constitutive shedding of IL-6Rα, while
ADAM17 is better known for rapid, inducible shedding(38, 61). The roles of both ADAM17 and
ADAM10 in shedding IL-6Rα in fibrotic lungs have not been examined.
In an initial attempt to determine whether or not the generation of soluble IL-6Rα in
fibrotic lungs involves the actions of ADAM17 and ADAM10, transcript levels of these
proteases were assessed in mice with adenosine-mediated (ADA-/-) or bleomycin-mediated
pulmonary fibrosis. Microarray analysis of lungs from these mice was conducted, and results
revealed a significant increase in ADAM17 and ADAM10 transcript in fibrotic lungs (Figure
4.0). This data suggested that these proteases may mediate IL-6Rα shedding and prompted us to
look more closely at this mechanism in pulmonary fibrosis.
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Figure 4.0. ADAM10 and ADAM17 transcripts in murine models of pulmonary fibrosis.
Microarray analysis of (A) ADAM10 and (B) ADAM17 transcripts using mRNA isolated from
lungs of ADA+/- and ADA-/- mice (day 42) and wild type C57Blk6 mice after exposure to saline
or bleomycin (day 21). Results presented as mean fold increases ± SEM, n=3. *significant
difference from ADA+/- or saline. Data provided by Tingting Weng, PhD.
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Given the preliminary microarray results, we set out to test the hypothesis that proteasemediated shedding is the main mechanism of generation of soluble IL-6Rα in fibrotic lungs. In
particular, we were interested in the role of ADAM17 in the process and wanted to answer the
following questions:
4.1

Is ADAM17 elevated in bleomycin-induced pulmonary fibrosis?

4.2

What happens to ADAM17 expression as pulmonary fibrosis develops
and progresses?

4.3-4.4

Can ADAM17 shed IL-6Rα from membranes of bone-marrow-derived
macrophages? Can this process be blocked by pharmacologic inhibitors
or small interfering RNA?

4.5

Can ADAM17 shed IL-6Rα from membranes of primary alveolar
macrophages from fibrotic lungs?
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RESULTS
4.1 - ADAM17 is increased in bleomycin-induced pulmonary fibrosis.
To assess the underlying mechanism of soluble IL-6Rα production in fibrotic lungs, we
explored the role of the proteases ADAM 17 and ADAM 10 in cleaving membrane IL-6Rα to
produce the soluble IL-6 receptor. To determine whether these proteases are elevated in
pulmonary fibrosis, we evaluated their expression in the IPB model. Protein lysates were made
from day 33 lungs, a stage when fibrosis was prominent, and western blotting was performed.
Immature (130 kDa) and mature (93 kDa) forms of ADAM17 were increased in bleomycinexposed, fibrotic lungs in comparison to PBS-exposed, non-fibrotic lungs (Figure 4.1A). No
difference in ADAM10 expression was observed between bleomycin and PBS lungs (Figure
4.1B). Thus we focused our efforts on further characterizing ADAM17 expression.
Bronchoaveolar lavage (BAL) was performed in day 33 PBS and bleomycin-exposed
mice. BAL fluid was analyzed for presence of ADAM17 in the bronchoalveolar compartment of
the lung. Western blot analysis detected an increase in mature ADAM17 in bleomycin samples
(Figure 4.1C). Immature ADAM17 was absent in PBS samples but present in bleomycin
samples, indicating increased production of ADAM17. Immunostaining of lung sections from
day 33 lungs revealed the most prominent increase of ADAM17 was in alveolar macrophages of
bleomycin-exposed lungs (Figure 4.1D). This observation, in combination with results presented
in the last chapter on expression of membrane and soluble IL-6Rα in IPF and bleomycin-induced
fibrotic lungs, further supports the hypothesis that ADAM17 is responsible for generating the
soluble IL-6 receptor in fibrotic lungs.
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Figure 4.1. ADAM17 expression in bleomycin-induced pulmonary fibrosis. Expression of
the protease ADAM17 was evaluated in mice with pulmonary fibrosis. Western blot analysis of
(A) immature (130 kDa) and mature (89 kDa) forms of ADAM17 and (B) ADAM10 in lung
lysates from wildtype C57Bl/6 mice given saline or bleomycin, day 33. (C) Western blot
analysis of bronchoalveolar lavage fluid from day 33 mice. (D) Immunostaining for ADAM17
(brown) in the lungs of day 33 mice. Arrows denote positive cells. Images are representative of
n≥4 animals from each group. Scale bars: 50µm, 100x oil immersion. (E) Immunofluorescence
staining for membrane IL-6R alpha (green) and DAPI (blue) on BAL fluid cells. Arrows denote
positive cells. Images are representative of n≥4 animals from each group, 20x magnification.
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We know that macrophages isolated from IPF lungs expressed abundant mIL-6Rα
(Figure 3.4B). We also saw that sIL-6Rα was increased in the bronchoalveolar compartment of
fibrotic lungs (Figure 3.1 and 3.2B&C), suggesting that that might be where the soluble receptor
was generated. In the last chapter, we reported increased expression of mIL-6Rα in BAL cells
lavaged out of bleomycin-exposed lungs (Figure 3.6B). These cells are comprised mainly of
alveolar macrophages but also include lymphocytes, neutrophils and eosinophils(33). The fact
that there was an increase in ADAM17 in alveolar macrophages and these macrophages also
expressed more membrane IL-6Rα than normal raise the possibility of ADAM17 acting in these
cells to shed their membrane IL-6Rα to generate soluble IL-6Rα.
To provide secondary confirmation of the increase in mIL-6Rα in BAL macrophages
seen on western blot analysis (Figure 3.6B), we isolated alveolar macrophages from day 33
bleomycin-exposed mouse lungs using bronchoalveolar lavage. The cells cytospun onto
microscope slides and subjected to immunofluorescence staining for membrane IL-6Rα. It was
evident that macrophages from day 33 bleomycin lungs had abundant expression of membrane
IL-6Rα (Figure 4.1E). These findings confirm physical proximity of mature ADAM17 and
membrane IL-6Rα to suggest a role for ADAM17 in shedding the membrane receptor.

4.2 - ADAM17 is increased in association with increasing soluble IL-6R alpha and alveolar
macrophages in fibrotic lungs.
Further characterization of ADAM17 expression during the onset and development of
fibrosis was achieved via western blot analysis of BAL fluid samples collected throughout the
duration of the IPB model (days 5, 10, 15, 20, 25, and 33). Results indicated a temporal increase
in ADAM17 expression (Figure 4.2A) that mirrored the increase in sIL-6Rα as pulmonary
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fibrosis developed and progressed (Figure 3.3C). Specifically, just as sIL-6Rα became prominent
in BAL fluid in day 20 samples, mature ADAM17 also started increasing with day 20 samples.
Immature ADAM17 was absent in samples from the first 15 days of the model but appeared in
BAL fluid samples from day 20. These results further strengthened our suspicions that ADAM17
is involved in generation of the soluble IL-6 receptor in fibrotic lungs.
Since our data had been pointing to the alveolar macrophage as the source of shedding,
we wanted to determine if there was a temporal increase in alveolar macrophages in fibrotic
lungs that would explain the temporal increase in ADAM17 in the bronchoalveolar
compartment. Using BAL fluid samples collected throughout the duration of the IPB model from
PBS and bleomycin mice, total BAL cell count was determined and cellular differentials
performed. In comparison to total BAL cells from PBS-injected, non-fibrotic lungs, total cells
from bleomycin-exposed, fibrotic lungs rose over time, starting with significant changes on day
20 (Figure 4.2B). Total BAL cells in bleomycin-exposed lungs dropped between day 25 and 33
but were still significantly different from those of PBS-exposed lungs. Analysis of cell
differentials revealed that the number of BAL macrophages in these lungs also began increasing
significantly on day 20, with maximum macrophage numbers in day 25 samples and a drop in
numbers by day 33, though still significantly higher in comparison to controls (Figure 4.3C).
Collectively, these findings demonstrate an association between increases in alveolar
macrophages and ADAM17 and increases in soluble IL-6Rα in fibrotic lungs, suggesting that
ADAM17 activation in alveolar macrophages of fibrotic lungs induces shedding of membrane
IL-6Rα to produce soluble IL-6Rα.
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Figure 4.2. ADAM17 expression and alveolar macrophage accumulation in bleomycininduced pulmonary fibrosis. (A) Western blot analysis of ADAM17 in BAL fluid samples over
the course of the model, as pulmonary fibrosis develops and progresses secondary to chronic
bleomycin exposure. (B&C) Total BAL cell and BAL macrophages in samples at various points
during model. Data presented as mean ± SEM, n≥4. *significant difference from PBS-treated
cohort. *= p<0.05, **= 0.001<p<0.01, ***= p<0.001. Data from B-C obtained by Tina Melicoff,
MD, Tingting Weng, PhD and Harry Karmouty-Quintana, PhD.
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4.3-4.5 – ADAM17 mediates shedding of IL-6R alpha from bone marrow derived M2 activated
macrophage membranes.
Given the previous data, we suspected that the generation of sIL-6Rα revolved around the
alveolar macrophages in fibrotic lungs that co-express high levels of ADAM17 and mIL-6Rα.
Alveolar macrophages found in the lungs of IPF patients and mice with bleomycin-induced
pulmonary fibrosis are primarily M2 in phenotype and are reported to drive progression of
disease(31, 113-117). We asked whether we could replicate the in vivo conditions using an in
vitro cell system and show that activation of ADAM17 in M2 macrophages induces shedding of
membrane IL-6Rα to increase production of soluble IL-6Rα.
To generate M2 macrophages in vitro, we used the protocol detailed in Figure 4.3A
(courtesy of Dr. Sandeep Agarwal’s laboratory). We isolated bone marrow cells from wild-type
C57Blk6 mice and differentiated them into macrophages in culture. Macrophages were then
stimulated with interleukin-4 (IL-4) and interleukin-13 (IL-13). These cytokines were reported to
be important in the lung and their use in various studies has led to successful differentiation of
macrophages to the M2 phenotype(120-123). Arginase 1 is a marker of M2 macrophages, and its
expression after stimulation has been reported to be an indicator of successful
differentiation(114, 120, 122, 123). Western blot analysis of protein lysates from IL-4/IL-13stimulated macrophages revealed more arginase 1 expression than in unstimulated macrophages
(Figure 4.3B), suggesting they are M2 in phenotype.
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Figure 4.3. In vitro culture and differentiation of bone marrow derived cells into M2
macrophages. (A) Experimental protocol for generating bone marrow derived M2 macrophages.
Bone marrow cells were isolated from the femurs of wild-type C57Blk6 mice and cultured in
supplemented media for 1 week to induce macrophage development. After 1 week in culture,
adherent macrophages were collected and replated then stimulated with IL-4 and IL-13 for 3
days to polarize their differentiation into M2 macrophages. (B) Western blot analysis of
membrane IL-6Rα and arginase 1 expression in bone marrow-derived macrophages stimulated
with IL-4 and IL-13.
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Figure 4.4. Generation of soluble IL-6Rα following pharmacologic neutralization of
ADAM17 activity in bone marrow derived M2 macrophages. (A) Bone-marrow-derived M2
macrophages were either stimulated with PMA alone or pre-incubated with TAPI-1 and
stimulated with PMA in the presence of TAPI-1. Culture media and cell lysates were collected
after 2 hours. (B) ELISA measurement of soluble IL-6Rα in culture media of macrophages
stimulated with PMA, with and without TAPI-1. All data presented as mean ± SEM, n≥6.
*significant difference from media only cohort; #significant difference from PMA-stimulated
cohort; *= p<0.05, **= 0.001<p<0.01, ***= p<0.001.
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Figure 4.5. Generation of soluble IL-6Rα following siRNA-mediated silencing of ADAM17
activity in bone marrow derived macrophages. (A) Bone-marrow-derived macrophages were
stimulated with IL-4 and IL-13 and transfected with control or ADAM17 siRNA. Macrophages
are then stimulated with PMA. Culture media and cell lysates were collected after 2 hours. (B)
Western blot analysis of ADAM17 in protein lysates of transfected macrophages. (C) ELISA
measurement of sIL-6Rα in culture media of macrophages transfected with control or ADAM17
siRNA and then stimulated with PMA. All data presented as mean ± SEM, n≥6. *significant
difference from media only cohort; #significant difference from PMA-stimulated cohort; *=
p<0.05, **= 0.001<p<0.01, ***= p<0.001.
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Next, we evaluated mIL-6Rα expression in the M2 macrophages to see if the membrane
receptor is present to be cleaved. Western blot analysis showed more mIL-6Rα in IL-4/IL-13
stimulated macrophages than unstimulated macrophages (Figure 4.3B). The characteristics of
augmented ADAM17 and mIL-6Rα expression in our bone marrow derived M2 macrophages
mimicked those seen in alveolar macrophages isolated from IPF patients and fibrotic murine
lungs (Figure 3.4B & 3.5B). Thus, we proceeded to use these cells in our shedding experiments.
The experimental protocols are illustrated in Figures 4.4A and 4.5A. The experiments
involved using a phorbol ester to activate ADAM17 in bone marrow derived M2 macrophages in
order to induce shedding of IL-6R. Then, to support ADAM17’s role in shedding, we blocked
ADAM17 activity in the cells using a pharmacologic inhibitor or siRNA and observed changes
to sIL-6Rα generation in response to phorbol ester stimulation.
The reagent phorbol 12-myrstate 13-acetate (PMA) is known to activate ADAM17mediated shedding of membrane IL-6Rα(65, 124). IL-4/IL-13-stimulated macrophages were
incubated with PMA to activate ADAM17 and induce shedding. To assess shedding efficiency,
culture media was collected and sIL-6Rα was quantified using ELISA. PMA activation of
ADAM17 led to a significant, 4-fold increase in soluble IL-6Rα in the culture media (Figure
4.4B), suggesting that ADAM17 is responsible for the increase in shedding.
To further support the role of ADAM17 in this process, we assessed whether blocking
ADAM17 would alter the extent of shedding. We first attempted to block ADAM17 activity
pharmacologically using TAPI-1, a non-selective inhibitor of ADAM proteases(59, 124) (Figure
4.4A). Addition of TAPI-1 to macrophages without PMA stimulation was able to significantly
suppress baseline shedding; pre-incubation of macrophages with TAPI-1 resulted in inhibition of
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sIL-6Rα release into the media with PMA stimulation (Figure 4.4B). These results demonstrated
that ADAM17 mediated shedding of IL-6Rα from M2 macrophages to generate sIL-6Rα.
We confirmed these results using a second, more specific method of neutralizing
ADAM17 activity. Bone marrow derived M2 macrophages were transfected with ADAM17
siRNA(69) to silence ADAM17 (Figure 4.5A). Successful silencing was confirmed by western
blot analysis showing reduced expression of ADAM17 (Figure 4.5B). Macrophages were then
stimulated with PMA. There was a 4-fold increase in release of sIL-6Rα from non-transfected
macrophages and macrophages transfected with control siRNA. There was significant reduction
in release of sIL-6Rα from macrophages transfected with ADAM17 siRNA (Figure 4.5B).
Collectively, these findings support our hypothesis that ADAM17 activation in M2 macrophages
induces shedding of membrane IL-6Rα to increase production of sIL-6Rα in pulmonary fibrosis.

4.6 - ADAM17 promotes shedding of IL-6R alpha from alveolar macrophages collected from
bleomycin-induced fibrotic lungs.
To more accurately reflect what happens in active pulmonary fibrosis, we repeated the
above experiments, this time using primary alveolar macrophages isolated from day 33 mice
treated with PBS or bleomycin. Lungs were thoroughly lavaged (10-12 times) to ensure
evacuation of the majority of alveolar macrophages present in the bronchoalveolar compartment.
There were significantly more cells collected from bleomcyin-exposed lungs than PBS lungs,
consistent with our previous characterization studies, which showed higher total cell counts in
BAL fluid, indicative of enhanced levels of pulmonary inflammation in bleomycin-exposed mice
(Figure 4.2B). Cells collected in BAL fluid were then cultured for 4 hours in tissue culture plates
to allow for adherence of alveolar macrophages. All other non-adherent cells were washed away
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at the end of the incubation period. Adherent macrophages were then used in shedding
experiments.
PMA-induced activation of ADAM17 in primary alveolar macrophages from PBS lungs
induced an increase in soluble IL-6Rα in culture media (Figure 4.6). Pre-incubation with TAPI-1
reduced levels of released sIL-6Rα to below detection threshold. PMA stimulation of ADAM17
in macrophages from bleomycin lungs resulted in a 2-fold increase in sIL-6Rα in culture media
(Figure 4.6). Pre-incubation with TAPI-1 reduced levels of released sIL-6Rα to baseline levels.
This experiment validated findings from experiments with bone marrow derived M2
macrophages and revealed that ADAM17 can shed IL-6R from primary alveolar macrophages.
Overall, the results of our shedding experiments, both in bone marrow derived M2
macrophages and in primary alveolar macrophages from fibrotic mouse lungs have supported a
role for ADAM17 in shedding membrane IL-6Rα to generate soluble IL-6Rα in fibrotic lungs.
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Figure 4.6. Generation of soluble IL-6Rα following pharmacologic inhibition of ADAM17
activity in primary alveolar macrophages. Primary alveolar macrophages were isolated from
the lungs of day 33 PBS and bleomycin-exposed mice. Macrophages were stimulated with PMA
in the presence or absence of TAPI-1. ELISA measurement of soluble IL-6Rα in culture media
was performed. All data presented as mean ± SEM, n=1 for PBS and n=3 for bleomycin.
*significant difference from media only cohort; #significant difference from PMA-stimulated
cohort; *= p<0.05, **= 0.001<p<0.01, ***= p<0.001.
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DISCUSSION
The experimental results presented in this chapter suggest that generation of sIL-6Rα in
pulmonary fibrosis is due to cleavage of membrane IL-6Rα from activated pulmonary
macrophages via the action of the protease ADAM17.
A major finding in this study is that ADAM17 expression was elevated in alveolar
macrophages from bleomycin-induced, fibrotic mouse lungs (Figure 4.1). Lee et al have
previously demonstrated increased ADAM17 expression in mice with acute lung injury in
response to intratracheal bleomycin instillation(125). Our finding of increased ADAM17 in a
chronic model of intraperitoneally-instilled bleomycin agrees with their results.
To our knowledge, however, this is the first study to report a temporal increase in
ADAM17 expression as pulmonary fibrosis develops and progresses. This pattern of increase in
ADAM17 is associated with an increasing accumulation of alveolar macrophages in the lung
(Figure 4.3) and a progressively increasing level of soluble IL-6Rα (Figure 3.3). The coordinated
changes in ADAM17, alveolar macrophages and sIL-6Rα all support the hypothesis that
increased activation of ADAM17 in alveolar macrophages of fibrotic lungs results in shedding of
IL-6Rα to increase production of sIL-6Rα. Indeed, our in vitro experiments with bone marrow
derived M2 macrophages and primary M2 alveolar macrophages confirmed the role of ADAM17.
Activation of ADAM17 in these macrophages led to shedding and increases generation of sIL6Rα. Inhibition of ADAM17, both with a pharmacologic inhibitor and with ADAM17 siRNA,
resulted in inhibition of shedding and a reduction in amounts of sIL-6Rα.
As mentioned in Chapter 3, fibrosis is progressive in the IPB model (Figure 3.3A). Our
findings presented in this chapter suggest a mechanism for the progressive nature of fibrosis in
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the model. Augmented ADAM17-mediated generation of sIL-6Rα could be the mechanism by
which sIL-6Rα accumulates in the lung over time, causing progressively increasing fibrosis.
This finding is provocative in that it begs the question of ADAM17-targeted therapies in
alleviating lung fibrosis. It also suggests a mechanism for the contribution of activated
macrophages to pulmonary fibrosis and raises the possibility of targeting this potentially pivotal
player in disease. ADAM17 could also be used as an important indicator of the progression of
pulmonary fibrosis. It must be noted, however, that Garbers et al have argued that ADAM17 is
the main protease responsible for cleavage of mIL-6Rα in humans, but that in mice, ADAM10 is
primarily responsible(126). We do not deny that ADAM10 may be able to cleave mIL-6Rα;
however, we have not been able to demonstrate an increase in ADAM10 in fibrotic murine lungs
(Figure 4.1B). Our in vitro experiments with stimulation and neutralization of ADAM17 in
macrophages have led us to conclude that ADAM17 is responsible for the generation of sIL-6Rα
in our mouse model of chronic bleomycin exposure.
In summary, the experiments conducted in this chapter demonstrated a temporal pattern
of increasing ADAM17 expression in association with increasing pulmonary fibrosis and
increasing levels of soluble IL-6Rα. Our stimulation and neutralization experiments supported a
role for ADAM17 in shedding IL-6Rα from the membrane of activated pulmonary macrophages
in order to increase production of soluble IL-6Rα in fibrotic lungs. The data presented in Chapter
3 and this chapter have provided sufficient evidence and the rationale needed to propose in vivo
neutralization of soluble IL-6Rα and resulting antagonism of IL-6 trans signaling in the IPB
model to determine whether or not therapeutic benefits could be achieved. The results of in vivo
neutralization of IL-6 trans signaling will be presented in the next chapter.
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CHAPTER 5
In Vivo Neutralization of
Interleukin-6 (IL-6) Trans Signaling in a
Chronic Bleomycin Murine Model
of Pulmonary Fibrosis
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EXPERIMENTAL RATIONALE AND KEY QUESTIONS
In the previous two chapters, we have demonstrated that soluble IL-6Rα was elevated in
association with pulmonary fibrosis as a result of ADAM17-mediated cleavage of the membrane
receptor. We have also provided evidence to suggest that IL-6 trans signaling is associated with
increasing severity of disease. The role of IL-6 trans signaling in Idiopathic Pulmonary Fibrosis,
however, is unknown.
IL-6 trans signaling via the soluble receptor has been implicated in the pathogenesis of
rheumatoid arthritis(73), asthma(74), inflammatory bowel disease (colitis)(76) and colitisassociated cancer(78). In pulmonary fibrosis, O’Donoghue et al. and Pedroza et al demonstrated
that IL-6 ablation attenuated fibrosis in bleomycin-induced murine models(29, 87). What is not
known from their work is the differentiation between the contribution of IL-6 classical versus
trans signaling with regards to the development and progression of pulmonary fibrosis. It is with
the intention of filling this gap in knowledge that the experiments in this chapter were designed.
This chapter will emphasize the importance of IL-6 trans signaling by evaluating
potential benefits of blocking this signaling pathway in vivo in a murine model of pulmonary
fibrosis. So how is specific blockade of IL-6 trans signaling in vivo achieved? The answer lies
with soluble gp130. As previously mentioned, the receptor protein gp130 is constitutively
expressed in cell membranes and serves the function of signal transduction for various cytokines,
including interleukin 6. Soluble forms of gp130 (sgp130) have been identified in human serum
and urine(127, 128). Since the initial discovery, soluble gp130 has been shown to be a natural
inhibitor of IL-6 trans signaling(105, 106) and a number of studies have employed its use as a
mean of specifically blocking IL-6 trans signaling in vivo.
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In various animal models of disease, the use of soluble gp130 has resulted in amelioration
of disease states. In vivo neutralization of IL-6 trans signaling resulted in suppression of colitis in
an experimental mouse model(76), lessened disease in a mouse experimental arthritis model(79),
and resulted in clinical improvement in a systemic arthritis model(80). Blocking IL-6 trans
signaling resulted in improvement in survival in a mouse sepsis model(77) and reduced colitisassociated premalignant cancer (CApC) in a mouse model(78). Specifically targeting IL-6 trans
signaling in vivo reduced ascites formation and enhanced the sensitivity of ovarian tumors to
chemotherapy(103).
Given the successful precedent of using soluble gp130 to neutralize IL-6 trans signaling
in vivo in other disease models, we used a similar approach to assess the impact of IL-6 trans
signaling in pulmonary fibrosis and answered the following key questions:
5.1-5.2

Is recombinant gp130Fc able to neutralize IL-6 trans signaling in vivo?

5.3-5.4

Does recombinant gp130Fc treatment attenuate pulmonary inflammation?

5.5-5.8

Does recombinant gp130Fc treatment attenuate pulmonary fibrosis?

5.9

Does recombinant gp130Fc treatment improve oxygen saturation?

5.10

Does recombinant gp130Fc treatment reduce pulmonary hypertension?

5.11

Does recombinant gp130Fc treatment decrease activation of STAT3?

5.12-18

Does IL-6 trans signaling affect fibroblast proliferation, apoptosis and
extracellular matrix protein production in vitro? If so, will recombinant
gp130Fc inhibit the effects in vitro?

5.19

Does recombinant gp130Fc administration affect in vivo IL-6 classical
signaling?
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Figure 5.1. In vivo neutralization of soluble IL-6Rα using mouse recombinant gp130Fc in a
mouse model of chronic bleomycin exposure. (A) Illustration of the mechanism of action of
mouse recombinant gp130Fc on neutralization of sIL-6Rα. (B) Experimental setup for in vivo
neutralization of sIL-6Rα in the Intraperitoneal Bleomycin murine model of pulmonary fibrosis.
Wildtype C57Blk6 male mice were injected intraperitoneally with saline or bleomycin twice
weekly for 4 weeks. Beginning on day 19, when pulmonary fibrosis has been established, daily
treatment with vehicle (saline) or recombinant gp130Fc was performed. Arterial oxygen
saturation measurements were performed on live, shaved mice on day 32. Mice were sacrificed
and samples collected on day 33.
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Figure 5.2. Soluble IL-6Rα and IL-6 following chronic bleomycin exposure in mice treated
with recombinant gp130Fc in a mouse model of chronic bleomycin exposure. Wildtype
C57Blk6 male mice were injected intraperitoneally with saline or bleomycin twice weekly for 4
weeks. Beginning on day 19, when pulmonary fibrosis has been established, daily treatment with
vehicle (saline) or recombinant gp130Fc was performed. Mice were sacrificed and samples
collected on day 33. (A) Western blot analysis and (B) ELISA measurement of sIL-6Rα levels in
BAL fluid from day 33 lungs. (C) ELISA quantification of sIL-6Rα in plasma samples. (D)
ELISA measurement of IL-6 protein in day 33 BAL fluid and (E) Q-rtPCR evaluation of IL-6
transcript level in day 33 whole lung RNA. All data presented as mean ± SEM, n≥6 for B & C,
n≥3 for D & E. *significant difference from PBS-treated cohort; #significant difference from
bleomycin-exposed mice. *= p<0.05, **= 0.001<p<0.01, ***= p<0.001.
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RESULTS
5.1 – Protocol for in vivo neutralization of IL-6 trans signaling using recombinant gp130Fc.
In vivo neutralization of sIL-6Rα was performed in the IPB model using mouse
recombinant gp130Fc, a commercially available reagent shown in previous studies to be an
effective and selective inhibitor of IL-6 trans signaling(73, 74, 76, 78). Recombinant gp130Fc
binds the only the complex of IL-6/sIL-6Rα, selectively inhibiting signaling through the trans
pathway(44), as illustrated in Figure 5.1A. It does not bind IL-6 alone or sIL-6Rα alone, mIL6Rα, or the complex of IL-6/mIL-6Rα, thus leaving classical signaling intact.
The neutralization treatment protocol was as illustrated in Figure 5.1B. The dosage and
schedule for administration of recombinant gp130Fc are adapted from previous published studies
that have shown effectiveness of soluble gp130 at blocking IL-6 trans signaling in vivo in
various models(76-80, 103). Treatment with gp130Fc began late in the disease process, on day
19 of the model, when pulmonary fibrosis was established. Treatment continued until day 32.
Hypoxia was assessed in live mice on day 32 via measurement of arterial oxygen saturation.
Mice were sacrificed on Day 33 and pulmonary phenotypes were assessed for changes to
pulmonary inflammation and fibrosis.
The decision of when to begin treatment with gp130Fc was based on preliminary data
regarding the temporal course of disease development in the IPB model. Data from our
characterization studies informed us that though collagen levels began rising as early as 5 days
after the first dose of bleomycin, levels significantly jumped between day 15 to day 20 of the
model, as does levels of soluble IL-6Rα (Figure 3.3A-B). This suggests that it is around this time
in the model that fibrosis becomes much more robust and trans signaling takes a more prominent
role in the disease process. This led us to choose day 19, coinciding with the 6th injection of
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bleomycin, as the best time to initiate therapeutic blockade of the trans signaling pathway. In this
way, we were able to determine the therapeutic rather than preventative benefits of antagonizing
trans signaling.

5.2 – Administration of recombinant gp130Fc reduced sIL-6Rα.
To determine whether our neutralization protocol was sufficient to reduce levels of the
soluble receptor and inhibit trans signaling, Day 33 BAL fluid samples were collected and
subjected to ELISA analysis of sIL-6Rα. Bleomycin-treated mice exhibited a significant
elevation in sIL-6Rα in BAL fluid (Figure 5.2A&B), similar to what was demonstrated in our
earlier characterization studies (Figure 3.2B&C). Treatment with gp130Fc significantly lowered
levels of sIL-6Rα in BAL fluid. Interestingly, levels of sIL-6Rα in plasma were not significantly
different among the treatment groups (Figure 5.2C). This suggests that recombinant gp130Fc is
able to alter levels of soluble IL-6Rα and antagonize IL-6 trans signaling in the lung
microenvironment but not the systemic circulation.
A consideration when using recombinant gp130Fc to inhibit trans signaling is whether it
would inadvertently interact with IL-6 alone and thereby inhibit classical signaling. As previous
studies have demonstrated, the inhibitory effects of gp130Fc are limited to trans signaling
because it only binds IL-6/sIL-6Rα complexes(76-80, 103, 129). However, to confirm that
gp130Fc administration in our mice did not have off-target effects, IL-6 transcript in whole lung
RNA and protein levels in BAL fluid were determined. IL-6 protein and transcript levels were
elevated in the lungs of bleomycin-treated mice in comparison to PBS-treated mice (Figure
5.2D&E). No significant differences were seen in protein and transcript levels between
bleomycin and bleomycin + gp130Fc groups, though there was a trend for decrease. These
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results tell us that gp130Fc is not directly affecting IL-6 classical signaling since IL-6 protein
levels were relatively unchanged.

5.3 – Treatment with recombinant gp130Fc reduced inflammatory cells in the lungs.
Once we confirmed neutralization of trans signaling in our experimental setup, we began
evaluating changes to pulmonary phenotype. The histopathology of IPF lungs include presence
of spatial and temporal heterogeneity in fibrosis, with regions of dense scarring and
honeycombing alternating with less severe fibrosis or normal pulmonary architecture(1). Regions
of fibrosis are usually packed with dense collagen and scattered fibroblastic foci (areas of
proliferating fibroblasts and myofibroblasts). Areas of honeycombing (cystic fibrotic airspaces)
consist of airspaces that are filled with inflammatory cells and mucus and lined with bronchiolar
epithelium. When inflammation is present in the interstitium, it is typically mild, with
lymphocytes and plasma cells making up a patchy infiltrate(1).
To assess changes in pulmonary phenotype, we first examined the effects of recombinant
gp130Fc administration on pulmonary inflammation. In the IPB model, mice develop extensive
pulmonary fibrosis as well as pulmonary inflammation, consisting of an influx of inflammatory
cells, including macrophages, lymphocytes and neutrophils(33, 91). Using a hemocytometer,
total cell counts were performed on BAL fluid samples from day 33 mice. Mice treated with
bleomycin exhibited increased inflammation, as evident by an increase in total inflammatory
cells recovered in lavage fluid (Figure 5.3A). Treatment with gp130Fc was associated with
decreased inflammation, as indicated by a significant reduction in total cell counts. Cell
differential analysis of BAL fluid revealed a reduction in macrophages, lymphocytes, neutrophils
and eosinophils (Figure 5.3B-D).
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Figure 5.3. Pulmonary inflammation following chronic bleomycin exposure in mice treated
with recombinant gp130Fc. Wildtype C57Blk6 male mice were injected intraperitoneally with
saline or bleomycin twice weekly for 4 weeks. Beginning on day 19, when pulmonary fibrosis
has been established, daily treatment with vehicle (saline) or recombinant gp130Fc was
performed. Mice were sacrificed and samples collected on day 33. (A-D) Total cell count and
cell differential from bronchoalveolar lavage fluid (BAL fluid) of wild type C57Blk6 mice given
saline or bleomycin, with and without gp130Fc. Data presented as mean ± SEM, n≥6.
*significant difference from PBS-treated cohort; #significant difference from bleomycin-exposed
mice. *= p<0.05, **= 0.001<p<0.01, ***= p<0.001.
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5.4 – Treatment with recombinant gp130Fc reduced inflammatory cytokines in the lungs.
The ability of gp130Fc to dampen pulmonary inflammation led us to evaluate changes to
relevant pro-inflammatory and IL-6 responsive mediators, including monocyte chemoattractant
protein 1 (MCP-1), chemokine (C-X-C motif) ligand 1 (CXCL-1), interleukin 17 (IL-17), and
tissue inhibitor of metalloproteinases (TIMP-1). Whole lung RNA analysis revealed a significant
reduction in MCP-1, CXCL-1, IL-17 and TIMP-1 in mice treated with gp130Fc (Figure 5.4A-D).
These findings demonstrate that gp130Fc-mediated neutralization of IL-6 trans signaling in the
lungs can attenuate pulmonary inflammation and decrease pro-inflammatory and IL-6 responsive
mediators in this model.

5.5 – Treatment with recombinant gp130Fc reduced collagen transcript in the lungs.
Having

demonstrated

attenuation

of

pulmonary

inflammation

with

gp130Fc

administration, we next determined the effects of gp130Fc on pulmonary fibrosis. Aberrant
fibroblast activation, differentiation into myofibroblasts, and excessive collagen and fibronectin
production and deposition in the lungs are hallmarks of pulmonary fibrosis(2). Therefore, we
asked whether treatment with recombinant gp130Fc affected these indices.
To assess collagen production, day 33 whole lung RNA samples were analyzed for
transcript expression of collagen 1 isoforms. In comparison to levels of collagen transcript in the
non-fibrotic lungs of PBS-treated mice, bleomycin-treated mice exhibited increased transcript
levels of collagen 1A1 and collagen 1A2 (Figure 5.5A-B), consistent with the presence of
pulmonary fibrosis in those lungs. Treatment with gp130Fc resulted in significant reductions in
collagen 1A2 and and a trend for reduction in collagen 1A1.
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Figure 5.4. Expression of pro-inflammatory and IL-6 responsive mediators following
chronic bleomycin exposure in mice treated with recombinant gp130Fc. Wildtype C57Blk6
male mice were injected intraperitoneally with saline or bleomycin twice weekly for 4 weeks.
Beginning on day 19, when pulmonary fibrosis has been established, daily treatment with vehicle
(saline) or recombinant gp130Fc was performed. Mice were sacrificed and samples collected on
day 33. (A-D) Expression of MCP-1, CXCL-1, IL-17, and TIMP-1 transcript in whole lung
RNA. Data presented as mean ± SEM, n≥3. *significant difference from PBS-treated cohort;
#

significant difference from bleomycin-exposed mice. *= p<0.05, **= 0.001<p<0.01, ***=

p<0.001.
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Figure 5.5. Changes in collagen transcript following chronic bleomycin exposure in mice
treated with recombinant gp130Fc. Wildtype C57Blk6 male mice were injected
intraperitoneally with saline or bleomycin twice weekly for 4 weeks. Beginning on day 19, when
pulmonary fibrosis has been established, daily treatment with vehicle (saline) or recombinant
gp130Fc was performed. Mice were sacrificed and samples collected on day 33. (A-B) Whole
lung RNA was prepared and subjected to q-rtPCR evaluation for analysis of transcript levels of
collagen 1A1 and collagen 1A2. All data presented as mean ± SEM, n≥3. *significant difference
from PBS-treated cohort; #significant difference from bleomycin-exposed mice. *= p<0.05, **=
0.001<p<0.01, ***= p<0.001.
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5.6 – Recombinant gp130Fc reduced collagen protein expression in the lungs.
We validated the results of mRNA evaluation by measuring soluble collagen protein in
BAL fluid using Sircol assay. Gp130Fc administration resulted in a significant reduction in
collagen protein (Figure 5.6A). To see if this effect could be correlated to the decrease of soluble
IL-6Rα in the lungs, we subjected matched data of soluble IL-6Rα level and soluble collagen in
BAL fluid to correlation analysis. As seen in Figure 5.6B, when soluble IL-6Rα levels are
displayed on the x-axis and corresponding levels of soluble collagen in each sample plotted on
the y-axis, there is a significant correlation between receptor level and collagen level.

5.7 – Recombinant gp130Fc reduced collagen deposition and attenuated pulmonary fibrosis.
Changes in collagen transcripts and protein expression suggested gp130Fc mediated a
reduction in collagen production, so we proceeded to evaluate whether it also led to a reduction
in collagen deposition in the lungs. Day 33 lung sections were stained using Masson’s trichrome
protocol to visualize collagen deposition (blue). Untreated bleomycin-exposed lungs were
fibrotic and had extensive collagen deposition while gp130Fc-treated lungs had diminished
collagen presence (Figure 5.7A). To assess how the reduction in collagen production and
deposition affected pulmonary fibrosis in our mice, we performed Ashcroft scoring on the
stained sections. This is a subjective method of quantifying morphologic fibrosis that has been
used extensively(130). Bleomycin-treated lungs had mean scores of about 6 on a scale of 0-8,
with 8 being the highest severity of fibrosis. Gp130Fc treatment improved overall scores by
almost 50% (Figure 5.7B). These findings revealed that blockade of IL-6 trans signaling resulted
in a significant reduction in collagen production and deposition in the lungs, resulting in
attenuation of pulmonary fibrosis.
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Figure 5.6. Changes in collagen protein expression following chronic bleomycin exposure in
mice treated with recombinant gp130Fc. Wildtype C57Blk6 male mice were injected
intraperitoneally with saline or bleomycin twice weekly for 4 weeks. Beginning on day 19, when
pulmonary fibrosis has been established, daily treatment with vehicle (saline) or recombinant
gp130Fc was performed. Mice were sacrificed and samples collected on day 33. (A) Sircol
measurement of soluble collagen in BAL fluid on day 33. (B) Matched results of soluble IL-6Rα
level and corresponding soluble collagen level of each mouse subjected to correlation analysis;
analysis representative of 2 independent experiments. All data presented as mean ± SEM, n≥6.
*significant difference from PBS-treated cohort; #significant difference from bleomycin-exposed
mice. *= p<0.05, **= 0.001<p<0.01, ***= p<0.001.
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Figure 5.7. Changes in collagen deposition following chronic bleomycin exposure in mice
treated with recombinant gp130Fc. Wildtype C57Blk6 male mice were injected
intraperitoneally with saline or bleomycin twice weekly for 4 weeks. Beginning on day 19, when
pulmonary fibrosis has been established, daily treatment with vehicle (saline) or recombinant
gp130Fc was performed. Mice were sacrificed and samples collected on day 33. (A) Lung
sections from day 33 mice were stained with Masson’s trichrome for visualization of collagen
deposition (blue). Sections are representative of n≥6 mice from each group. Scale bars: 200µm.
(B) Pulmonary fibrosis was quantified by Ashcroft method. All data presented as mean ± SEM,
n≥6. *significant difference from PBS-treated cohort; #significant difference from bleomycinexposed mice. *= p<0.05, **= 0.001<p<0.01, ***= p<0.001.
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5.8 – Recombinant gp130Fc reduced myofibroblast accumulation and fibronectin expression.
To better understand how in vivo neutralization of IL-6 trans signaling attenuated
fibrosis, we assessed myofibroblast accumulation in gp130Fc-treated lungs. Myofibroblasts are a
central cellular player in pulmonary fibrosis, the main collagen-producing culprit(131). Lung
sections from day 33 mice were stained for alpha smooth muscle actin (α-SMA) for detection of
myofibroblasts. Whereas fibrotic lungs exhibited prominent red α-SMA staining that is
indicative of extensive myofibroblast accumulation, gp130Fc treated lungs presented with
diminished myofibroblast accumulation (Figure 5.8A). Comparisons between bleomycin versus
gp130Fc-treated lung sections visually emphasized the reduction in pulmonary fibrosis seen with
gp130Fc treatment. We also analyzed the expression of fibronectin, an extracellular matrix
protein found to be elevated in IPF lungs and is an additional indicator of fibrosis (132-135).
Protein lysates were made from day 33 lungs and western blot analysis was performed to detect
changes to fibronectin content. In comparison to bleomycin-exposed lungs, which have increased
expression of fibronectin, lungs treated with gp130Fc exhibit less fibronectin (Figure 5.8B).
PBS-injected mice treated with gp130Fc also experienced a reduction in fibronectin expression
in the lungs.
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Figure 5.8. Changes in myofibroblast presence and activity following chronic bleomycin
exposure in mice treated with recombinant gp130Fc. Wildtype C57Blk6 male mice were
injected intraperitoneally with saline or bleomycin twice weekly for 4 weeks. Beginning on day
19, when pulmonary fibrosis has been established, daily treatment with vehicle (saline) or
recombinant gp130Fc was performed. Mice were sacrificed and samples collected on day 33.
Lung sections from day 33 mice were stained for: (A) alpha smooth muscle actin (α-SMA) for
detection of myofibroblast accumulation (red). Sections are representative of n≥6 mice from
each group. Scale bars: 1mm. (B) Western blot analysis of fibronectin expression in whole lung
lysates.
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5.9 – Recombinant gp130Fc administration improved oxygen saturation.
Hypoxia is a feature of IPF and oxygen saturation measurements are often used clinically
to evaluate presence and severity of hypoxia(1). We evaluated changes to hypoxia in mice
treated with gp130Fc by measuring oxygen saturation. We observed a decrease in oxygen
saturation in untreated, bleomycin-injected mice that was inhibited by gp130Fc treatment (Figure
5.9). Collectively, these findings demonstrate that gp130Fc treatment attenuates pulmonary
fibrosis, leading to physiologic improvement in mice.

5.10 – Recombinant gp130Fc reduced pulmonary hypertension.
Pulmonary hypertension (PH, mean pulmonary artery pressure > 25 mmHg at rest)
occurs in 8.1-14.9% of IPF patients, with higher numbers seen in advanced (30-50%) and endstage (>60%) patients(136). Its presence in IPF patients is associated with increased mortality
risk(1). Karmouty-Quintana et al recently presented data suggesting that adenosine receptor 2Bmediated release of IL-6 from human pulmonary artery smooth muscle cells (PASMCs) is the
mechanism via which PH develops secondary to pulmonary fibrosis(91). We wanted to know
whether in vivo neutralization of sIL-6Rα affected development of PH in our mice. Right
ventricular systolic pressure (RVSP) is commonly used to indicate presence of PH. Measurement
of RVSP in mice administered bleomycin revealed significantly higher RVSP values in
comparison to PBS-treated mice (Figure 5.10). This is consistent with previous published results
demonstrating pulmonary hypertension secondary to bleomycin-induced pulmonary fibrosis(91).
Gp130Fc treatment resulted in significant reduction in RVSP, demonstrating that neutralization
of trans signaling led to improvement in pulmonary hypertension.
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Figure 5.9. Changes in arterial oxygen saturation following chronic bleomycin exposure in
mice treated with recombinant gp130Fc. Wildtype C57Blk6 male mice were injected
intraperitoneally with saline or bleomycin twice weekly for 4 weeks. Beginning on day 19, when
pulmonary fibrosis has been established, daily treatment with vehicle (saline) or recombinant
gp130Fc was performed. Pulse oximetry was conducted using neck collar on Day 32. All data
presented as mean ± SEM, n≥4. *significant difference from PBS-treated cohort; #significant
difference from bleomycin-exposed mice. *= p<0.05, **= 0.001<p<0.01, ***= p<0.001.
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Figure 5.10. Changes in pulmonary hypertension following chronic bleomycin exposure in
mice treated with recombinant gp130Fc. Wildtype C57Blk6 male mice were injected
intraperitoneally with saline or bleomycin twice weekly for 4 weeks. Beginning on day 19, when
pulmonary fibrosis has been established, daily treatment with vehicle (saline) or recombinant
gp130Fc was performed. Right ventricular systolic pressure (RVSP) was measured on Day 33.
All data presented as mean ± SEM, n≥4. *significant difference from PBS-treated cohort;
#

significant difference from bleomycin-exposed mice. *= p<0.05, **= 0.001<p<0.01, ***=

p<0.001. Data obtained by Harry Karmouty-Quintana, PhD.
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5.11. – Recombinant gp130Fc decreased STAT3 activation in lungs.
In search of the mechanism behind the reduction in pulmonary fibrosis when IL-6 trans
signaling is neutralized, we examined intracellular signaling effects of IL-6. IL-6 signaling
phosphorylates and activates Signal Transducer and Activator of Transcription 3 (STAT3)
(Figure 1.1), a transcription factor important in the pathogenesis of liver, skin and kidney
fibrosis(137, 138). Increased STAT3 activation has been reported in IPF(87, 139). Its role in
pulmonary fibrosis was evaluated by O’Donoghue et al., who demonstrated that IL-6-mediated
STAT3 activation increased bleomycin-induced fibrosis in a mouse model(87). Thus, we
evaluated changes to STAT3 activation in mice treated with gp130Fc. Western blot analysis of
protein lysates made from day 33 lungs revealed that phospho-STAT3 was increased in
bleomycin lungs compared to PBS lungs, and treatment with gp130Fc reduced STAT3 activation
(Figure 5.11A). Co-staining of P-STAT3 and cell-specific markers allowed us to determine,
more specifically, that there was a decrease in P-STAT3-positive myofibroblasts in gp130Fctreated lungs (Figure 5.11B). We confirmed this finding in human samples, where we saw an
abundant presence of P-STAT3-positive myofibroblasts in IPF lung sections in comparison to
control sections (Figure 5.11C). These results suggest that IL-6 trans signaling in this population
of cells could be crucial to the fibrotic process. We therefore focused our efforts on examining
IL-6 trans signaling in fibroblast biology to understand its contribution to pulmonary fibrosis.

119

Figure 5.11. STAT3 activation following chronic bleomycin exposure in mice treated with
mouse recombinant gp130Fc and in IPF lungs. Wildtype C57Blk6 male mice were injected
intraperitoneally with saline or bleomycin twice weekly for 4 weeks. Beginning on day 19, when
pulmonary fibrosis has been established, daily treatment with vehicle (saline) or recombinant
gp130Fc was performed. Mice were sacrificed and samples collected on day 33. (A) Western
blot analysis of phospho-STAT3 expression in lung lysates from C57Bl6 mice given saline or
bleomycin with and without gp130Fc, Day 33. (B) P-STAT3 immunofluorescence (red) in
myofibroblasts (green) in these lungs. (C) P-STAT3 immunopositivity (brown) in
myofibroblasts (red) in IPF lungs. Arrows denote positive cells. Images are representative of n≥4
animals from each group. Scale bars: 50µm, 100x oil immersion.
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5.12-5.13 - IL-6 trans signaling promoted extracellular matrix protein production in vitro.
Aberrant fibroblast activation, differentiation into myofibroblasts, and excessive collagen
and fibronectin production and deposition in the lungs are hallmarks of pulmonary fibrosis(2). In
an effort to better understand the effects of IL-6 trans signaling on fibroblast biology, we
examined these endpoints in vitro, using normal and IPF fibroblast cell lines.
To evaluate the effect of IL-6 trans signaling on production of extracellular matrix
proteins, normal and IPF fibroblasts were serum-starved and stimulated with transforming
growth factor β (TGF-β) or IL-6 and sIL-6Rα for 24, 48 and 72 hours. Protein lysates were
collected from these cells and subjected to western blot analyses for detection of collagen and
fibronectin. TGF-β was used as a positive control since it has been shown to be a potent inducer
of extracellular matrix protein production and myofibroblast differentiation and to play a central
role in pulmonary fibrosis(133, 140, 141).
In control fibroblasts, TGF-β stimulation induced expression of collagen and fibronectin
and increased expression of α-SMA and membrane IL-6Rα at all three time points (Figure
5.12A-C). Stimulation of trans signaling via addition of IL-6 and sIL-6Rα resulted in increased
collagen production visibly by 24 hours, with greater levels of protein seen at 48 hours; by 72
hours, collagen levels had begun trending down to baseline. The trend in collagen levels was
associated with fibronectin levels that were unchanged at 24 and 48 hours, though mildly
decreased at 72 hours. There were no changes in α-SMA at 24 and 48 hours but a decrease in αSMA at 72 hours. Changes in expression of membrane IL-6Rα mirrored the changes in collagen
production. Membrane IL-6Rα was mildly elevated by 24 hours, greatly enhanced by 48 hours,
and was visibly decreased by 72 hours (Figure 5.12A-C).
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Figure 5.12. Effect of IL-6 trans signaling on ECM protein production in control and IPF
fibroblasts over time. Control and IPF fibroblasts were serum-starved for 24 hours and then
stimulated with IL-6 and sIL-6Rα. Western blot analyses were performed for expression of
collagen, fibronectin, α-SMA, and membrane IL-6Rα after 24, 48 and 72 hours in (A-C) normal
fibroblasts and (D-F) IPF fibroblasts. Western blot pictures are representative of n=2.

In IPF fibroblasts, TGF-β stimulation induced expression of collagen and fibronectin and
increased expression of α-SMA and membrane IL-6Rα at all three time points, though to a lesser
extent than in control fibroblasts (Figure 5.12D-F). Stimulation of trans signaling via addition of
IL-6 and sIL-6Rα resulted in no difference at 24 hours and increased collagen production at 48
and 72 hours. Fibronectin levels were mildly elevated at 24 hours and experienced greater
increases at 48 and 72 hours. α-SMA was mildly increased at 24 and unchanged at 48 and 72
hours. Membrane IL-6Rα was elevated at 24, 48 and 72 hours, in comparison to non-stimulated
fibroblasts (Figure 5.12D-F).
These findings suggest that IL-6 trans signaling promote production of collagen and
fibronectin in control and IPF fibroblasts, perhaps through regulation of membrane IL-6Rα
expression. Since expression of collagen and fibronectin appeared to be associated with changes
in membrane IL-6Rα, we asked whether IL-6 classical signaling alone would alter collagen and
fibronectin levels and to what extent in comparison to trans signaling. So, we repeated the
stimulation experiment, but this time, fibroblasts were stimulated with TGF-β, IL-6 alone, or IL6 + sIL-6Rα. Stimulation occurred for 48 hours since the previous experiment indicated greatest
changes in protein expression in 48-hour samples.

123

Figure 5.13. Differential effects of IL-6 classical and trans signaling on extracellular matrix
protein production in control and IPF fibroblasts in vitro. (A) Control and (B) IPF
fibroblasts were serum-starved for 24 hours and then stimulated with IL-6 alone or IL-6 and sIL6Rα for 48 hours. Western blot analyses were performed for expression of collagen, fibronectin,
EDA-fibronectin, α-SMA, membrane IL-6Rα and phospho-STAT3. Western blot pictures are
representative of n=2.
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In control fibroblasts, IL-6 alone increased collagen expression slightly. IL-6 + sIL-6Rα
induced a pronounced increase in collagen to levels comparable to or higher than those seen with
TGF-β stimulation (Figure 5.13A). In IPF fibroblasts, both IL-6 alone and IL-6 + sIL-6Rα were
able to induce collagen expression to levels comparable to those of TGF-β stimulation (Figure
5.13B). In control fibroblasts, IL-6 alone increased fibronectin expression slightly. IL-6 + sIL6Rα induced a pronounced increase in fibronectin, to levels higher than those seen with TGF-β
stimulation (Figure 5.13A). IL-6 stimulation in IPF fibroblasts led to an increase in fibronectin,
while IL-6 + sIL-6Rα led to an increase that was even greater than that induced by TGF-β
(Figure 5.13B). Recently, Muro et al demonstrated that IPF lung fibroblasts produce more of a
specific isoform of cellular fibronectin, fibronectin containing extra type III domain A (EDAfibronectin), than normal fibroblasts(142). They also reported that mice lacking EDA-fibronectin
were protected against development of pulmonary fibrosis after bleomycin challenge. Thus, we
evaluated whether IL-6 trans signaling regulated expression of EDA-fibronectin. Results
revealed variable expression of EDA-fibronectin in response to IL-6 alone or IL-6 + sIL-6Rα in
control fibroblasts (Figure 5.13A). In IPF fibroblasts, however, IL-6 alone induced EDAfibronectin expression and IL-6 + sIL-6Rα increased expression even further (Figure 5.13B).
IL-6 alone or IL-6 + sIL-6Rα did not change α-SMA and mIL-6Rα expression in control
fibroblasts while inducing increased α-SMA and mIL-6Rα expression in IPF fibroblasts (Figure
5.13A&B). In control fibroblasts, IL-6 alone did not promote phosphorylation of STAT3 while
IL-6 + sIL-6Rα resulted in increased P-STAT3. In IPF fibroblasts, both IL-6 alone and IL-6 +
sIL-6Rα stimulated increased activation of STAT3 (Figure 5.13A&B). These results suggest that
both classical and trans signaling can regulate collagen and fibronectin production. Although IL6 trans signaling increases protein production in both normal and IPF fibroblasts, the effect on
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collagen and fibronectin production is similar in normal fibroblasts, while in IPF fibroblasts, its
effect on fibronectin production appear greater than on collagen production.

5.14-5.15 – IL-6 trans signaling promoted proliferation & resistance to apoptosis in IPF
fibroblasts in vitro.
Having demonstrated the effect of trans signaling on extracellular matrix protein
production, we next analyzed changes to proliferation and apoptosis subsequent to stimulation of
trans signaling in these cells. Excessive proliferation and resistance to apoptosis are features of
fibroblasts from IPF lungs that perpetuate their presence in the diseased lung and contribute to
ongoing fibrotic changes(143). Moodley et al reported that IL-6 inhibited proliferation of
fibroblasts isolated from normal lungs while promoting proliferation of IPF fibroblasts(144).
They also demonstrated that IL-6 mediated enhanced Fas-induced apoptosis in normal
fibroblasts while inhibiting apoptosis in IPF fibroblasts(145). However, evidence exists to
suggest that there is much heterogeneity in fibroblast populations in IPF lungs and they respond
differently to IL-6 signaling(119). Thus, we set out to determine the differential effects of IL-6
classical and trans signaling on normal and IPF fibroblast proliferation and apoptosis in vitro.
Baseline proliferation rates of IPF fibroblasts were already higher than those of normal
fibroblasts (Figure 5.14A). Stimulation with IL-6 alone resulted in a significant increase in
proliferation in IPF fibroblasts but not normal fibroblasts. The combination of IL-6 and soluble
IL-6Rα significantly promoted proliferation in both normal and IPF fibroblasts. When
proliferation rates were reported as a change from baseline rates, stimulation with IL-6 and sIL6Rα resulted in a significant 1.2-fold difference in normal fibroblasts (Figure 5.14B). In IPF
fibroblasts, IL-6 stimulation alone was sufficient to induce a significant 1.4-fold increase in
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proliferation, and IL-6 in combination with sIL-6Rα resulted in a 1.5-fold increase in
proliferation. The difference in response to trans signaling may be due to baseline expression of
membrane IL-6Rα in control versus IPF fibroblasts (Figure 5.14C).
In terms of spontaneous apoptosis, IL-6 alone had no effect on normal fibroblasts while
IL-6 + sIL-6Rα caused a slight decrease in apoptosis at a lower confluency (Thesis Figure
5.15A) and increased apoptosis significantly at a higher confluency (Figure 5.15B). In IPF
fibroblasts, IL-6 alone enhanced spontaneous apoptosis at low and high levels of confluency
(Figure 5.15C&D). IL-6 + sIL-6Rα also enhanced apoptosis at low confluency but there was no
significant increase at higher confluency of fibroblasts. In all, these experiments demonstrate a
role for IL-6 trans signaling in proliferation and apoptosis of pulmonary fibroblasts.

5.16 – Neutralization of IL-6 trans signaling in vitro inhibited production of collagen in
control and IPF fibroblasts.
To evaluate whether blockade of IL-6 trans signaling affects protein production in vitro,
control and IPF fibroblasts were stimulated with IL-6 and sIL-6Rα for 48 hours in the presence
or absence of recombinant gp130Fc. Protein lysates were prepared and subjected to western blot
analyses for detection collagen expression. Results revealed inhibition of collagen production
with addition of gp130Fc in both control and IPF fibroblasts (Figure 5.16A&B).

5.17-5.18 – Neutralization of IL-6 trans signaling in vitro inhibited fibroblast proliferation
and altered spontaneous apoptosis.
To evaluate whether blockade of IL-6 trans signaling affects proliferative capacity of
normal and IPF fibroblasts in vitro, proliferation rates were assessed in response to in vitro
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neutralization of trans signaling via addition of recombinant gp130Fc. In normal fibroblasts,
increasing concentrations of gp130Fc resulted in significant dose-dependent inhibition of
proliferation, beginning at smaller doses (Figure 5.17A&B). In IPF fibroblasts, there was a trend
for increasing inhibition of proliferation, with significant inhibition occurring at a higher dose of
gp130Fc (Figure 5.17C&D). The difference in response to neutralization concentrations may be
due to the higher responsiveness of IPF fibroblasts to stimulation by trans signaling in
comparison to normal fibroblasts (Figure 5.14C).
In terms of spontaneous apoptosis, in normal fibroblasts, IL-6 + sIL-6Rα caused a
significant reduction in apoptosis, which was reversed with gp130Fc (Figure 5.18A). In IPF
fibroblasts, IL-6 + sIL-6Rα enhanced spontaneous apoptosis, an effect that began to show
evidence of reversing at the highest dose of gp130Fc (Figure 5.18B).
In all, the findings from these in vitro experiments support a role for IL-6 trans signaling
in enhancing fibroblast proliferation, activation and extracellular matrix protein production that
could lead to the overpopulation of the lung parenchyma and excessive protein deposition
observed in pulmonary fibrosis.
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Figure 5.14. Effect of IL-6 trans signaling on proliferation rates in control and IPF
fibroblasts in vitro. Control and IPF fibroblasts were serum-starved for 24 hours and then
stimulated for 48 hours with IL-6 alone or IL-6 and sIL-6Rα. Proliferation rates were assessed in
response to IL-6 and soluble IL-6Rα and expressed in raw data (A) and change from baseline
proliferation (B). (C) Membrane IL-6Rα expression in control and IPF fibroblasts. All data
presented as mean ± SEM, n≥8. *significant difference from media only cohort; #significant
difference from IL-6 only group; *= p<0.05, **= 0.001<p<0.01, ***= p<0.001.
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Figure 5.15. Effect of IL-6 trans signaling on spontaneous apoptosis in control and IPF
fibroblasts in vitro. Control and IPF fibroblasts were serum-starved for 24 hours and then
stimulated for 48 hours with IL-6 alone or IL-6 and sIL-6Rα. Spontaneous apoptosis at low and
high confluency in (A&B) control fibroblasts and (C&D) IPF fibroblasts was assessed in
response to IL-6 and soluble IL-6Rα and expressed in raw data. All data presented as mean ±
SEM, n≥8. *significant difference from media only cohort; #significant difference from IL-6 only
group; *= p<0.05, **= 0.001<p<0.01, ***= p<0.001.
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Figure 5.16. Effect of neutralizing IL-6 trans signaling on collagen production in control
and IPF fibroblasts in vitro. Control and IPF fibroblasts were serum-starved for 24 hours and
then stimulated for 48 hours with IL-6 and sIL-6Rα in the presence of absence of recombinant
gp130Fc. Western blot analyses of collagen expression in (A) normal fibroblasts and (B) IPF
fibroblasts.
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Figure 5.17. Effect of neutralizing IL-6 trans signaling on proliferation rates in control and
IPF fibroblasts in vitro. Control and IPF fibroblasts were serum-starved for 24 hours and then
stimulated for 48 hours with IL-6 alone or IL-6 and sIL-6Rα in the presence of absence of
recombinant gp130Fc. (A&B) Changes to proliferation rate of normal fibroblasts in response to
increasing concentrations of gp130Fc, expressed as raw data and changes with respect to
baseline. (C&D) Changes to proliferation rate of IPF fibroblasts in response to increasing
concentrations of gp130Fc, expressed as raw data and changes with respect to baseline All data
presented as mean ± SEM, n≥6. *significant difference from media only cohort; #significant
difference from IL-6 only group; %significant difference from IL-6+sIL-6Rα cohort; *= p<0.05,
**= 0.001<p<0.01, ***= p<0.001.
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Figure 5.18. Effect of neutralizing IL-6 trans signaling on spontaneous apoptosis in control
and IPF fibroblasts in vitro. Control and IPF fibroblasts were serum-starved for 24 hours and
then stimulated for 48 hours with IL-6 alone or IL-6 and sIL-6Rα in the presence of absence of
recombinant gp130Fc. (A&B) Changes to spontaneous apoptosis of normal fibroblasts in
response to increasing concentrations of gp130Fc, expressed as raw data and changes with
respect to baseline. (C&D) Changes to spontaneous apoptosis of IPF fibroblasts in response to
increasing concentrations of gp130Fc, expressed as raw data and changes with respect to
baseline All data presented as mean ± SEM, n≥6 for control and n≥4 for IPF. *significant
difference from media only cohort; #significant difference from IL-6 only group; %significant
difference from IL-6+sIL-6Rα cohort; *= p<0.05, **= 0.001<p<0.01, ***= p<0.001.
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5.19 – Recombinant gp130Fc reduced mIL-6Rα protein in whole lung and BAL cells.
In our in vitro mechanistic studies of control and IPF fibroblasts, we saw an association
between increases and decreases in membrane IL-6Rα protein expression after stimulation of
trans signaling in control and IPF fibroblasts and resulting changes in proliferation and protein
production. This association suggested a cooperative effect of IL-6 trans and classical signaling
in development of pulmonary fibrosis. Given this knowledge, we wanted to evaluate changes to
mIL-6Rα after in vivo blockade of trans signaling to see if the same association is seen in vivo.
Whole lung RNA and protein lysates were prepared from Day 33 bleomycin-exposed and
gp130Fc-treated mice. Whole lung RNA was subjected to q-rtPCR analysis for transcript levels
of mIL-6Rα. Protein lysates were subjected to western blot analysis of mIL-6Rα expression.
Western blot analyses revealed elevated expression of membrane IL-6Rα protein in bleomycinexposed lungs (Figure 5.19A), consistent with the results of our initial characterization studies
(Figure 3.4A). Gp130Fc treatment resulted in a reduction in protein expression. Protein lysates
were also prepared from Day 33 BAL cells and western blot performed for evaluation of mIL6Rα. BAL cells from bleomycin-exposed lungs exhibited elevated mIL-6Rα protein expression
(Figure 5.19B), once again consistent with our previous results (Figure 3.4B). Gp130Fc-treated
lungs experienced a reduction in mIL-6Rα. Immunofluorescence staining of day 33 BAL cells
revealed augmented expression of mIL-6Rα in bleomycin-exposed, fibrotic lungs (Figure
5.19B). BAL cells from gp130Fc-treated mice displayed less expression of mIL-6Rα. These
results, in combination with our in vitro results, indicate that in vivo neutralization of IL-6 trans
signaling using gp130Fc had effected a reduction in classical signaling as well.
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Figure 5.19. Changes in membrane IL-6R alpha following chronic bleomycin exposure in
mice treated with recombinant gp130Fc. Wildtype C57Blk6 male mice were injected
intraperitoneally with saline or bleomycin twice weekly for 4 weeks. Beginning on day 19, when
pulmonary fibrosis has been established, daily treatment with vehicle (saline) or recombinant
gp130Fc was performed. Mice were sacrificed and samples collected on day 33. Western blot
analysis of mIL-6Rα expression in (A) whole lung and (B) BAL cell pellet protein lysates. (C)
Immunofluorescence detection of mIL-6Rα on macrophages isolated from bleomycin-exposed
mice treated with saline or gp130Fc; membrane IL-6Rα (green), dapi (blue). Arrows point to
positive cells.
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DISCUSSION
In support of a role for IL-6 trans signaling in pulmonary fibrosis, we have demonstrated
ADAM17-mediated increases in soluble IL-6Rα in association with disease. To determine if
there were therapeutic benefits to in vivo neutralization of sIL-6Rα and resulting antagonism of
IL-6 trans signaling in disease, we utilized recombinant gp130Fc to neutralize sIL-6Rα and
selectively block IL-6 trans signaling in our chronic bleomycin model and evaluated the effects
on pulmonary inflammation and fibrosis.
In the IPB model, bleomycin-exposed mice developed significant pulmonary
inflammation. In mice challenged with bleomycin and treated with gp130Fc, there were marked
reductions in pulmonary inflammation, as evident by a reduction in the number of inflamatory
cells recovered in BAL fluid, including reductions in macrophages, lymphocytes, neutrophils and
eosinophils. The reduction in pulmonary inflammation with gp130Fc treatment in our model is
consistent with previous studies demonstrating that inhibition of IL-6 trans signaling resulted in
improvement in chronic inflammatory conditions like colitis(76), arthritis(73), and colitisassociated premalignant cancer(78). These results suggest that IL-6 trans signaling is responsible
for the pro-inflammatory property of IL-6 in a model of pulmonary fibrosis. Though the role of
inflammation in the pathogenesis of IPF is now controversial, there is still much interest in
exploring specific cellular players in the lung and their roles in fibrosis. Of particular interest is
the gp130Fc-mediated decrease in macrophages and lymphocytes that we saw in our study. This
could point to mechanisms for reduced severity of disease with gp130Fc administration. Both
macrophages and lymphocytes have been suggested to play roles in the development of
pulmonary fibrosis (113-117, 146, 147), but their exact contribution to IPF has not been
examined. Further evaluation of these cell types and their role in disease is needed.

136

Another point of interest is the gp130Fc-mediated reduction in IL-6-responsive mediators
IL-17 and TIMP-1. Wilson et al previously reported increased IL-17A levels in bronchoalveolar
lavage fluid from IPF patients and demonstrated an essential role for IL-17A in bleomycin and
IL-1β-induced pulmonary fibrosis in mice(148). Conte et al demonstrated that a reduction in IL17-producing cells and IL-17 expression protected mice from bleomycin-induced pulmonary
fibrosis(149). However, other studies suggest differently and the role of IL-17 in pulmonary
diseases is controversial(150). Galati et al reported a significant reduction in Th17 cells and an
increased TGF-α/IL-17 ratio in IPF patients(151). Interestingly, Ge et al demonstrated that lack
of IL-17 receptor A (IL-17RA), which mediates IL-17A signaling, led to decreased numbers of
tissue macrophages and attenuated inflammation and fibrosis in the kidneys(152). Nuovo et al
demonstrated localization of IL-17 expression to regenerating epithelial cells and alveolar
macrophages in IPF lungs(147). Our study demonstrated decreased macrophage numbers in
association with decreased IL-17 in mice treated with gp130Fc treatment. This would suggest
that IL-6 trans signaling may be regulating macrophage accumulation in the lung via IL-17 and
needs further study.
Our study revealed that TIMP-1 transcript was increased in bleomycin-exposed fibrotic
lungs but decreased with gp130Fc treatment. This change in TIMP-1 is consistent with a
previous study showing induction of TIMP-1 in human synovial fibroblasts after stimulation of
IL-6 trans signaling, resulting in decreased collagenolytic activity(153). This suggests that
blockade of IL-6 trans signaling by gp130Fc lifted the inhibitory effect of TIMP-1 and restored
collagenolytic activity in the lung. Further study is needed to evaluate whether protein expression
was reduced and whether it resulted in increased degradation of deposited collagen and
resolution of fibrosis.
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The compelling finding of this study was the novel observation that neutralization of IL-6
trans signaling resulted in attenuation of pulmonary fibrosis in our chronic bleomycin model.
The hallmark features of IPF include excessive fibroblast activation, accumulation of α-smapositive myofibroblasts and excessive production and deposition of matrix proteins, including
collagen and fibronectin(2). Our study demonstrated that neutralization of IL-6 trans signaling
resulted in a reduction in myofibroblast accumulation and extracellular matrix protein production
and deposition in the lungs, which translated to a reduction in pulmonary fibrosis and
improvement in pulmonary oxygenation. Previous studies have suggested a role for IL-6 trans
signaling in liver fibrosis(154), renal fibrosis(82) and myocardial fibrosis(72), though none have
demonstrated improvement in fibrosis with blockade of trans signaling in vivo using gp130Fc.
This is the first study to examine the role of IL-6 trans signaling in pulmonary fibrosis and
demonstrated a therapeutic benefit to antagonism of this pathway in vivo.
In search of the underlying mechanism that would explain the improvement in fibrosis
seen with gp130Fc treatment, we performed in vitro mechanistic studies that revealed the ability
of IL-6 trans signaling to promote proliferation and collagen and fibronectin production in
control and IPF fibroblasts, events crucial to disease progression. Findings from our in vitro
studies of IL-6 trans signaling in fibroblasts are consistent with previous studies that have
demonstrated that trans signaling can induce hepatocyte proliferation and intracellular
signaling(154), promote collagen production in cardiac fibroblasts(72) and induce proliferation
and extracellular matrix protein production in fibroblasts from hypertrophic scars(155). What
may warrant further study is the downstream effects of IL-6 classical versus trans signaling in
fibroblasts that may explain the differences in stimulation of fibronectin versus collagen
production.
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Figure 5.20. Proliferation rates in control fibroblasts in vitro. Control fibroblasts were serumstarved for 24 hours and then stimulated IL-6 alone or IL-6 and sIL-6Rα. (A) Changes to
proliferation rate after 24 hours of stimulation. (B) Changes to proliferation rate after 48 hours of
stimulation with increasing concentrations of IL-6 alone or IL-6 and sIL-6Rα. All data presented
as mean ± SEM, n≥4. *significant difference from media only cohort; #significant difference
from IL-6 only group;

%

significant difference from IL-6+sIL-6Rα cohort; *= p<0.05, **=

0.001<p<0.01, ***= p<0.001.
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It must be noted, however, that Moodley et al examined the effect of IL-6 on fibroblast
proliferation and concluded that IL-6 inhibits proliferation and enhanced Fas-induced apoptosis
in normal fibroblasts but enhanced proliferation and increased resistance to apoptosis in IPF
fibroblasts(144, 145) Differences between these findings may be related to the source of cells or
conditions used. For example, the starvation and stimulation times were different between our
studies. To confirm our results seen with 48 hours of stimulation, we evaluated proliferation in
control fibroblasts after 24 hours of stimulation with IL-6 or IL-6 + sIL-6Rα. We did not show
growth inhibition with IL-6 stimulation, even at 24 hours (Figure 5.20A). In the study by
Moodley et al, changes in proliferation in response to IL-6 stimulation was compared to time 0
fibroblasts. In our study, changes were reported in comparison to fibroblasts that have been
cultured without stimulation for the same period of time as stimulated fibroblasts, i.e. fibroblasts
cultured in media only for 24 0r 48 hours. Both studies agree that stimulation of normal
fibroblasts with IL-6 ≤50ng/ml does not result in inhibition of proliferation. Moodley et al
reported growth inhibition with IL-6 stimulation ≥100ng/ml, while in our hands, even higher
concentrations of IL-6 were not anti-proliferative in normal fibroblasts (Figure 5.20B). It is
unclear the reason for this difference in observations. However, Moodley et al did not examine
the effect of trans signaling on fibroblast proliferation, whereas our study did.
With regards to our apoptosis data, we did not examine Fas-induced apoptosis but rather
only spontaneous apoptosis, so our results cannot be accurately compared to those of Moodley et
al. We did not show enhanced apoptosis in normal fibroblasts stimulated with IL-6 alone, but we
did see enhanced apoptosis in those stimulated with IL-6 + sIL-6Rα. In IPF fibroblasts, we saw
enhanced apoptosis with stimulation of classical signaling and no change to apoptosis with
stimulation of trans signaling. Thus, these results regarding spontaneous apoptosis, when
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analyzed along with the proliferation data, suggest that classical signaling doesn’t affect
proliferation or spontaneous apoptosis in normal fibroblasts. Trans signaling in normal
fibroblasts, however, increases proliferation and exert different effects on apoptosis depending
on the availability of space. Trans signaling may act to inhibit apoptosis when there is room for
growth; however, when space is limited, trans signaling increases apoptosis of normal fibroblasts
to control expansion. On the other hand, in IPF fibroblasts, IL-6 classical signaling alone can
promote proliferation and increases apoptosis in low and high confluency states. Trans signaling
in IPF fibroblasts, promotes apoptosis at lower confluency while inhibiting apoptosis at higher
confluency, failing to control growth, leading to unregulated expansion. Further work is needed
to evaluate differential effects of IL-6 trans signaling with regards to stimulus-induced apoptosis.
The finding of improvement in pulmonary hypertension with recombinant gp130Fc
treatment in our study was intriguing. As mentioned in chapter 1, PH is a recognized
complication of the disease process in IPF. The presence of PH greatly increases mortality risk
and decrease survival of IPF patients(2, 6, 11). Yet, there are no recommendation for therapy
except in very advanced cases of PH associated with IPF. Hypoxemia (which can occur in lung
disease) leads to PH and we were able to show that gp130Fc treatment caused an improvement in
pulmonary hypertension. It’s possible that hypoxemia affects generation of sIL-6Rα, leading to
PH. The improvement in PH could be due improvement in hypoxemia or a reduction in
pulmonary fibrosis. It would be interesting and fruitful to explore the role of IL-6 trans signaling
in pulmonary hypertension. This has not been studied and needs further exploration.
Surprisingly, our analysis of changes to IL-6 classical signaling in response to
neutralization of sIL-6Rα in vivo also generated some interesting theories. The decrease in
membrane IL-6Rα mRNA in bleomycin-induced fibrotic lungs was consistent with published
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results showing IL-6-mediated suppression of mIL-6Rα mRNA expression in a hepatoma cell
line(156) or colitis-associated decreased mIL-6Rα mRNA(78). Yet, protein expression of
membrane IL-6Rα was elevated in fibrotic lungs (in association with increased soluble receptor)
and decreased with gp130Fc treatment, suggesting that the membrane receptor protein
expression, and therefore IL-6 classical signaling, may be directly or indirectly regulated by
trans signaling. Our in vitro studies appear to support this idea. Activation of pulmonary
fibroblasts, via stimulation of trans signaling, can increase expression of membrane IL-6Rα
(Figure 5.12). This would suggest a mechanism of action in fibrotic lungs, whereby IL-6 trans
signaling may work to enhance classical signaling by increasing expression of the membrane
receptor. The increased expression of the membrane receptor can either: 1) increase classical
signaling if the membrane receptor is not cleaved or 2) increase trans signaling if the membrane
receptor is cleaved to form the soluble receptor. In this way, there is potential for perpetuation of
IL-6 signaling that leads to over-amplification of effects, resulting in progression of disease. We
need to further study the effect of trans signaling on other pulmonary cell types as well as
examine the changes to ADAM17 expression and production of sIL-6Rα from pulmonary
fibroblasts after stimulation of IL-6 trans signaling in order to better understand the consequence
of this pathway in the lung.
The results of our in vitro studies raises questions about the existence of a cross-talk
between TGF-β and IL-6 in pulmonary fibroblasts. We know TGF-β is increased in IPF and has
been shown to be a pivotal player in disease(143). There is evidence of crosstalk between these
two cytokines in other diseases. Yamamoto et al reported that TGF-β potentiates IL-6 induced
STAT3 activation and resulting gene expression in hepatoma cells(157). Walia et al
demonstrated TGF-β1 negatively regulated IL-6 signaling in intestinal epithelial cells(158).
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Yamada et al provided evidence of a crosstalk betweent TGF-β1 and IL-6 in biliary tract cancer
cells resulting in conferrence of malignant features, including epithelial-mesenchymal transition,
increased invasiveness, and resistance to chemotherapy(159). More recently, O’Reilly et al
revealed that IL-6 trans signaling, through phosphorylation of STAT3 and downstream
activation of gremlin, leads to activation of TGF-β signaling and collagen production in dermal
fibroblasts from systemic sclerosis patients(160). The intricacies of interaction of IL-6 and TGFβ in IPF lungs, however, remains unclear.
Elias et al has demonstrated that TGF-β induces IL-6 production in normal human
pulmonary fibroblasts(161). Gallelli et al illustrated the role of membrane IL-6 receptor alpha in
mediating TGF-β-induced proliferation of normal and fibrotic lung fibroblasts by showing
decreased proliferation with the use of an antagonist against the receptor(162). In this study, we
showed that TGF-β stimulation of control and IPF lung fibroblasts in vitro resulted in enhanced
expression of mIL-6Rα protein in association with increased collagen and fibronectin production
and increased myofibroblast differentiation (Figure 5.12). Our results are consistent with
published results demonstrating TGF-β-mediated regulation of mIL-6Rα mRNA in a hepatoma
cell line(156) and mIL-6Rα protein expression in biliary tract cancer cells(159). No previous
study has reported changes to mIL-6Rα protein expression in response to TGF-β stimulation of
lung fibroblasts though. The change in mIL-6Rα protein expression we have shown in response
to TGF-β stimulation may represent mechanisms of positively regulating TGF-β activity since
IL-6 has been reported to increase TGF-β1 signaling by regulating TGF-β receptor
compartmentalization and turnover in human renal tubular epithelial cells (163). It could also be
a means of counteracting the effects of TGF-β. Chen et al demonstrated that IL-6 protects
hepatoma cells from TGF-β-induced apoptosis(164). Exactly how IL-6 and TGF-β interact – at
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what time, in what cells – in order to exert their effects and whether this crosstalk perpetuates the
actions of both these cytokines in fibrotic lungs needs further analysis to fully understand.
Our in vivo and in vitro findings also led to questions regarding the role of IL-6 classical
and trans signaling in macrophages and macrophage-fibroblast interactions. Murray et al
demonstrated that TGF-β-mediated pulmonary fibrosis is dependent on macrophages of the M2
phenotype(116). In our timecourse study, we have demonstrated an increase in macrophages in
our chronic bleomycin model of pulmonary fibrosis (Figure 4.2C). In our in vivo neutralization
study, we showed a reduction in these macrophages in gp130Fc-treated lungs associated with
decreased pulmonary fibrosis (Figure 5.3B). These macrophages are known to be primarily M2
in phenotype (Figure 2.4B) and we have reported increased mIL-6Rα protein expression on these
cells as well as increased shedding of the membrane receptor from these cells to produce sIL6Rα (Figure 4.1 & 4.2). Thus we have supported an important role for them in disease, in
agreement with Murray et al. We have also suggested a role for IL-6 trans signaling in
recruitment and activation of M2 macrophages. Further study is needed to determine what the
roles of IL-6 classical and trans signaling are in generation of these activated macrophages as
well as in regulating their activities.
We also know from the literature that TGF-β expression has been shown to be localized
to epithelial cells and alveolar macrophages after bleomycin-induced pulmonary fibrosis(165,
166). We know TGF-β transcript levels are elevated in normal alveolar macrophages and
peripheral monocytes but only when the cells are activated do protein synthesis and TGF-β
secretion occur(167). That knowledge, along with what we have seen in our studies, suggests a
possible model of recruitment and activation of macrophages in the lungs in response to injury,
which increases TGF-β secretion, which in turn can regulate mIL-6Rα expression in these

144

macrophages and other cells in the lung, including fibroblasts, to influence cellular activation,
mediator production and induce collagen and fibronectin synthesis and secretion, all of which
contributes to pulmonary fibrosis. It would also be interesting to determine if this proposed
model is supported in the case of IPF patients. Of particular interest is the role of macrophagefibroblast interactions in development of fibrosis. Ma et al reported that co-cultures of
macrophages and cardiac fibroblasts led to macrophage stimulation of IL-6 production in cardiac
fibroblasts, resulting in activation of TGF-β1 and promotion of cardiac fibrosis(168). The same
could be true in pulmonary fibrosis and needs to be studied.
Overall, our in vivo and in vitro data suggest that IL-6 trans signaling mediates proproliferative, pro-fibrotic effects in the lungs. We demonstrated the essential role of trans
signaling in pulmonary fibrosis and the therapeutic benefits of its neutralization, providing a
novel, potentially effective treatment modality for IPF. However, the contribution of IL-6
classical signaling to disease cannot be denied as it appears that classical signaling in the lungs
seem to be intimately connected with trans signaling. Our studies have provided a more detailed
understand of IL-6 classical and trans signaling in IPF and our mouse model of pulmonary
fibrosis, but there are many questions that remain unanswered and need further evaluation.
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CHAPTER 6
Interleukin-6 (IL-6)
Classical and Trans Signaling in the
Adenosine-deaminase (ADA)-Deficient
Murine Model of Pulmonary Fibrosis
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EXPERIMENTAL RATIONALE & KEY QUESTIONS
Having demonstrated, in chapters 3-5, the involvement and role of both IL-6 classical and
trans signaling in IPF and in our chronic bleomycin mouse model of pulmonary fibrosis, we
proceeded to characterize these pathways in another mouse model, the adenosine-deaminase
(ADA)-deficient model (Figure 1.4). In the ADA-deficient murine model of pulmonary fibrosis,
genetic removal of the enzyme ADA results in adenosine-mediated pulmonary inflammation,
emphysematous distal airspace enlargement and pulmonary fibrosis(28, 94, 95). Studying IL-6
classical and trans signaling in this model will serve to confirm and enhance the results we
obtained in the IPB model. At the same time, we will benefit from a second animal model that
consists of the co-existence of pulmonary fibrosis and emphysema.
Based on the analyses of recent retrospective studies, the prevalence of IPF patient with
features of co-existing emphysema is about 28-55% depending on the population(17, 18). Over
the past decade, there has been controversy about whether the presence of pulmonary fibrosis
and emphysema represents a subgroup of IPF or a distinct clinical entity in itself. Cottin et al first
coined the name Combined Pulmonary Fibrosis and Emphysema (CPFE) in 2005 when they
formally described clinical characteristics comprising this syndrome. Those characteristics
included findings of dyspnea on exertion, basal crackles, finger clubbing, upper lobe emphysema
and lower lobe pulmonary fibrosis on CT, abnormal spirometry, severe gas exchange
impairment, and high prevalence of pulmonary hypertension(18). What is clear though, is that
the presence of both pulmonary fibrosis and emphysema carries a poorer prognosis than IPF
alone and mortality is even worse if pulmonary hypertension is also present(6, 17, 18). Thus,
better comprehension of pulmonary fibrosis with co-existing emphysema is of interest to us, and
the ADA-deficient mouse model provides a medium to explore these manifestations.
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Figure 6.0. Adenosine level and disease progression in adenosine-mediated pulmonary
fibrosis. ADA-deficient (ADA-/-) mice were identified at birth and maintained on ADA enzyme
replacement therapy until postnatal day 25. Therapy was then discontinued and disease allowed
to develop. BAL fluid samples were collected at various timepoints during the course of disease
progression. (A) Measurement of adenosine levels was performed in BAL fluid samples from
ADA-/- mice and their ADA-competent (ADA+/-) littermates. (B) Soluble collagen was quantified
in BAL fluid samples using Sircol assay. Results from A&B obtained by Ernestina Melicoff,
MD. All data presented as mean ± SEM, n≥4. *significant difference from ADA+/- cohort; *=
p<0.05, **= 0.001<p<0.01, ***= p<0.001.
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In the ADA-deficient model (Figure 1.4), ADA-deficient (ADA-/-) mice are identified at
birth and maintained on ADA enzyme replacement therapy from postnatal day 1 to 25 to allow
for normal pulmonary development. Discontinuation of therapy then allows for progressive
accumulation of endogenous adenosine in the lungs (Figure 6.0A), leading to chronic injury and
inflammation, enlargement of distal airways and development of pulmonary fibrosis, as indicated
by increasing presence of collagen in the lungs (Figure 6.0B). Elevations in adenosine have been
linked to development of disease in this model and reversal of disease was seen with therapy to
lower adenosine levels, thus demonstrating the influence of adenosine in lung disease(28, 95,
96). The ADA-deficient model has been used extensively by our lab as well as others to study
processes involved in adenosine-mediated lung injury(28-30, 97-102, 169).
Adenosine is a signaling nucleoside generated in response to lung injury. Through
activation of its G-protein-coupled receptors (A1AR, A2AAR, A2BAR and A3AR), adenosine
exerts various effects on inflammation, repair and remodeling processes, and fibrosis, producing
either tissue-protective or tissue-destructive results(25, 27, 170). Adenosine has been shown, in
humans and mouse models, to be elevated in and contribute to chronic lung disorders, including
asthma, COPD, and pulmonary fibrosis. Recent publications have reported, specifically, that it is
the activation of the A2B receptor by adenosine that mediates production of pro-fibrotic
molecules, like interleukin-6, leading to chronic lung diseases(25, 28-31, 91). Adenosine
regulates production and release of IL-6 from various cell types, including from lung epithelial
cells(32), macrophages(33), smooth muscle cells(34) and fibroblasts(35). More recently, Pedroza
et al demonstrated the role of IL-6 in mediating pulmonary fibrosis in this model(29). To further
clarify the roles of IL-6 classical versus trans signaling in this model, we set out to characterize
the pathways and answer the following questions:

149

6.1 Is soluble IL-6Rα increased in adenosine-mediated pulmonary fibrosis? What
happens as disease progresses?
6.2 Is membrane IL-6Rα increased in pulmonary fibrosis? What happens to levels as
pulmonary fibrosis develops and progresses?
6.3 Is ADAM17 elevated in adenosine-mediated pulmonary fibrosis? What happens to
expression throughout the model?
6.4-6.7 Does in vivo neutralization of IL-6 trans signaling attenuate pulmonary
inflammation? What about pulmonary fibrosis?
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RESULTS
6.1 – Soluble IL-6R alpha is elevated in adenosine-mediated pulmonary fibrosis.
As an initial assessment of whether sIL-6Rα is elevated in adenosine-mediated lung
disease, we examined its levels in the lungs of day 42 ADA-deficient (ADA-/-) mice and their
ADA-competent (ADA+/-) littermates. BAL fluid samples were collected and analyzed for
presence of the soluble receptor in the bronchoalveolar compartment of the lung. ELISA
quantification revealed a significant, more than 2-fold elevation in sIL-6Rα in ADA-/- samples in
comparison to their ADA+/- littermates (Figure 6.1A). Secondary confirmation was performed
using western blot analysis of these samples. It confirmed the presence of sIL-6Rα in ADA-/samples (Figure 6.1B). Knowing soluble receptor levels were elevated in established adenosinemediated lung disease, we next set out to evaluate changes to expression of sIL-6Rα during
disease onset and progression in ADA-deficient lungs.
Lung protein lysates were prepared and BAL fluid samples were collected from the lungs
of ADA+/- and ADA-/- mice at various stages of development between postnatal day 26 and 44
(on postnatal days 26, 30, 34, 38, and 42). Western blot analysis of lung protein lysates
demonstrated increasing appearance of sIL-6Rα as adenosine accumulates and injury progresses
in these lungs (Figure 6.1C). ELISA measurement and western blot analysis of sIL-6Rα in BAL
fluid samples confirmed this temporal increase in sIL-6Rα in ADA-/- lungs (Figure 6.1D&E).
There was a visible increase in soluble receptor by day 38. By day 42, there was a significantly
elevated level of sIL-6Rα in ADA-/- lungs in comparison to ADA+/- lungs. These findings
demonstrate an association between increases in soluble IL-6Rα and adenosine-mediated lung
disease and suggest a role for IL-6 trans signaling in disease onset and progression.
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Figure 6.1. Soluble IL-6R alpha expression in an adenosine-mediated mouse model of
pulmonary fibrosis. Soluble IL-6Rα expression was assessed in mice with pulmonary fibrosis.
(A & B) ELISA measurement and western blot analysis of sIL-6Rα in BAL fluid from postnatal
day 41-42 ADA+/- and ADA-/- mice. (C) Western blot analysis of sIL-6Rα in ADA-/- lung lysates
at various timepoints between postnatal day 26 and 44. (C) ELISA quantification of sIL-6Rα in
BAL fluid samples from ADA+/- and ADA-/- mice at various timepoints between postnatal days
26 and 42. (D) Western blot confirmation of sIL-6Rα in BAL fluid samples from ADA-/- mice
throughout progression of disease in model. All data presented as mean ± SEM, n≥4. *significant
difference from ADA+/- cohort; *= p<0.05, **= 0.001<p<0.01, ***= p<0.001.
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6.2 – Membrane IL-6R alpha is elevated in adenosine-mediated pulmonary fibrosis.
It was noted from our findings in human IPF samples and the IPB model that IL-6
classical signaling also has a role in pulmonary fibrosis. There is evidence to indicate that
increased IL-6 trans signaling may promote a feedback loop that enhances mIL-6Rα expression
and enhanced mIL-6Rα expression can either increase classical signaling and/or provides more
supply for production of soluble receptor. Membrane IL-6Rα was elevated in bleomycin-induced
pulmonary fibrosis and neutralization of trans signaling in vivo reduced mIL-6Rα expression in
association with reduction of fibrosis (Figure 5.19B&C). Trans signaling promoted recruitment
of inflammatory cells to the lung (Figure 5.3), cells that possessed enhanced membrane IL-6Rα
expression (Figure 3.4B&3.5B, 4.1E). These cells can then be stimulated to shed their receptors
to produce the soluble receptor (Figure 4.5). Stimulation of trans signaling in fibroblasts resulted
in increased mIL-6Rα, associated with increased proliferation and extracellular matrix protein
production (Figure 5.12&5.14). These results support the hypothesis that, in the lungs, classical
signaling and trans signaling interact to over-amplify the effects of IL-6, leading to fibrosis.
We wondered if the same pattern would hold in the ADA-deficient model, so we began
evaluating expression of mIL-6Rα in ADA-/- mice. BAL fluid samples were collected from
postnatal day 41-42 ADA+/- and ADA-/- mice. Western blot analysis of mIL-6Rα revealed
increased mIL-6Rα in ADA-/- samples (Figure 6.2A). BAL cells were isolated and also examined
for expression of mIL-6Rα. Immunofluorescence staining with membrane IL-6Rα (green) and
DAPI (blue) demonstrated enhanced expression of mIL-6Rα in ADA-/- samples (Figure 6.2B).
Furthermore, to determine if mIL-6Rα levels change over time, lung protein lysates were
prepared and BAL fluid samples were collected from the lungs of ADA-/- mice at various stages
of development between postnatal day 26 and 44 (on postnatal days 26, 30, 34, 38, and 42).

153

Western blot analysis of lung lysates showed no difference in mIL-6Rα expression over time
(Figure 6.2C). Western blot analysis of mIL-6Rα expression in BAL fluid samples over time
demonstrated a temporal increase (Figure 6.2D) resembling the pattern of increase in sIL-6Rα,
adenosine and collagen. These findings suggest that there is an increase in mIL-6Rα expression
in the bronchoalveolar compartment of the lungs, but perhaps not in the whole lung.

6.3 - ADAM17 is increased in adenosine-mediated pulmonary fibrosis.
Having demonstrated elevations in soluble IL-6Rα in ADA-deficient mice with
pulmonary fibrosis, we next assessed the underlying mechanism of sIL-6Rα production in their
lungs. From our studies in the IPB model, we know the protease ADAM17 to play a pivotal role
in shedding membrane IL-6Rα from activated macrophages to produce the soluble receptor
(Figure 4.5). Thus, we explored the possibility of ADAM 17 cleaving membrane IL-6Rα to
produce the soluble receptor in ADA-deficient lungs.
BAL fluid was collected from postnatal day 41-42 ADA+/- and ADA-/- mice and analyzed
for presence of ADAM17 in the airways and airspaces of the lung. Western blot analysis
detected increases in immature and mature forms of ADAM17 in ADA-/- samples (Figure 6.3A).
We further localized the increase in ADAM17. Immunostaining of sections from postnatal day
41-42 lungs revealed the most prominent increase of ADAM17 in alveolar macrophages of
ADA-deficient lungs (Figure 6.3B). These macrophages are the same ones that, when stained for
membrane IL-6Rα, expressed higher levels of the receptor than in the control (Figure 6.2B).
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Figure 6.2. Membrane IL-6R alpha expression in a mouse model of adenosine-mediated
pulmonary fibrosis. Membrane IL-6Rα expression was assessed in mice with pulmonary
fibrosis. (A) Western blot analysis of mIL-6Rα in BAL fluid from ADA+/- and ADA-/- mice,
postnatal day 41-44. (B) BAL cells were collected and immunofluorescence staining performed
for detection of membrane IL-6Rα (green) and DAPI (blue). Arrows denote positive cells.
Images are representative of n≥4 animals from each group. Scale bars: 50µm, 100x oil
immersion. (C) Western blot analysis of mIL-6Rα in ADA-/- lung lysates at various timepoints
between postnatal day 26 and 44. (D) Western blot confirmation of mIL-6Rα expression in BAL
fluid samples from ADA-/- mice throughout progression of disease in model.
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Figure 6.3. ADAM17 expression in a mouse model of adenosine-mediated pulmonary
fibrosis. Expression of the protease ADAM17 was evaluated in mice with pulmonary fibrosis.
(A) Western blot analysis of immature (130 kDa) and mature (89 kDa) forms of ADAM17 in
bronchoalveolar lavage fluid from postnatal day 41-42 ADA+/- and ADA-/- mice. (B)
Immunostaining for ADAM17 (brown) in the lungs of postnatal day 41-42 ADA+/- and ADA-/lungs. Arrows denote positive cells. Images are representative of n≥4 animals from each group.
Scale bars: 50µm, 100x oil immersion. Western blot analysis of ADAM17 in (C) lung protein
lysates and (D) BAL fluid as disease develops and progresses in an adenosine-mediated model.
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Further characterization of ADAM17 expression during onset and development of
fibrosis was achieved via preparation of lung protein lysates and collection of BAL fluid from
ADA-/- lungs at various stages of development between postnatal day 26 and 44 (on postnatal
days 26, 30, 34, 38, and 42). Western blot analysis of lung lysates revealed no difference in
ADAM17 expression, though there may be a slight reduction on days 42 and 44 in the mature
form and an increase in a potential isoform found at a lower molecular weight (Figure 6.3C).
Western blot analysis of mIL-6Rα in BAL fluid samples, on the other hand, indicated a temporal
increase in ADAM17 expression that mirrored the increase in sIL-6Rα in this model (Figure
6.1C&E). Collectively, these findings demonstrate an association between increases in ADAM17
and increases in soluble IL-6Rα in the bronchoalveolar compartment of ADA-deficient lungs,
suggesting a role for the protease in generating the soluble receptor in ADA-deficient lungs.

6.4 – In vivo neutralization of IL-6 trans signaling in the ADA-deficient model.
We have characterized increases in membrane and soluble IL-6Rα in ADA-deficient,
fibrotic mouse lungs and suggested a role for ADAM17 in generation of the soluble receptor in
these lungs. We saw similar patterns of expression of soluble IL-6Rα in the IPB model and were
able to demonstrate therapeutic benefits of neutralizing sIL-6Rα in vivo in that model. We
wanted to see if the same benefits would apply when we neutralize sIL-6Rα in ADA-/- mice.
In vivo neutralization of sIL-6Rα was performed in the ADA-deficient model using
mouse recombinant gp130Fc, shown in our studies and published literature to be an effective
inhibitor of IL-6 trans signaling(73, 74, 76, 78). The treatment protocol was as illustrated in
Figure 6.4A. Treatment with gp130Fc occurred from postnatal day 30 to 41. Mice were
sacrificed on postnatal day 42 and pulmonary phenotypes were assessed for pulmonary
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inflammation and fibrosis. The dosage and schedule for administration of recombinant gp130Fc
are adapted from previous studies that have shown effectiveness of soluble gp130 at blocking IL6 trans signaling in vivo,(76-80, 103) including our attempts to neutralize trans signaling in the
IPB model. The decision of when to begin treatment with gp130Fc was based on previous work
by Pedroza et al, who used the ADA-deficient model to study the role of IL-6 in adenosinemediated injury(29). They initiated pharmacologic blockade of IL-6 signaling on postnatal day
26 and demonstrated attenuation of fibrosis. Also, data from our characterization studies in this
model informed us that soluble IL-6Rα was already present in the lungs as early as postnatal day
26 in ADA-/- mice even though significant changes in collagen levels did not occur until between
day 34 and 38 (Figure 6.1C & 6.0B). This suggests that fibrosis became much more robust and
trans signaling takes a more prominent role in the disease process between days 34 and 38. Thus,
we attempted to antagonize trans signaling in a preventative manner by initiating recombinant
gp130Fc therapy on day 30.
To determine whether our neutralization protocol was sufficient to reduce levels of the
soluble receptor and inhibit trans signaling, Day 42 BAL fluid samples were collected and
subjected to ELISA analysis of sIL-6Rα. ADA-/- mice exhibited an elevation in sIL-6Rα in BAL
fluid (Figure 6.4B), though not significant and not to the levels observed in our characterization
studies. Treatment with gp130Fc led to a trend for lower levels of sIL-6Rα in BAL fluid but not
significantly different. This suggests us that the administration of recombinant gp130Fc in this
experiment was unable to significantly alter levels of soluble IL-6Rα and antagonize IL-6 trans
signaling in the lung microenvironment.
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Figure 6.4. Protocol for in vivo neutralization of soluble IL-6Rα using mouse recombinant
gp130Fc in a mouse model of adenosine-mediated pulmonary fibrosis. (A) Experimental
setup for in vivo neutralization of sIL-6Rα in the adenosine deaminase (ADA)-deficient murine
model of pulmonary fibrosis. ADA-/- mice were identified at birth and maintained on PEG-ADA
enzyme replacement therapy until postnatal day 25. Therapy is then discontinued and
endogenous adenosine allowed to accumulate in the lungs. Beginning on postnatal day 30 and
continuing until day 41, daily treatment with vehicle (saline) or recombinant gp130Fc was given.
Mice were sacrificed and samples collected for analysis on postnatal day 42. (A) ELISA
measurement of sIL-6Rα levels in BAL fluid from day 42 lungs. All data presented as mean ±
SEM, n=2 for ADA+/- + PBS, n≥4 for other cohorts. *significant difference from ADA+/- cohort
given PBS; #significant difference from ADA-/- mice given PBS. *= p<0.05, **= 0.001<p<0.01,
***= p<0.001.
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6.5 – Effects of treatment with recombinant gp130Fc on pulmonary inflammation.
Despite not being able to show a significant reduction in sIL-6R alpha in our
neutralization study, we proceeded to evaluate changes to pulmonary phenotype. The
histopathology of ADA-/- lungs included pulmonary inflammation, emphysematous distal airway
enlargement and pulmonary fibrosis.
To assess changes in pulmonary phenotype, we first examined the effects of recombinant
gp130Fc administration on pulmonary inflammation. Using a hemocytometer, total cell counts
were performed on BAL fluid samples from day 42 ADA-/- mice. Analysis of BAL fluid samples
revealed a significant elevation in total BAL cells in ADA-/- lungs, consistent with the presence
of inflammation (Figure 6.5A). Though there was a trend for decrease, there was no significant
reduction in total BAL cells in ADA-/- mice treated with gp130Fc (Figure 6.5A). Surprisingly,
cellular differential analysis revealed a significant reduction in BAL macrophages in ADA-/mice treated with gp130Fc (Figure 6.5B). No significant trends could be concluded from
examination of the other cell types in BAL fluid (Figure 6.5C&D).

6.6 – Effect of recombinant gp130Fc on collagen protein expression in the lungs.
We next attempted to evaluate pulmonary fibrosis in gp130Fc-treated and untreated
ADA-/- mice. We assessed collagen production in the lungs by measuring soluble collagen
protein in BAL fluid using Sircol assay. ADA-/- lungs exhibited significantly higher levels of
soluble collagen in BAL fluid, indicative of fibrosis (Figure 6.6A), though not to the extent
expected based on previous descriptive studies (Figure 6.0B). Gp130Fc administration did not
result in a significant reduction in collagen protein though there was a trend for decrease. These
results were confirmed in second manner by evaluation of collagen deposition in the lungs. Lung
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sections from day 42 ADA+/- and ADA-/- mice, placebo and treated groups, were prepared and
stained using Masson’s trichrome protocol to visualize collagen deposition (blue). Untreated
ADA-/- lungs had evidence of emphysematous distal airway enlargement and mild pulmonary
fibrosis (Figure 6.6B). Gp130Fc-treated ADA-/- lungs appeared mildly improved, though there
was not enough fibrosis in either cohorts to accurately draw conclusions about changes.

6.7 – Effect of recombinant gp130Fc on pulmonary fibrosis and myofibroblast accumulation.
We next attempted to quantify extent of pulmonary fibrosis in gp130Fc-treated and
untreated ADA-/- mice. Ashcroft scoring was performed on Masson’s trichrome-stained sections.
Untreated ADA-/- lungs had evidence of mild pulmonary fibrosis, with Ashcroft scores of around
3 (Figure 6.7A). There was a trend for decrease in scores in gp130Fc-treated lungs, though it was
not significant. Lung sections were also stained with α-SMA for detection of myofibroblasts.
Neither ADA-/- treated nor untreated lungs displayed very much SMA staining (Figure 6.7B). In
combination with the collagen data, these results support the idea that the collected ADA-/- +
PBS samples in this experiment were not representative of what is typically expected of diseased
lungs and no valid comparisons can be made between treated and untreated mice.
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Figure 6.5. Pulmonary inflammation after recombinant gp130Fc treatment in a mouse
model of adenosine-mediated pulmonary injury. ADA-/- mice were identified at birth and
maintained on PEG-ADA enzyme replacement therapy until postnatal day 25. Therapy is then
discontinued. Beginning on postnatal day 30 and continuing until day 41, daily treatment with
vehicle (saline) or recombinant gp130Fc was given. Mice were sacrificed and samples collected
for analysis on postnatal day 42. (A-D) Total BAL cells count and differentials, including
macrophages, lymphocytes, eosinophils and others were determined in day 42 samples. All data
presented as mean ± SEM, n=2 for ADA+/- groups, n≥3 for ADA-/- cohorts. *significant
difference from ADA+/- cohort given PBS; #significant difference from ADA-/- mice given PBS.
*= p<0.05, **= 0.001<p<0.01, ***= p<0.001.
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Figure 6.6. Collagen production and deposition following treatment with recombinant
gp130Fc in a mouse model of adenosine-mediated pulmonary injury. ADA-/- mice were
identified at birth and maintained on PEG-ADA enzyme replacement therapy until postnatal day
25. Therapy is then discontinued. Beginning on postnatal day 30 and continuing until day 41,
daily treatment with vehicle (saline) or recombinant gp130Fc was given. Mice were sacrificed
and samples collected for analysis on postnatal day 42. (A) Lung sections from day 42 ADA+/and ADA-/- mice, placebo and treatment groups, were immunostained using Masson’s trichrome
protocol for detection of collagen deposition (blue). (B) Sircol measurement of soluble collagen
in BAL fluid samples from Day 42. All data presented as mean ± SEM, n=2 for ADA+/- groups,
n≥4 for ADA-/- cohorts. *significant difference from ADA+/- cohort given PBS; #significant
difference from ADA-/- mice given PBS. *= p<0.05, **= 0.001<p<0.01, ***= p<0.001.
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Figure 6.7. Pulmonary fibrosis following treatment with recombinant gp130Fc in a mouse
model of adenosine-mediated pulmonary injury. ADA-/- mice were identified at birth and
maintained on PEG-ADA enzyme replacement therapy until postnatal day 25. Therapy is then
discontinued. Beginning on postnatal day 30 and continuing until day 41, daily treatment with
vehicle (saline) or recombinant gp130Fc was given. Mice were sacrificed and samples collected
for analysis on postnatal day 42. (A) Ashcroft scoring was performed on Day 42 from ADA+/and ADA-/- mice, placebo and treated groups. (B) Day 42 lung sections were immunostained
with alpha-smooth muscle actin for detection of myofibroblasts (red). All data presented as mean
± SEM, n=2 for ADA+/- groups, n≥4 for ADA-/- cohorts. *significant difference from ADA+/cohort given PBS; #significant difference from ADA-/- mice given PBS. *= p<0.05, **=
0.001<p<0.01, ***= p<0.001.
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DISCUSSION
With the encouraging results found in the IPB mouse model, we approached the study of
IL-6 classical and trans signaling in the ADA-deficient model with the hopes of secondary
validation of our findings and the potential of exploring the role of these pathways in combined
pulmonary fibrosis and emphysema states. We were able to characterize increases in soluble IL6Rα, membrane IL-6Rα and ADAM17 expression in adenosine-induced pulmonary disease that
were similar in most respects to the patterns seen in bleomycin-induced pulmonary fibrosis. Our
characterization studies suggested: 1) a role for IL-6 classical and trans signaling in adenosinemediated disease, and 2) ADAM17 in shedding IL-6Rα from alveolar macrophages. Our initial
attempt to neutralize soluble IL-6Rα in vivo in the ADA-deficient model, however, failed to
achieve significant reduction in sIL-6Rα in the lungs. Further optimization of the neutralization
protocol is needed in order to more accurately determine the significance of IL-6 trans signaling
in this model and decipher its part in the pathogenesis of adenosine-mediated pulmonary disease.
Our characterization experiments were able to support a role for IL-6 trans signaling in
the ADA-deficient model. We saw that soluble IL-6Rα was elevated in both bronchoalveolar and
parenchymal compartments of ADA-deficient lungs. This elevation was seen in established
pulmonary disease, which includes pulmonary inflammation and pulmonary fibrosis. We also
demonstrated that soluble IL-6Rα increased in ADA-deficient lungs in association with
increasing disease, as indicated by increasing adenosine and collagen content. This pattern of
increase in sIL-6Rα is in agreement with the pattern seen in the IPB model and suggests trans
signaling could be involved in adenosine-mediated pulmonary injury in this model. This would
not be surprising since adenosine regulates IL-6 expression and release in various pulmonary
sources(32-35). It would be interesting to assess whether adenosine also regulates expression of
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IL-6Rα. Also, more work is necessary to understand the trans signaling-mediated activation of
intracellular pathways in the ADA-deficient model.
In contrast to the overall increase in membrane IL-6Rα expression in whole lung in the
IPB model, we determined that membrane IL-6Rα is elevated only in the bronchoalveolar
compartment of ADA-deficient lungs. This increase was further localized to the alveolar
macrophages, similar to the observation made in the IPB model. This observation suggests that
alveolar macrophages may represent the source of soluble IL-6Rα generation in this model as
well. When we examined ADAM17 expression in the model, we saw increased levels over time
in the bronchoalveolar compartment of ADA-deficient lungs, in association with increasing sIL6Rα. The increase was localized to alveolar macrophages. In comparison to the pattern seen in
the IPB model, the more specific localization of membrane IL-6Rα and ADAM17 to the alveolar
macrophages in ADA-deficient lungs further implicate the protease and these cells in generation
of sIL-6Rα. Macrophage stimulation experiments similar to those conducted in the IPB model
needs to be performed to further assess the role of ADAM17 in producing sIL-6Rα.
As for our attempt at in vivo neutralization of sIL-6Rα in the ADA-deficient model, we
were unable to demonstrate a significant reduction in sIL-6Rα in the cohort treated with mouse
recombinant gp130Fc. As such, we were unable to draw solid conclusions regarding pulmonary
inflammation and fibrosis since we are unsure whether or not antagonism of IL-6 trans signaling
was successful. There could be several possibilities as to the reason for our failure to demonstrate
a significant difference in sIL-6Rα levels with gp130Fc treatment. Failure could be due to
inadequate dosing, treatment frequency and/or duration of therapy. Our attempt at neutralization
in ADA-deficient mice was based on what was effective in the IPB model. However, every
model is different, and the metabolism of recombinant gp130Fc in ADA-deficient could be
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entirely different than that of bleomycin-exposed mice. Perhaps the same dose of recombinant
gp130Fc is metabolized too quickly in the ADA-/- lungs or is being shuttled to other sites of
inflammation and disease since we know ADA-/- mice to have metabolic disturbances in many
organs, including spleen, liver and kidney(94, 95). Treatment failure could also be due to timing
of therapy initiation or the duration of therapy. Perhaps gp130Fc treatment needs to be started
earlier in the model.
Another valid possibility could be that we did not examine the quantity and quality of
mice necessary to observe a difference with treatment. One of the difficulties of the ADAdeficient model is in timing of sample collection. Several ADA-/- mice treated with PBS were
lost to collection due to death occurring before day 42. They were excluded from the study.
Thus, the most severely ill mice were eliminated from the analysis. The ones that survived to day
42 did not appear to be sufficiently ill, given the low sIL-6Rα and soluble collagen levels
measured in BAL fluid. Neither the levels of sIL-6Rα nor soluble collagen in BAL fluid samples
from our untreated ADA-/- cohort were consistent with what was observed in our previous
descriptive study (Figure 6.0B). This suggests that we weren’t capturing the mice representative
of the severity of disease seen in our characterization studies. As such, perhaps because we did
not have adequate positive controls (i.e. sick ADA-/- + PBS mice), we were unable to assess
changes with treatment with gp130Fc. Surprisingly, our analysis of BAL cells yielded a
significant reduction in macrophages in gp130Fc-treated ADA-/- mice. However, in the face of
unaltered levels of sIL-6Rα, we are uncertain what conclusion can be drawn from these results.
Overall, our experiments in the ADA-deficient model validated elevations in soluble sIL6Rα in onset and progression of adenosine-mediated pulmonary disease. We confirmed
elevations in mIL-6Rα and ADAM17 in alveolar macrophages of ADA-deficient lungs. Our
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studies in this model have provided preliminary data to support further need for analysis of IL-6
classical and trans signaling as well as the role of ADAM17 in adenosine-mediated lung injury.
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CHAPTER 7
Summary & Conclusions
and
Future Directions
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SUMMARY OF RESULTS
The published literature suggests an important role for IL-6 trans signaling in diseased
states, yet trans signaling has not been examined in IPF, a deadly form of pulmonary fibrosis and
the most common interstitial lung disease(1). This project was intended to 1) characterize IL-6
classical and trans signaling in fibrotic lungs, 2) examine protease-mediated generation of
soluble IL-6 receptor alpha, and 3) evaluate the therapeutic benefit of blocking IL-6 trans
signaling in pulmonary fibrosis.
Characterization of IL-6 classical and trans signaling in IPF lungs revealed elevations of
soluble IL-6Rα in parenchyma and bronchoalveolar compartments. Membrane IL-6Rα is
augmented in M2 macrophages in IPF lungs. M2 macrophages, fibroblasts and myofibroblasts
from IPF lungs are capable of responding to classical and trans signaling, while type II
pneumocytes are only responsive to trans signaling. Enhanced activation of STAT3 was seen in
IPF lungs in a number of different cell types. These results supported a role for IL-6 trans
signaling in amplifying the effects of IL-6 in IPF lungs.
Evaluation of IL-6 trans signaling in a chronic bleomycin mouse model, the
Intraperitoneal Bleomycin (IPB) model, revealed elevations in both membrane and soluble IL6Rα levels in association with fibrosis initiation and progression. The soluble receptor was
generated via protease-mediated cleavage of membrane IL-6Rα from M2 macrophages and the
protease ADAM17 was responsible. Neutralization of IL-6 trans signaling in vivo resulted in
attenuation of pulmonary inflammation and fibrosis in the model, which translated to
improvement in pulmonary hypertension and hypoxia. In vitro mechanistic studies revealed that
IL-6 trans signaling promoted fibroblast proliferation and production of extracellular matrix
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proteins. In all, these results revealed an essential role for IL-6 trans signaling in development of
disease in a mouse model.
Attempts to validate our findings in a second model, the Adenosine Deaminase (ADA)deficient model, resulted in confirmation that IL-6 trans signaling was augmented in association
with disease in ADA-deficient mice. Membrane IL-6Rα and ADAM17 were elevated in
activated M2 alveolar macrophages, same as in the IPB model. An initial attempt to antagonize
IL-6 trans signaling in this model failed to significantly reduce levels of the soluble receptor.
Further optimization of neutralization protocol is needed. Results obtained in this second model
were able to validate some findings from IPF and the IPB model.
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Figure 7.0. Working model of IL-6 trans signaling in pulmonary fibrosis. In fibrotic lungs,
elevated ADAM17 expression in M2 macrophages leads to cleavage of membrane IL-6Rα to
produce soluble IL-6Rα. Soluble IL-6Rα binds IL-6, which is released by a number of cells,
including alveolar macrophages, in response to adenosine stimulation (work done by Yang Zhou,
PhD). The IL-6/sIL-6Rα complex can then activate various cells in the lung in a paracrine
manner or further activate M2 macrophages in an autocrine manner. (A&B) Stimulation of IL-6
trans signaling in fibroblasts results in (1) increased extracellular matrix protein production and
(2) increased proliferation. (C) Stimulation of trans signaling in type II pneumocytes has been
shown to induce EMT (results obtained by Mesias Pedroza, PhD). (D) Stimulation of IL-6 trans
signaling in M2 macrophages has not been examined yet. The resulting effects are unknown.
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WORKING MODEL
Given what is known from published literature, the work done previously in our lab, as
well as data obtained from studies in this project, we propose the following working model for
IL-6 trans signaling in pulmonary fibrosis (Figure 7.0). As pulmonary fibrosis develops and
progresses, there is increasing recruitment and accumulation of macrophages in the lung. In
response to stimulatory signals present in the lung, these macrophages adopt the M2 phenotype
and express augmented levels of membrane IL-6Rα. Activation of ADAM17 in M2 macrophages
allows them to shed their membrane receptor to generate soluble IL-6Rα. Because of this, sIL6Rα accumulates in the lung as disease progresses. Soluble IL-6Rα acts by first binding IL-6,
which is released from a number of cells in fibrotic lungs, including alveolar macrophages
(under stimulation by adenosine). The complex of IL-6/sIL-6Rα can then activate IL-6 trans
signaling, amplifying the effects of IL-6. These effects include increasing recruitment of
inflammatory cells, including more macrophages. IL-6/sIL-6Rα can activate IL-6 trans signaling
in fibroblasts and myofibroblasts, promoting their proliferation and synthetic capabilities,
resulting in expansion of these cells and increased production and deposition of extracellular
matrix proteins like collagen and fibronectin in the parenchyma. Over time, this process results
in progressive fibrosis, alterations of pulmonary architecture and impairment of gas exchange,
manifested as hypoxia and respiratory dysfunction, ultimately leading to respiratory failure and
death.

CONCLUSIONS
In this project, we have emphasized the significance of IL-6 trans signaling by showing
elevations in soluble IL-6Rα in IPF lungs. We demonstrated a temporal increase in sIL-6Rα
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during onset and progression of pulmonary fibrosis in two separate murine models, suggesting
IL-6 trans signaling is involved in disease pathogenesis. We characterized IL-6 classical
signaling and demonstrated a role for ADAM17 in generating soluble IL-6Rα by shedding the
membrane receptor from mouse M2 macrophages. Neutralization of sIL-6Rα and resulting
antagonism of IL-6 trans signaling attenuated bleomycin-induced pulmonary inflammation and
fibrosis in a mouse model. In vitro studies using human normal and IPF fibroblasts suggested
activation of IL-6 trans signaling results in effects that are relevant to the progression of lung
fibrosis. These findings are consistent with the hypothesis that IL-6 trans signaling is essential in
mediating pro-inflammatory and pro-fibrotic effects in the lungs. Further studies are necessary to
validate these observations in additional human IPF tissues and samples. However, this study
presents, to our knowledge, the first in vivo preclinical evidence that blockade of IL-6 trans
signaling may be of therapeutic value to the management of IPF.

FUTURE DIRECTIONS
Though we have made some progress in understanding some of the events that govern the
initiation and progression of pulmonary fibrosis, much remains unclear. Our findings in this
project, along with what is known from the published literature, have directed our thought
process to generate the following questions that will drive our future studies and our search for
more answers to this complex condition.
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7.1 – Validate preliminary human findings & mouse model findings in more IPF samples
This thesis has yielded some intriguing findings regarding soluble IL-6Rα and trans
signaling in pulmonary fibrosis. To provide even more preclinical data to support targeting this
pathway in humans, we would like to validate our mouse findings in more human samples. I am
most interested in the following questions.
1) Can we replicate the data showing that sIL-6Rα is increased specifically in a fibrotic
lobe and not a non-fibrotic lobe (Figure 3.1A)? We would need to obtain more BAL fluid
samples from different lobes of each patient and assess enough patients to see if the pattern
holds. If we can show that this pattern of increased sIL-6Rα only occurs in fibrotic areas of the
lungs, then it would support the idea of using sIL-6Rα as a biomarker of fibrosis in IPF.
2) Can we confirm in IPF samples the finding in both IPB and ADA-deficient models
showing a temporal increase in sIL-6Rα with increasing severity of fibrosis (Figures 3.3 and
6.1)? We would need samples from patients at different stages of the disease, as representatives
of varying (or increasing) severity of disease. There are a few issues with that plan. Ideally, we
would recruit newly diagnosed IPF patients and follow them with periodic BALs and tissue
collection. However, there are no known therapeutic justifications for subjecting patients to
invasive procedures for periodic BALs and tissue collection. The other problem is that IPF is
such a heterogeneous disease, with different phenotypes of IPF. How would initial classification
of patients be done? What factors would be important? Imaging findings? Pulmonary function?
Genotype? Duration of symptoms? As mentioned in chapter 1, rapidly progressing forms of IPF
present with similar lung volumes, capacities and findings as stable or slowly progressing IPF.
We would need to follow those patients to make sure they were classified correctly based on how
they progress. That would take tremendous time and effort for follow-ups. However, if we are
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able to gather enough samples representative of the spectrum of IPF disease and stratify them
appropriately, it would provide valuable information about the disease process. If we can show
the pattern of sIL-6Rα expression replicates in IPF, it would support the use of sIL-6Rα as a
prognostic marker and indicator of disease severity/stage.
3) Can we validate the finding in the IPB model showing a temporal increase in M2
macrophages and ADAM17 in association with increasing sIL-6Rα (Figure 4.2)? Can we
stimulate shedding from M2 macrophages from IPF lungs? Doing so would provide the rationale
to block ADAM17 activity specifically in macrophages to prevent generation of sIL-6Rα in IPF
lungs.
4) What is the expression of membrane IL-6Rα in IPF lungs? We need to determine if the
preliminary results in IPF samples regarding expression of the membrane receptor is true (Figure
3.4A). We would like to evaluate mIL-6Rα expression in more IPF lung lysate samples and
using a more specific antibody for the membrane receptor. Doing so would allow us to determine
how much of the mouse model findings with regards to mIL-6Rα could apply to the human
disease and direct our future efforts.
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Figure 7.1. Activation of STAT3 in IPF patients with and without pulmonary hypertension.
(A) Immunostaining for phospho-STAT3 and α-SMA around vessels in lung sections from IPF
patients. Scale bars: 50µm, 100x oil immersion. (B) Western blot analysis of sIL-6Rα and PSTAT3 in lung lysates from explanted IPF samples from patients with and without co-existing
pulmonary hypertension.
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7.2 – Over-express soluble IL-6Rα to induce pulmonary fibrosis in wildtype mice
We were able to show that neutralization of IL-6 trans signaling using gp130Fc was
therapeutic in our IPB model. To further support the role of sIL-6Rα in disease, we could overexpress the IL-6/sIL-6R complex in wildtype mice to see if we can induce pulmonary fibrosis.
The use of Hyper IL-6(44), a fusion protein consisting of IL-6 and sIL-6Rα, would come in
handy for this purpose.

7.3 – Explore the role of IL-6 trans signaling in pulmonary hypertension associated with
pulmonary fibrosis
As mentioned in chapter one, the presence of pulmonary hypertension worsens prognosis
and survival. In this thesis, we showed that mice with bleomycin-induced pulmonary fibrosis
also exhibit pulmonary hypertension. In vivo antagonism of IL-6 trans signaling with gp130Fc
resulted in improvement in pulmonary hypertension (Figure 5.10). This could represent an
effective therapy for fibrosis-associated PH.
Ammit et al reported stimulation of IL-6 trans signaling in airway smooth muscle cells in
asthmatics promotes eotaxin and VEGF release, which may contribute to inflammation locally
and vessel expansion(85). This could have significance in the vascular changes leading to
development of PH. Karmouty-Quintana et al recently demonstrated the role of the adenosine 2B
receptor (A2BAR) in pulmonary hypertension associated with interstitial lung diseases (ILD)(91,
171). They provided evidence that receptor activation of vascular cells promoted IL-6 release.
Given what we have shown in our in vivo neutralization study as well as results from
analysis of P-STAT3 in IPF lungs, there is reason to suggest involvement of IL-6 signaling in PH
secondary to ILDs. Evaluation of the vessels in IPF lung sections (PH status unknown) revealed
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increased activation of STAT3 in alpha-SMA positive cells (Figure 7.1A), suggesting enhanced
IL-6 signaling may play a role in vascular and perivascular cells. To further assess whether trans
signaling might be involved in PH associated with IPF, IPF lung lysates samples were separated
by presence or absence of confirmed PH in medical history and evaluated by western blot for
expression of P-STAT3 and sIL-6Rα. Western blot revealed increased phospho-STAT3 in IPF
patients with PH (Figure 7.1B). Soluble IL-6Rα was present in every sample but did not show a
clear pattern of increase of decrease. Further analysis is needed to evaluate whether there is a
difference in sIL-6Rα or membrane IL-6Rα among IPF patients with and without PH. If not due
to IL-6 signaling, then something else must explain the difference in P-STAT3 expression among
IPF patients with and without PH. Other than IL-6, STAT3 is known to be activated in response
to other IL-6 family cytokines, including interleukin 11, leukemia inhibitory factor (LIF),
oncostatin M (OSM), cardiotrophin 1 (CT-1) cardiotrophin-like cytokine (CLC), among others.
Whatever the case, these findings need further exploration.
What was interesting in our studies was the analysis of sIL-6Rα and P-STAT3 expression
in explanted samples from COPD patients, who can have pulmonary fibrosis and develop PH as
a complication of their disease process. COPD patients without pulmonary hypertension
expressed sIL-6Rα in 7/7 samples (Figure 7.2). COPD patients with PH did not express sIL-6Rα
in 5/7 samples. Expression of P-STAT3 was variable, with 4/7 COPD with PH samples showing
greater activation of STAT3 than COPD without PH. If these patterns hold up with analysis of
more samples, the presence of sIL-6Rα in COPD lungs may indicate a protective effect from PH
or that those COPD lungs have fibrosis and the other ones do no. It could also mean that IL-6
trans signaling has no role in development of PH in COPD.
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Figure 7.2. Activation of STAT3 in COPD with and without pulmonary hypertension. (A)
Immunostaining for phospho-STAT3 and α-SMA around vessels in lung sections from IPF
patients. Scale bars: 50µm, 100x oil immersion. (B) Western blot analysis of phospho-STAT3 in
lung lysates from explanted IPF samples from patients with and without co-existing pulmonary
hypertension.
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7.4 – Optimize protocol for neutralization of IL-6 trans signaling in ADA-deficient model
As mentioned in the introduction and chapter 6, combined pulmonary fibrosis and
emphysema represents a clinical presentation that confers bad prognosis. There are no available
recommendations regarding therapy at this time due to a lack of knowledge of how these
combined features developed. The ADA-deficient model provides what could be considered a
potential model for this condition of combined fibrosis and emphysema since ADA activity has
been shown to be significantly reduced in COPD (which consists of emphysema & chronic
bronchitis) and IPF lungs and ADA-deficient mice are known to exhibit these two features of
chronic lung disease secondary to chronically elevated adenosine(30, 31).
Though our first attempt at neutralizing sIL-6Rα in the ADA-deficient model did not
yield significant reductions in receptor levels, we would like to make another attempt at
neutralizing sIL-6Rα in this model and exploring the impact of IL-6 trans signaling in the
disease process. We may just need to increase the dosage of gp130Fc and/or start therapy earlier
to see if we can effect significant changes. The other option is to over-express IL-6/sIL-6R by
injecting Hyper IL-6 in our ADA-deficient mice and see if that would worsen severity of disease
or hasten disease progression.

7.5 – Evaluate role of membrane IL-6R alpha and IL-6 classical trans signaling in regulation
and function of M2 macrophages
Characterization studies in this thesis were able to determine that membrane IL-6Rα
expression is increased in M2 macrophages from IPF lungs (Figure 3.4B), bleomycin-induced
fibrotic mouse lungs (Figure 4.1E), and adenosine-mediated fibrotic mouse lungs (Figure 6.2B).
We provided evidence that M2 macrophages from bleomycin-induced fibrotic mouse lungs shed
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their membrane IL-6Rα to generate soluble IL-6Rα in those lungs (Figure 4.5). We have shown
that antagonism of IL-6 trans signaling in bleomycin-induced pulmonary fibrosis led to a
reduction in the number of macrophages in the lungs (Figure 5.3B).
These findings support an essential role for activated macrophages in the development of
pulmonary fibrosis in our chronic bleomycin mouse model. Analysis of IPF human samples
provided some validation. A search of the literature base also supports a role for these cells in
IPF(115). We need to explore the functions of M2 macrophages in fibrotic lungs, beyond serving
as the source of IL-6R shedding. Our thesis findings have sparked the following questions.
Is the reduction in total BAL macrophages with gp130Fc treatment a reduction in M2
macrophages? We suspect that is the case since the type of macrophage that is increased in IPF
and fibrotic mouse lungs are M2 in phenotype. However, we need to confirm that by either
performing immunofluorescence staining of BAL cells from gp130Fc-treated mice for CD206, a
marker of M2 macrophages or by western blot analysis probing for expression of arginase 1,
another M2 marker.
Is enhanced expression of membrane IL-6Rα an indication of M2 phenotype? The human
and mouse data seem to suggest so. What role does IL-6 classical signaling have in M2
macrophage function? Does it regulate release of mediators? What happens to the cells after the
membrane receptor is cleaved off? Do the cells retain their M2 phenotype?
What regulates expression of membrane IL-6Rα in these macrophages? Since adenosine
can stimulate production of IL-6 from these cells(31), does it also stimulate expression of the
membrane receptor? Is the A2B receptor involved in the process since this receptor is also
elevated in M2 macrophages(31)?
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7.6 – Explore the effect of IL-6 trans signaling on M2 macrophage activity
We have shown that antagonism of IL-6 trans signaling in bleomycin-induced pulmonary
fibrosis led to a reduction in the number of macrophages in the lungs (Figure 5.3B). We still
need to confirm that this is a decrease in M2 macrophages, though the suspicion is high that it is.
As such, it would suggest that IL-6 trans signaling may have important effects in this cell. The
effects of stimulating IL-6 trans signaling in M2 alveolar macrophages have not been examined.
I am particularly interested in whether stimulation of IL-6 trans signaling would induce
production/release of fibronectin from these cells. Rennard et al reported that alveolar
macrophages from IPF patients secreted more fibronectin than those from normal lungs and that
fibronectin has a chemoattractant effect on fibroblasts. Does IL-6 trans signaling regulate TGFβ, IL-6 or other pro-fibrotic mediator production and release from these macrophages?

7.7 – Evaluate adenosine-mediated activation of ADAM17 in macrophages and evaluate
ADAM17 neutralization specifically in macrophages on development of pulmonary fibrosis
ADAM17 is activated by PMA and bacterial pathogens. The process of ADAM17mediated shedding of IL-6Rα is dependent on PKC activation(58). We know adenosine can
activate PKC. We know A2B receptor expression is enhanced in activated alveolar
macrophages(31). This begs the question of whether adenosine is involved in the regulation of
ADAM17 activation in activated macrophages in order to cause shedding of IL-6Rα. Further
study is necessary to elucidate the mechanism of shedding in alveolar macrophages. Further
analysis is needed to support the hypothesis that adenosine activation of its A2BAR in M2
macrophage leads to enhanced activation of ADAM17 in these cells, resulting in shedding of IL6Rα.
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Since the our results seem to indicate an essential role for ADAM17 in generating soluble
IL-6Rα in fibrotic lungs, the next reasonable step would be to attempt neutralization of
ADAM17 to see if there is any therapeutic benefit. However, because ADAM17 cleaves
numerous different substrates in the body, many of which are physiologically necessary, global
blockade of ADAM17 is not appropriate. In fact, ADAM17-deficiency in mice is embryonically
lethal. Thus, since we demonstrate that the scene of the crime in fibrotic lungs is the activated
alveolar macrophage, we wonder if it would be possible to neutralize ADAM17 specifically in
macrophages to prevent shedding of IL-6Rα and determine effects on development of pulmonary
fibrosis in the IPB model.

7.8 – Explore the effect of trans signaling on senescence of airway epithelial cells
We have demonstrated effects of stimulating IL-6 trans signaling in fibroblasts and
myofibroblasts that are pertinent to pulmonary fibrosis. We have not examined the effects in
airway epithelial cells (AEC). Given the current theory regarding IPF development, a theory that
is epithelium-centered, with the thought that injury responses in alveolar airway epithelial cells is
central to the initiation of a series of events that culminate in fibrosis, it would seem that we
should also examine the role of IL-6 trans signaling in AECs. This pathway may be even more
important in AECs than in other pulmonary cell types since we did not see expression of
membrane IL-6Rα in AECs (Figure 3.4D), which suggests that these cells are not capable of
classical signaling and only susceptible to trans signaling.
Pedroza et al (unpublished data) demonstrated that stimulation of IL-6 trans signaling in
AEC induces epithelial to mesenchymal transition (EMT). We are interested in further exploring
effects of trans signaling in AEC, particularly proliferation, senescence and apoptosis, since the

184

current view in the field is that there is premature senescence and excessive apoptosis of AECs in
response to alveolar injury that is at the source of pulmonary fibrosis. It would be fascinating to
see if IL-6 trans signaling has any effect on these processes.

7.9 – Clarify whether there is any change in M1 macrophages as disease develops and
progresses.
Though our focus in this thesis has been on the increase in M2 macrophages as fibrosis
progressed in our mouse model, we can’t help but wonder if changes to M1 macrophages also
contribute to the pathogenesis of IPF. M1 and M2 macrophages appear to play different roles in
renal fibrosis(172). Can the same be true in pulmonary fibrosis? We would need to characterize
and monitor changes to M1 markers in the IPB model over the course of the model to answer that
question.

7.10 – Evaluate the increase in lymphocytes during disease onset and progression in IPB as
another source of shedding or release of mediators
In our characterization studies, we showed a temporal increase in lymphocytes in
bleomycin-induced fibrotic mouse lungs (Figure 7.3). We should determine if lymphocytes shed
their membrane receptor to generate soluble receptor. We could also explore whether activation
of IL-6 classical signaling in these cells alter their phenotype or activities.
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Figure 7.3. Lymphocyte accumulation in bleomycin-induced pulmonary fibrosis. Number of
lymphocytes in BAL fluid samples from PBS-injected and bleomycin-exposed mice at various
points throughout the model. Data presented as mean ± SEM, n≥4. *significant difference from
PBS-treated cohort. *= p<0.05, **= 0.001<p<0.01, ***= p<0.001. Data obtained by Tina
Melicoff, MD, Tingting Weng, PhD and Harry Karmouty-Quintana, PhD.
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7.11 – Evaluate the role of IL-6 trans signaling and ozone exposure on exacerbation of
fibrosis in IPF patients
We are interested in how ozone exposures affect IPF because ozone is known to play an
important role in chronic lung disorders like asthma and chronic obstructive pulmonary disease
(COPD)(173) and ambient ozone has been reported to increase IL-6 production in the lungs(174,
175). However, nothing is known about the impact of ozone on pulmonary fibrosis, so much
work is required in this area. I will utilize mouse models and human samples to examine the
hypothesis that IL-6 trans signaling contributes to pulmonary fibrosis and ozone exposure
exacerbates pulmonary fibrosis. First, I will characterize IL-6 classical and trans signaling
components during the development of pulmonary fibrosis. Then I will assess the effect of block
IL-6 trans signaling on fibrosis. Lastly, I will determine the effect of ozone exposure on the
onset and progression of pulmonary fibrosis. We hope to achieve novel findings with this project
that will translate into innovative therapeutics for the disease.

FINAL WORDS
As mentioned from the beginning, there is an urgent need to develop effective therapies
for IPF. In this thesis, we have emphasized the significance of IL-6 trans signaling during the
development and progression of pulmonary fibrosis and achieved novel findings that contribute
to the understanding of the pathogenesis of IPF. Though the effect of recombinant gp130Fc in
mice with pulmonary fibrosis was only partial, it was still significant enough to indicate this may
be effective in slowing or perhaps even halting progression of disease in IPF patients. Our
findings support the use of recombinant gp130Fc, and perhaps ADAM17 inhibition specifically
in alveolar macrophages, for treatment of IPF patients. However, there is a need to further
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validate our mouse findings in more human samples and a need to evaluate the safety profile and
effects of long-term use of gp130Fc in humans. Much work remains to better understand the
complex interactions of the pulmonary micro-environment in order to develop even better
therapies against this deadly disease.
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